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Abstract 
 
The central hypothesis for this thesis is that antibody-targeted superparamagnetic iron 
oxide  nanoparticles  (SPIONs)  can  be  used  for  diagnosis  and  therapy  of  cancer.  The 
hypothesis is based on the knowledge that firstly, recombinant single chain Fv antibody 
fragments (scFv) are effective targeting reagents and second, SPIONs can substantially 
improve the sensitivity of magnetic resonance imaging (MRI). Furthermore, SPIONs 
can be induced to generate heat when subjected to an alternating magnetic field (AMF). 
  
The aim of the thesis was to test the cancer imaging and therapeutic potential scFv-
functionalised nanoparticles by: (1) Generating scFvs reactive with carcinoembryonic 
antigen (CEA) a cell surface tumour marker. (2) Developing conjugation methods to 
attach the scFv, in functional form, to SPIONs. (3) Evaluating the cellular interaction 
(targeting and specificity) of functionalised SPIONs and (4) Measuring the imaging and 
therapeutic heating effect of the targeted SPIONs.  
 
ScFvs reactive to CEA were generated in Pichia pastoris and conjugation chemistries 
optimised for attachment of purified scFv to SPION surface. Targeting efficacy of the 
scFv functionalised SPIONs was tested by ELISA, cellular uptake, confocal microscopy 
and MRI. Results demonstrated unequivocal CEA-specific  cellular uptake and CEA-
specific MRI, using SPIONs conjugated with Sm3E, a high affinity humanized anti-
CEA scFv. Cellular interaction of the Sm3E-SPIONs was found to be influenced by size 
and surface properties; neutrally charged Sm3E functionalised dextran SPIONs localised 
preferentially  to  the  outside  of  the  cell  membrane,  whilst  negatively  charged  Sm3E 
functionalised PEGylated SPIONs showed evidence of intracellular uptake. The SPIONs 
were shown to be effective generators of heat when exposed to AMF of 150V, 0.74A 
and  1MHz.  AMF  treatment  of  Sm3E-SPION  targeted  cells  was  found  to  induce 
expression of the stress protein HSP70 and lead to hyperthermic cell death in vitro.  
 
These results indicate that scFv-SPION conjugates have potential for selective tumour 
imaging and therapy.    III
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Chapter 1 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   2 
1.1   Cancer 
 
Cancer is one of the major causes of illness and death worldwide. One in 3 people 
will  develop  malignancies  in  their  lifetime,  with  half  the  people  diagnosed  with 
cancer dying within 5 years (cancerresearchuk.org).  Cancer occurs in a wide range 
of tissues with different outcomes. For example, in the UK there are over 200 types 
of cancers, with lung, breast, prostate and colon cancer accounting for the majority of 
deaths (Fig. 1.1).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. The 20 most commonly diagnosed cancers in the UK in 2005 (www.cancerresearchuk.org) 
 
Cancer  arises  from  an  accumulation  of  genetic  and  epigenetic  alterations  within 
proto-oncogenes  and  tumour  suppressor  genes,  which  consequently  leads  to 
disruptions in numerous signalling pathways (Grady & Carethers, 2008; Smith & 
Theodorescu, 2009). The deregulation of these tightly controlled signalling pathways 
causes  a  breakdown  in  the  cell  cycle,  causing  the  cells  to  present  unscheduled 
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proliferation  and  genomic  and  chromosomal  instability,  key  properties  in  the 
transformation of normal cells into cancerous cells (Malumbres, 2009).  
 
The  uncontrolled  proliferation,  further  mutations  and  a  process  of  Darwinian 
evolution allows the development of the primary tumour (Stratton et al., 2009; Klein, 
2009).  Infiltration of cancerous cells from the primary tumour to other organs in the 
body (metastasis) is governed by their ability to leave the primary tumour, invade 
through membranes and tissues, survive in circulation by avoiding immune attack, 
seed at distant organs and eventually establishing themselves in surrounding tissues 
(Smith  &  Theodorescu,  2009;  Joyce  &  Pollard,  2009).  Furthermore,  to  maintain 
growth,  cancer  cells  require  the  capacity  to  initiate  the  formation  of  new  blood 
vessels (angiogenesis) (Hanahan & Weinberg, 2000), providing a constant supply of 
nutrients. Once tumour cells have metastasised and taken over distant organs, they 
become  difficult  to  treat  and  often  results  in  the  patient  mortality  (Klein,  2009). 
Although treatments for cancers are improving, the survival rate has only increased 
by 10% therefore; there is still a great need to develop new therapies.   
 
As normal cells transform into cancerous cells their cell surface properties change, 
showing unique expression or over-expression of certain antigens and receptors. The 
over-expression of these molecules relative to normal cells makes them attractive 
targets for targeted therapies. A number of targets have already been exploited, these 
include: HER2, a mutated epidermal growth factor receptor (EGFR) over-expressed 
on 25% of breast cancers; EGFR1, over-expressed in lung, breast, colorectal, prostate 
and head and neck cancers; CEA (see section: Carcinoembryonic antigen); VEGF 
(vascular endothelial growth factor) a target for angiogenesis; and CD20, CD22 and 
CD52, that are targets for the treatment of lymphoma (Adams & Weiner et al., 2005) 
(see section: Treatment of cancer with antibodies).  
 
1.2 Carcinoembryonic antigen  
 
Gold  and Freedman  first described  CEA in  1965 and thought it to be a specific 
marker for adenocarcinoma (Gold & Freedman, 1965b). They hypothesised CEA to 
only be expressed during embryonic development stages then switched off and only   4 
re-expressed  in  cancerous  tissues  (Gold  &  Freedman,  1965b)  hence  the  name. 
However, subsequent studies have revealed CEA to be up-regulated in 50-70% of all 
human cancer including colorectal, lung, breast and stomach cancer (Bates et al., 
1992; Hammerstrom et al., 1999; Chan et al., 2007), although, the level of CEA 
expression  does  vary  between  cancers  (Chung  et  al.,  1994).  In  addition,  normal 
tissues  have  been  found  to  express  CEA  but  at  a  less  differentiative  level 
(Hammerstrom et al., 1999). 
 
CEA is a highly glycosylated cell surface protein with a MW between 180-200 kDa 
and its carbohydrate content makes up over half of its weight (Kamark et al., 1987;  
Hefta et al., 1988; Takami et al., 1988; Bates et al., 1992). From nucleotide sequence 
analysis it was deduced that CEA contains 668 amino acids residues; containing  a 
leader sequence, an NH2 terminal domain, 3 homologous repeating domains, which 
individually contain 2 immunoglobulin domains (A and B) and a COOH terminal 
domain (Oikawa et al., 1987c; Zimmermann et al., 1988; Hefta et al., 1988; Takami 
et al., 1988; Bates et al., 1992). CEA is anchored to the cancer cell membrane via 
linkage to glycosylphospalidylinositol moiety (Sack et al., 1988; Hefta et al., 1988; 
Takami et al., 1988).  When cleaved by phospholipace C, CEA secretes into the body 
(Sack et al., 1988; Takami et al., 1988). The typical domain structure of CEA is N-
A1-B1-A2-B2-A3-B3-GPI  (Beauchemin  et  al.,  1987;  Thompson  et  al.,  1987; 
Hammarstrom et al., 1999). Sequence analysis has shown CEA to have similarities to 
the variable and constant domains of immunoglobulins, making CEA and the other 
members of the CEA gene family, members of the immunoglobulin super-family 
(Paxton et al., 1987; Berling et al., 1990). 
 
Since the discovery of CEA other antigens have been identified that are structurally 
similar. These include non-specific cross reacting antigen (NCA or CEACAM6) (von 
Kleist et al., 1972; Oikawa et al., 1987b; Thompson et al., 1987; Hefta et al., 1988; 
Neumaier  et  al.,  1988;  Arakawa  et  al.,  1990),  biliary  glycoprotein  (BGP  or 
CEACAM1)  (Svenberg  et  al.,  1976;  Hefta  et  al.,  1988;  Hinoda  et  al.,  1988), 
Pregnancy  specific  glycoprotein  (PSG)  (Khan  et  al.,  1990)  and  faecal  antigen 
(Kamarck et al., 1987). These genes are collectively part of the CEA gene family, at 
present there are approximately 29 characterised gene members (Olsen et al., 1994;   5 
Teglund et al., 1994) and all are on chromosome 19q13.2 (Kamarck et al., 1987; 
Zimmermann et al., 1988; Inazawa et al., 1989). 
 
The  actual  function  of  CEA  in  cancerous  tissues  is  still  un-clear.  Reports  have 
suggested it to have a role in cell differentiation, disruption of cell architecture, cell-
cell adhesion and recognition, promotion of cell survival through release of IL-6 and 
IL-10  and  inhibition  of  caspase  mediated  anoikis  resistance  (Hefta  et  al.,  1988; 
Eidelman et al., 1993; Benchimol et al., 1989; Hostetter et al., 1990; Virji, 2001; 
Ilantzis et al., 2002; Taheri et al., 2003; Chan et al., 2007; Camacho-Leal et al., 
2008). The high expression of CEA in cancerous tissues in addition to its role in 
cancer development makes it an ideal target for imaging and therapy. 
 
1.3 Antibodies and their use in cancer therapy 
 
1.3.1 Antibody structure and function 
  
Antibodies, also known as immunoglobulins (IgG, IgM, IgA, IgE and IgD) exhibit 
exceptional targeting ability and can initiate immune responses crucial in the bodies 
defence against pathogenic organisms and toxins. Due to these properties, antibodies 
have become a desirable molecule for use as a selective cancer therapeutic. The most 
abundant of the immunoglobulins is IgG, generally depicted as a Y shape format 
(Fig. 1.2), it is the main immunoglobulin structure used in the design of therapeutic 
antibodies. 
 
Antibodies were first identified in 1939 by Kabat and Tiselius (Tiselius et al., 1939). 
Subsequently, their structure was discovered by Porter and Edelman in the 1950s 
(Edelman 1958; Porter, 1958). The basic antibody structure consists of two identical 
light chains (L) of approximately 250 residues and two identical heavy chains (H) of 
approximately 450 residues (Porter et al., 1962; Edelman et al., 1975). These four 
chains  are  held  together  by  covalent  disulphide  bridges  and  non-covalent  forces 
(Edelman 1973). Within the first 110 amino acids of the L and H chain there are 
large  variations  between  immunoglobulins,  this region  was  therefore  denoted  the 
variable region (V) and constitutes the antigen-binding site of the immunoglobulin   6 
(Riechmann et al., 1988; Skerra & Pluckthun, 1988). The variation in amino acid 
sequence allows for different binding specificities, creating a diverse population of 
antibodies.  
 
The  basic  IgG  format  can  be  de-associated  into  two  fragments  via  proteolytic 
cleavage by papain digestion (Porter, 1958). The first fragment, known as the Fab 
fragment consists of the VL-CL and the first two domains of the heavy chain VH-CH1. 
The Fab region is primarily involved in the antigen binding property of the antibody. 
The second fragment is the Fc fragment, which contains the rest of the constant 
heavy chains CH2-CH3 (Fig. 1.2). The Fc domain is responsible for maintaining the 
structure of the IgG, as well as initiating the biological effector function (Tao & 
Morrison, 1989; Krapp et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. Schematic diagram of the structure of immunoglobulins IgG shows it consists of two 
identical  heavy  chains  and  two  identical  light  chains.    The  heavy  chain  consists  of  four 
domains, VH, CH1, CH2, and CH3, a flexible hinge region separates the CH1 and CH2 domains 
of the heavy chain. The light chain consists of only two domains, VL and CL. The heavy and 
light  chains  are  linked  together  through  a  disulphide  bridge  formed  between  a  cysteine 
residue in the hinge region and the C-terminal  cysteine on the light chain. Carbohydrate 
chains (CHO) are attached to the CH2 group. 
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Characterisation of the Fab fragment by sequence analysis revealed the difference in 
the amino acid sequence within the V domains to be confined to six regions, 3 within 
the VH and 3 within the VL. These regions are termed the hypervariable regions, also 
known as complementarily determining regions (CDRs). The CDRs are responsible 
for the antibodies vast array of antigen binding specificity (Wu & Kabat, 1970). The 
region within the VH and VL chains where there is less amino acid variation is termed 
the framework regions. The conserved sequence in the framework region forms a β 
sheet structure, which acts as a scaffold to the three hypervariable loops within the 
VH and VL regions. The rest of the Fab arm contains the CH and CL regions, these 
have a number of roles including: assisting in the antigen interaction, increasing the 
maximum rotation of the Fab arms and holding the VH and VL chains together by an 
inter-chain disulfide bond.  
  
Further sequence analysis found the light chain family to consist of two basic amino 
acid sequences denoted lambda (λ) and kappa (κ); a single antibody can only contain 
one type of light chain (Cook & Tomlinson, 1995; Tonegawa, 1983). In comparison, 
the heavy chain family contains five different amino acid sequences, with each of 
these isotypes being denoted  , δ, γ, ε and α. The five different heavy chain isotypes 
gives rise to the five different subgroups of immunoglobulins, IgM ( ), IgD (δ), IgG 
(γ),  IgE  (ε)  and  IgA  (α),  which  ultimately  determines  the  function  of  the 
immunoglobulin. The length of the isotypes amino acid sequence also varies, with δ, 
γ and α having 330 amino acids, which constitutes three C regions CH1, CH2, CH3 
and a hinge region. Where as, the isotypes   and ε have 440 amino acids, constituting 
four C regions CH1, CH2, CH3 and CH4 and no hinge region. The hinge region is a 
flexible proline rich region, found between the CH1 and CH2 domain, giving the Fab 
arm extra flexibility when binding to antigens (Harris et al., 1997).    
 
The  understanding  of  how  diverse  antibodies  are  produced  in  vivo  through 
combinational  rearrangement  (Tonegawa,  1983)  and  somatic  hypermutations 
(Neuberger, 2008), has allowed the development of genetic engineering technology 
(Hoogenboom  et  al.,  2005).  Antibody  engineering  has  advance  at  a  fast  rate; 
enabling the generation and construction of large-scale amounts of high specificity 
and affinity monoclonal antibodies to be produced, for diagnostic and therapeutic 
applications.    8 
1.3.2 Hybridoma technology 
 
The concept of antibody-targeted therapeutics took momentum in the 70s, with the 
development of hybridoma technology in 1975 by George Kohler and Cesar Milstein 
(Kohler et al., 1975). This development was a massive step forward in Paul Ehrlich 
vision of the “magic bullet” (Strebhardt & Ullrich, 2008). The progress of hybridoma 
technology paved the way for the mass production of monoclonal antibodies (mAbs) 
that react with specific antigens. Hybridoma technology makes use of B cells clones, 
that produce antibodies specific for a single epitope, fused to immortalised myeloma 
cells  (malignant  plasma  cells)  to  form  hybridomas  (B  cell  /  myeloma  hybrids) 
(Kohler et al.,1975). These hybridomas can grow continuously, secreting the specific 
antibody, in large quantities against virtually every antigen.  However, owing to their 
murine  origin  the  development  of  effective  mAb  based  therapeutics  has  proved 
difficult.  Murine  antibodies  when  used  in  humans  induce  human  anti  mouse 
antibodies (HAMA) response (Tjandra et al., 1990; Mountain et al., 1992), resulting 
in  accelerated  clearance  of  mAbs  and  therefore  lower  efficacy  of  treatment.  In 
addition, murine mAbs are also poor recruiters of effector functions (Adams et al., 
2005). 
 
1.3.3 Humanisation 
 
To overcome the immunogenicity murine mAbs presents, chimeric and humanised 
mAbs were genetically engineered. The generation of chimeric mAbs involves fusing 
all of the murine variable regions into the human IgG framework (Boulianne et al., 
1984; Colcher et al., 1998). In comparison, humanisation of mAbs only involves 
grafting of the murine CDR regions into the human IgG framework (Fig. 1.3) (Jones 
et al., 1986; Adams et al: 2005). These advances in antibody engineering have led to 
the development of a number of therapeutically promising mAbs pre-clinically and 
clinically.  
   9 
 
      Human           Humanised                       Chimeric 
 
Fig. 1.3. Schematic image of a fully human IgG, a humanised IgG, where the CDR regions are of 
mouse origin and a chimeric IgG, where the variable domains are of mouse origin.  
 
 
1.3.4 Treatment of cancer with antibodies 
 
1.3.4.1 Non-conjugated mAbs 
 
The first mAb to gain FDA approval for the treatment of cancer was Rituximab in 
1997,  a  chimeric  mAb  for  the  treatment  of  B-cell  non-hodgkin’s  lymphoma. 
Trastuzumab,  in  1998,  a  humanised  mAb  for  the  treatment  of  HER2  expressing 
breast cancer, quickly followed. Since then 2 more humanised mAbs, Alemtuzumab 
for  chronic  lymphocytic  leukaemia  and      Bevacizumab  for  colorectal  cancer,  1 
chimeric  mAb,  Cetuximab  for  colorectal  cancer  and  1  fully  human  mAb, 
Panitumumab also for the treatment of colorectal cancer have received FDA approval 
(Table 1.1)  (Magdelaine-Beuzelin et al., 2007).  
 
The mechanisms of action of these FDA approved mAbs are still under investigation, 
but  are  likely  to  act  in  multiple  ways  (Adams  &  Weiner  2005).  Reports  have 
suggested  Rituximab,  Cetuximab,  Tastuzamab  and  Alemtuzumab  are  involved  in 
mediating  antibody  dependent  cellular  cytotoxicity  (ADCC).  (Adams  &  Weiner 
2005; Arnould et al., 2006; Frieze et al., 2006; Golay et al., 2006; Nahta et al., 2006; 
Magdelaine-Beuzelin et al., 2007). In addition, complement dependent cytotoxicity 
(CDC)  has  been  found  to  play  a  significant  role  in  the  therapeutic  effect  of 
Rituximab (Di et al., 2003; Adams et al., 2005; Golay et al., 2006), showing reduced 
toxicity in C1q knock out mice (Golay et al., 2006). Another mechanism of action is   10 
the  inhibition  of  signalling  pathways  and  angiogenesis.  Anti  EGFR  mAbs 
Cetuximab,  Trastuzumab  and  Panitumumab  have  been  reported  to  be  potent 
inhibitors of a number of downstream signalling pathways (Adams & Weiner 2005; 
Arnould  et  al.,  2006;  Frieze  et  al.,  2006;  Nahta  et  al.,  2006);  thus  ultimately 
inhibiting  tumour  growth  (Jean  et  al.,  2008;  Capdevila  et  al.,  2009).  Where  as 
Bevacizumab  targets  and  blocks  vascular  endothelial  growth  factors  (VEGF), 
preventing the proliferation of new tumour blood vessels (Sharkey et al., 2006).  
 
 
Table 1.1 FDA approved recombinant mAbs currently used in the treatment of 
cancer. 
Non conjugated 
mAbs 
Format  Target  Main indication  Date of FDA 
approval 
Rituximab 
(Mabthera®) 
 
Chimeric  CD-20  Treatment of non-
hodgkins lymphoma 
26
th Nov 1997 
Trastuzumab 
(Herceptin®) 
 
Humanised  EGFR2 
/HER2 
Metastatic breast 
cancer 
25
th Sept 1998 
Alemtuzumab 
(MabCampath®) 
Humanised  CD-52  B cell chronic 
lymphocytic 
leukaemia  
5th July 2001 
Cetuximab 
(Erbitux®) 
Chimeric  EGRF 
/HER1 
Treatment of 
advanced colorectal 
cancer 
12
th Feb 2004 
Bevacizumab 
(Avastin®) 
 
Humanised  VEGF  Colorectal cancer  26
th Feb 2004  
Panitumumab 
(Vectibix®) 
 
Fully Human  EGFR  Metastatic colorectal 
cancer 
27
th Sept 2006 
 
 
 
More recently, in April 2009 a mouse/rat mAb Catumaxomab gained EU approval 
(www.trionpharma.de). Catumaxomab is a bi-specific trifunctional mAb with two 
different antigen-binding sites, binding the epithelial cell adhesion molecule antigen 
(Ep-CAM) on tumour cells and CD3 on T lymphocytes (Sebastian et al., 2009). The 
intact  Fc  region  provides  a  third  functional  binding  site;  binding  and  activating 
immune effector cells leading to specific tumour cell kill (Sebastian et al., 2009). 
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Despite the early success of antibody therapeutics, they are yet to be curative and are 
generally used in combination with chemotherapy regimes (Sharkey et al; 2006). 
Promising  results  have  been  demonstrated  with  Rituximab  in  combination  with 
chemotherapy,  showing  improvements  in  response  rate,  time  to  progression  and 
event-free survival, similar results were was also reported for Trastuzumab (Sharkey 
et al; 2006).  
 
1.3.4.2 Immunoconjugates 
 
To improve the therapeutic potency of mAbs, immunoconjugates, where antibodies 
are  linked  to  cytotoxic  drugs,  toxins,  cytokines  or  radionuclides,  have  been 
developed. So far, three immunoconjugates have received FDA approval (Table 1.2).  
 
Table 1.2 FDA approved Immunoconjugates currently used in the treatment of 
cancer. 
Immunoconjugates 
 
 
Format  Target  Main indication  Date of FDA 
approval 
Gemtuzumab 
(Mylotarg) 
Humanised 
conjugated 
with 
calicheamicin 
CD33  Acute myeloid 
leukemia 
May 2000 
Ibrutumomab 
tuixetan (Zevalin) 
Murine 
conjugated to 
90Y 
CD20  B-cell non-Hodgkin 
lymphoma 
Feb 2002 
Tositumomab 
(Bexxar) 
Murine 
conjugated to 
131I 
CD20  Non-hodgkin 
lymphoma 
June 2003 
 
 
The  first  immunoconjugate  to  gain  FDA  approval  for  cancer  treatment  was  the 
antibody drug conjugate Gemtuzumab ozogamicin (GO). GO is a humanised anti 
CD-33  mAb  linked  to  the  anti  tumour  antibiotic  calicheamicin,  a  potent  DNA 
binding agent (Tsimberidou et al., 2005; Wu et al., 2005). The overall response rate 
of GO has been reported to be 30% (Wu et al., 2005).  
 
The other two immunoconjugates to have FDA approval are radioimmunotherapies 
(RAIT),  Yttrium-90  ibritumomab  tiuxetan  (Zevalin)  and  Iodine-131  tositumomab 
(Bexxar). Both are specific for the CD-20 surface antigen expressed on over 90% of   12 
B cell lymphomas and have shown an overall response rate of 60-80% (Lemieux et 
al., 2005; Pohlman  et al., 2006). Yttrium-90, used in Zevalin RAIT is a pure β-
emitter linked to ibritumomab mAb by the chelator tiuxetan and has a half life of 2.7 
days.  The  advantage  of  using 
90Y  β  particles  is  its  long  path  length  making  it 
effective against tumours with heterogeneous or low distribution of antigens enabling 
delivery  bystander  effects,  killing  directly  targeted  cells  as  well  as  neighbouring 
tumour cells (Wu  et al., 2005). On the other hand, Iodine-131 used in Bexxar RAIT 
emits β particles with a shorter path length, making this therapy more appropriate for 
diseases where there is minimal residual (Lemieux  et al., 2005).  
 
Another  form  of  targeted  therapy  is  antibody  directed  enzyme  pro-drug  therapy 
(ADEPT).  This  form  of  therapy  was  designed  by  Bagshawe  and  Senter  in  1988  
(Bagshawe et al., 1988; Senter et al., 1988; Senter, 1990; Bagshawe et al., 1995). 
Principally  ADEPT  involves  a  three-step  approach.  Firstly,  the  mAb-enzyme 
conjugate is administered intraveneously, the mAb targets and localises the enzyme 
at the tumour site. When the mAb-enzyme is cleared from the plasma a non-toxic 
prodrug is administered. This pro-drug is processed by the pre-localised enzyme, 
causing a potent cytotoxic agent to be produced only at the tumour site, which in turn 
causes cell death.  Its short half-life allows for occurrence of a bystander effect; thus 
minimising the killing of more distantly located healthy cells. 
 
Though mAb therapy has shown some success, its effectiveness has been limited due 
to poor tumour penetration (due to size), long circulatory half-life (increasing their 
toxicity to other tissues) and immunogenecity (HAMA response and activation of 
unwanted  immune  effector  functions).  These  limiting  factors  are  presently  being 
addressed through advances in recombinant antibody engineering.  
 
1.4 Recombinant antibody technology 
 
1.4.1 Phage display 
 
Progress  in  technologies  such  as  the  polymerase  chain  reaction  (PCR),  bacterial 
expression  systems  and  DNA  manipulation,  cloning,  expression  and  selection   13 
systems  has  enabled  the  development  and  use  of  phage  display  libraries.  Phage 
display  libraries  can  be  used  to  engineer  customised  humanised  antibodies  with 
defined  affinity,  specificity  and  less  immunogenic,  bypassing  the  need  to  make 
hybridomas (Winter et al., 1994; Mao et al., 1999; Nilsson et al., 2000). Antibody 
Phage display was first described in 1985 by George Smith and largely mimics the in 
vivo  process  of  antibody  generation  (Smith,  1985).  Phage  display  involves  the 
presentation of a library of peptides on the surface of filamentous phage, by fusing 
the peptide gene to the phage genome. Affinity selection of peptide-phage by binding 
to an antigen (panning), elution of bound peptide-phage, several rounds of selection 
and  re-amplification  of  the  selected  peptide-phage,  generates  a  large  amount  of 
specific antibodies (McCafferty et al., 1990). Phage technology is far more efficient 
in producing antibodies than hybridoma technology. So far, naïve scFv chain and 
Fab libraries have been generated with a diversity of over 10
10 clones (Sblattero & 
Bradbury,  2000;  Hoogenboom,  2005).  At  present  one  human  antibody  “Humira” 
generated  by  phage  display  has  been  FDA  approved.  Humira  is  an  anti  TNFα 
antibody used in patients with arthritis and is currently in phase 2/3 clinical trials for 
other applications (Hoogenboom, 2005). 
 
The selection of an antibody phage library can be done using cells, tissue sections, 
immune  sera  or  live  animals  (George  et  al.,  2003),  but  usually  purified  or 
recombinant antigens are used to enable conditions to be controlled and minimise 
non-specific binding (Yip et al., 2002; Hoogenboom, 2005). The antibodies selected 
from a phage display library are generally more amendable to genetic engineering 
and can be further modified via chain shuffling, error prone PCR or CDR centred 
mutagenesis to create higher affinity binding antibodies (Yip et al., 2002).  
 
Ribosomal display is another library system used for the selection of proteins and 
peptides. Ribosomal selection technology is performed entirely in vitro and therefore 
offers  two  main  advantages;  firstly,  diversity  is  not  limited  by  transformation 
efficiency  and second, random mutations can be  introduced  easily  (Zahnd  et  al., 
2007). Yeast display using Saccharomyces cerevisiae has also shown promise as a 
selection platform and has enabled the selection of high affinity antibodies (Boder et 
al., 2000). 
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1.4.2 Recombinant antibody fragments 
 
The development of phage library technology has made possible the generation of 
recombinant  antibodies  with  different  binding  affinities,  kinetics,  and  biophysical 
properties.  Library  technology  has  also  made  it  easier  to  generate  a  variety  of 
antibody fragment formats, including Fab, scFv and VH domains. Whole antibodies 
have shown excellent target binding specificity, however, their long blood half life 
results in poor contrast in imaging applications and their ability to initiate effector 
functions can lead to toxic effects, preventing repeat administration (Holliger et al; 
2005). Studies in recombinant antibody fragments have become increasingly more 
popular for their use in therapeutic and diagnostic application. Firstly, because of the 
ease and cost effectiveness in producing them, they are able to be expressed at high 
yields in a variety of hosts such as bacteria, yeast and plant (Worn et al., 2001) and 
secondly their size.  Fab, scFv and V domain fragments are 55 kDa, 27 kDa and 15 
kDa respectively, compared to a whole antibody of 150 kDa. This smaller size can be 
advantageous  in  imaging  applications  since  these  molecules  are  below  the  renal 
threshold and consequently are rapidly cleared via the kidneys. This in contrast to 
mAbs, where the tumour to blood ratio is a limiting factor in the use of mAbs as 
imaging tools (Adams et al., 1999).  
 
1.4.2.1 Fab 
 
Fab  fragments are attractive platforms for  antibody-based therapies. So far, three 
have  received  FDA  approval,  however  not  for  cancer  indications  (Nelson  et  al., 
2009). Fabs are made up of the antigen binding VH and VL domains bound to CH1 
and CL chains (Fig. 1.2 and 1.4). A disulphide bond covalently holds both chains 
together.  Although  Fab  fragments  express  well  in  bacteria,  the  presence  of  two 
chains can make genetic manipulation and large-scale production difficult (Carter et 
al., 1992; Skerra, 1993). Recently, the single chain Fab (scFab) antibody format has 
been  developed,  which  has  been  successfully  produced  in  E.coli,  Bacillus 
megaterium and Pichia pastoris (Hust et al., 2007; Jordan et al., 2007). The scFab is 
composed of the VH-CH1 and VL-CL domains connected by a 34 amino acid linker 
and combine the advantages of scFv and Fab fragments. 
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1.4.2.2 ScFv 
 
Single  chain  Fv  (27kDa)  (Fig.  1.4)  currently  account  for  53%  of  recombinant 
antibody  fragments  being  taken  through  the  clinical  pipeline,  dominating  mAb 
fragment clinical development (Nelson et al., 2009). ScFvs consist of 1 VH and 1 VL 
domain held together by a flexible, polypeptide linker (Huston et al., 1988, Bird et 
al., 1988). The choice of linker can affect the solubility, expression and stability of 
the scFv. The most common linker used is the (Gly4Ser)3 motif (Huston et al., 1988), 
due to its flexibility, neutral charge and solubility (Turner et al., 1997; Kortt et al., 
2001). However, other linkers have been investigated (Bird et al., 1988; Pantoliano 
et al., 1991; Whitlow et al., 1993; Tang et al., 1996; Deonarain et al., 1997; Turner 
et al., 1997; Hennecke et al., 1998).  
 
Due to the size and ability to retain the specific antigen binding affinity of the parent 
IgG  (Holliger  &  Hudson  2005),  scFvs  are  ideal  platforms  for  antibody-based 
therapies. In addition, they are readily obtained to virtually any target using phage 
display  libraries  and  recombinant  antibody  technology  and  furthermore,  can  be 
generated  for  clinical  use  to  high  yields  in  non-mammalian  expression  systems 
(Tolner et al., 2007). 
 
1.4.2.3 Domain antibodies 
 
Domain antibodies (VH and VL) (Fig. 1.4) are 11kDa-15kDa is size and were first 
isolated in the late 1980’s by phage display (Ward et al., 1989). In the past, murine 
and  human  VH  domains  exhibited  low  binding  affinity  to  their  target  antigen. 
Furthermore, they were generally unstable, with tendencies to aggregate in vivo due 
to  exposed  hydrophobic  areas  (Ward  et  al.,  1989;  Muyldermans  et  al.,  2001). 
However, the discovery of two types of organisms, Camelids and Cartilaginous fish, 
such as sharks, that can generate antibodies devoid of light chains, has heightened 
interest in this area (Hamers-Casterman et al., 1993). From sequence and structural 
analysis of these heavy domain VHH antibodies from Camelids (also referred to as 
nanobodies®) (Harmsen & De Haard, 2007) and sharks (V-NAR); extension of the 
CDR  loops  is  thought  to  compensate  for  the  absence  of  the  light  chains 
(Muyldermans et al., 1994). In comparison to the murine and human VH domain, the   16 
VHH domains are produced with good solubility and thermo-stability, attributed to 
four highly conserved hydrophilic mutations (Holt et al., 2003; Jesper et al., 2004). 
Through replacement of these residues (camelisation) and a further five framework 
substitutions,  increase of  CDR  length and  diversity, the solubility of murine and 
human  VH  domains  have  improved  (Holt  et  al.,  2003).  Furthermore,  it  is  also 
possible  to  isolate  VL  domains  from  VL  libraries,  generated  by  DNA  shuffling 
techniques  (Van  den  Beucken  et  al.,  2001).  Due  to  the  size,  domain  antibodies 
(dAbs) are especially effective for targeting enzyme active-site clefts (Holt et al., 
2003) and cryptic viral epitopes (Stijlemans et al., 2004), unattainable by classical 
antibodies. Advancements in the knowledge of dAbs has enabled the selection of 
high specificity and affinity dAbs from phage display libraries (Holt et al., 2003; 
Dufner et al., 2006).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1.4.  Schematic  diagram  of  genetically  engineered  antibody  constructs.  Include 
monovalent antibody fragments Fab, scFv and V domain (in this image the VL is depicted)  
Symbols used: Ag, antigen. 
 
Due  to  their  small  size,  Fabs,  scFvs  and  dAbs  are  able  to  diffuse  and  penetrate 
through solid tumours easily. Thus, allowing rapid delivery of toxins, potentially 
making them more effective at tumour destruction (Yokota et al., 1992; Adams et al., 
2000;  Fang  et  al.,  2003).  However,  their  monovalency  leads  to  issues  of  fast 
dissociation rates and modest retention times on the antigen (Adams et al., 1998; 
Yokota et al., 1992; Nielsen et al., 2000; Holliger et al., 2005; Huang et al., 2006). 
Work  is  ongoing  to  overcome  these  limitations,  with  strategies  to  improve  the   17 
retention  time  by  affinity  maturation  and  modification  of  size,  through  fusion  to 
toxins  (Kreitman  &  Pastan,  1998),  enzymes  (Michael  et  al.,  1996;  Bhatia  et  al., 
2000; Kousparou et al., 2002), cytokines (Scherf et al., 1996; Cooke et al., 2002; 
Kaspar et al., 2007), drugs (Sun et al., 2003), liposomes (Park et al., 2002; Weng et 
al., 2008), polyethylene-glycol (Lee et al., 1999; Yang et al., 2003; Kubetzko et al., 
2006) and albumin (Holt et al., 2003).   
 
1.4.2.4 Multivalency 
 
Improving the retention time by increasing the valency of Fabs, scFvs and dAbs, 
through multimerisation, is also under investigation (Adams et al., 1999; Nielsen et 
al., 2000; Todorovska et al., 2001). Spontaneous multimerisation can be encourage 
through linker shortening, forcing V domains to pair with complementary domains of 
another scFv (Atwell et al., 1999; Adams et al., 2000; Dolezal et al., 2000; Kortt et 
al., 2001). However, bio-stability issues have been reported, with these multimers 
dissociating into their monomeric forms in vivo (FitzGerald et al., 1997; Huang et 
al.,  2006).  A  more  stable  method  to  generate  diabodies  is  through  genetically 
engineering a cysteine residue onto the terminal end of the scFvs. The availability of 
a free cysteine allows formation of a disulphide bond that covalently cross-links the 
VL and VH domain, creating a stable diabody (FitzGerald et al 1997; Huang et al., 
2006). 
 
Increasing the valency of scFvs can increase its avidity to target antigens therefore, 
encouraging more scFv to be taken up by the tumour and retained thus, improving its 
therapeutic efficacy (Pluckthun et al., 1997).  
 
1.5 Anti CEA scFv MFE-23 and Sm3E  
 
The recombinant antibody fragments investigated in this thesis are the scFvs MFE-23 
and  its  humanised  variant  Sm3E.  Both  scFvs  are  directed  against  the 
carcinoembryonic antigen (CEA) (see section: Carcinoembryonic antigen), binding 
predominantly to the N and A1 (N-A1) domains of CEA (Boehm et al; 2000; Sainz-
Pastor et al., 2006).    18 
MFE-23 is a murine scFv and was the first scFv to be tested in the clinic, showing 
effective  targeting  of  CEA  expressing  colorectal  carcinoma  for  radio-
immunodetection (Begent et al., 1996) and radio-immunoguided surgery  (Mayer et 
al., 2000).  MFE-23  has also  been  used as the targeting arm in antibody-directed 
prodrug  therapy  (ADEPT),  which  has  recently  undergone  phase  I  clinical  trial. 
(Bagshaw et al., 1995; Sharma et al., 2005; Mayer et al., 2006). 
 
MFE-23 was produced from a phage display library made up of anti CEA scFvs, 
constructed  from  variable  region  genes  extracted  from  CEA  immunised  mice 
(Chester et al., 1994). Selection conditions favoured high affinity scFvs with MFE-
23 having a binding affinity of kD 2-4nM (Chester et al., 2000b).  
 
Through  knowledge  of  the  crystal  structure  (Boehm  et  al.,  2000),  MFE-23  was 
humanised to improve its therapeutic potential, reducing the possibility of HAMA 
responses and allowing repeat administration of the scFv.  Boehm et al., found MFE-
23 to be structurally similar to the human TR1.9 antibody (Boehm et al., 2000). This 
understanding led to the humanisation of the Fv framework by replacing the residues 
as mentioned in Boehm et al with the corresponding residues in the human TR1.9 
antibody  (Graff  et  al.,  2004).  The  humanised  version  of  MFE-23  termed  hMFE 
showed no change in its CEA immunoreactivity with a dissociation constant of kD = 
8.5nM  (Graff  et  al.,  2004).  Further  genetic  manipulation  of  hMFE  increased  its 
tumour retention time and  stability. Studies  by  Graff and Wittrup  found that the 
dissociation  rate  constant  (koff)  is  an  important  factor  in  the  tumour  retention  of 
antibodies (Graff & Wittrup, 2003). Two rounds of mutagenesis were performed to 
improve the affinity of hMFE. The first round of affinity maturation involved error 
prone PCR to produce variants with 10-100 fold improvement in off rates, the second 
round involved random mutagenesis and DNA shuffling to produce variants with up 
to a 1000 fold binding improvement. The affinity matured variant m3E was found to 
be the most promising clone with a koff = 1x10
-6 s
-1 and a dissociation half-life of 
several days at 37
0C, compared to that shown by the original hMFE of 10 min (Graff 
et al., 2004). However, the excellent binding affinity seen with these mutant variants 
came  with  the  problem  of  poor  expression,  which  correlates  with  poor  stability. 
Further improvement on these affinity-matured variants was achieved by stability 
maturation,  involving  4-5  mutations  within  the  VL  domain.  After  addressing  the   19 
humanisation,  affinity  and  stability  of  MFE-23  by  genetic  engineering  the  scFv 
Sm3E was produced (Graff et al., 2004). The Sm3E scFv has exceptional properties 
with a dissociation constants of 30pM, effectively irreversible binding to CEA. In 
addition, Sm3E showed a 100-fold increase in expression compared to hMFE, with a 
solubility of 8 mg/l compared to 0.08 mg/l (Graff et al., 2004). 
 
The  experiments  in  this  thesis  investigate  the  development  of  a  new  immuno-
conjugate, using the MFE-23 and Sm3E scFv conjugated to superparamagnetic iron 
oxide nanoparticles (see section: Superparamagnetic iron oxide nanoparticles), for 
dual application in cancer imaging (see section: Application of SPIONs in MRI) and 
therapy (see section: Application of SPIONs in hyperthermia). 
 
1.6 Superparamagnetic iron oxide nanoparticles (SPIONs) 
 
SPIONs are small nanomaterials consisting of iron oxide core crystals surrounded by 
a stabilising polymer or polysaccharide shell (Thorek et al., 2006). The two most 
commonly  studied  iron  oxides  have  been  magnetite  (Fe3O4)  and  maghemite  (g-
Fe2O3) (Gupta et al., 2005b). There are a number of different chemical methods for 
synthesizing  SPIONs  (Peng  et  al.,  2008).  The  most  reported  approach  is  by  co-
precipitation of Fe2+ and Fe3+ chloride, at pH 9-14, under non oxidising conditions 
(Gupta et al., 2005b; Peng et al., 2008). The balance of these requirements pH, type 
of salt, Fe2+ and Fe3+ ratio and ionic strength are reported  to control the shape, size 
and composition of the SPIONs (Gupta et al., 2005b). 
 
Due to their magnetic properties SPIONs have been extensively used in a number of 
bioapplications including magnetic drug and gene delivery (McBain et al., 2008), 
tissue repair, cell separation (Gupta et al., 2005), magnetic resonance imaging (MRI) 
(see  section:  Application  of  SPIONs  in  MRI)  and  magnetic  fluid  hyperthermia 
(MFH) (see section: Application of SPIONs in hyperthermia).  
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1.6.1 Stabilising coating 
 
SPIONs have a large surface area, are hydrophobic and at neutral pH have an iso-
electric point of zero this can lead to stability issues including agglomeration of the 
particles and eventual precipitation (Gupta et al., 2005b). For SPIONs to be used in 
biological  situations  they  are  required  to  be  soluble  in  physiological  solutions. 
Therefore, to prevent destabilisation due to particle-particle interaction, coating of 
the particles is essential, with the most common being dextran (Gupta et al., 2005b). 
 
1.6.1.1 Adsorption of dextran  
 
Dextran is a hydrophilic and neutrally charged polysaccharide consisting of glucose 
residues with α-1.6 linkages (Fig. 1.5.). Particles are generally embedded in a matrix 
of dextran, preventing interaction with neighbouring particles (Moore et al., 1997; 
Mornet  et  al.,  2004).  The  dextran  coat  has  shown  to  considerably  improve  the 
stability of particles at neutral pH. Another advantage of dextran is that it is non-
toxic and biodegradable. When taken up by cells the SPIONs accumulate within the 
lysosomes, and are eventually broken down, causing no detrimental affect to the cells 
(Okon et al., 1994; Thorek et al., 2006). Dextran is already used for stabilisation of 
the FDA approved SPIONs Endorem® EU (Ferridex USA; Guerbet/Berlex lab) and 
Resovist®  (Schering  AG),  furthermore,  Sinerem  EU  (Combidex  USA; 
Guerbet/Advance  Magnetics),  which  is  currently  in  phase  III  trial  (see  section: 
Application of SPIONs in MRI for more detail on these SPIONs).  
 
1.6.2 Stealth coatings 
 
SPIONs are rapidly cleared from the blood by the reticuloendothelial system (RES), 
accumulating mainly in the liver and spleen (Mornet et al., 2004). This happens very 
fast,  in a  matter  of minutes.  In some cases, it is a requirement that  the  SPIONs 
accumulate in organs of the RES, referred to as passive targeting (Mornet et al., 
2004). However, to enable SPIONs to reach other organs or tissues evasion of the 
RES is an important requirement. This can be achieved by preventing or reducing 
opsonisation of the SPIONs, thus delaying recognition by the RES and increasing 
blood circulation times. A number of reports have demonstrated that SPIONs with   21 
hydrophilic coating and a hydrodynamic diameter below 100nm show reduced levels 
of opsonisation (Tiefenauer et al., 1996; Gaur et al., 2000; Brannon-Peppas et al., 
2004; Gupta et al., 2005b; Mornet et al., 2004). The literature however, is quite 
conflicting on whether dextran can reduce opsonisation and RES recognition (Berry 
et al., 2004; Moore et al., 2000). Two other coatings investigated for stealth include 
liposomes and polyethylene glycol.  
 
1.6.2.1 Incorporation into liposomes 
 
Liposomes, are made up of a phospholipid bilayer membrane (Fig. 1.5) and were 
first  proposed  as  drug  carriers  in  cancer  chemotherapy  by  Gregoriadis  et  al. 
(Gregoriadis et al., 2008). Much research  has now gone  into encapsulating toxic 
drugs such as doxorubicin into non-toxic liposomes (Park et al., 2002; Cattel et al., 
2004). As drug delivery vehicles, liposomes prevent the toxicity of the drug affecting 
healthy tissues until it reaches its target site, upon where the drug is released. Shinkai 
et al has reported on the development of magnetoliposomes consisting of a magnetite 
core  coated  in  phopholipids  phosphatidylcholine  and  phophatidylethanolamine, 
results showed good aqueous stability (Shinkai et al., 1996b) but poor RES evasion 
(Yanase  et  al.,  1998b).  In  addition,  studies  have  reported  that  liposome  coated 
SPIONs are open to the same RES fate as naked or dextran coated SPIONs, so only a 
proportion of the injected drug reaches the target (Sofou et al., 2004).  
 
1.6.2.2 Addition of polyethylene glycol chains 
 
Synthetic polymers such as polyethylene glycol, polyethylene oxide and poloxamers 
are being used to generate a new family of stealth particles (Brigger et al., 2002; 
Berry et al., 2003). PEGylation was first applied to liposomes to increase their blood 
half-life, studies found that PEG could increase blood residency from seconds to hrs 
(Panagi et al., 2001; Gabizon et al., 2001; Shmeeda et al., 2009). PEG has also been 
used  in  a  number  of  FDA-approved  biotherapeutics  (Bailon  et  al.,  2009).  
Polyethylene glycol polymers are non-immunogenic and can be absorbed onto either 
unmodified, dextran or liposome stabilised particles, giving a brush like affect (Gref 
et al., 2000). The PEG chains sterically prevent plasma proteins attaching to the 
particles,  reducing  opsonisation  and  therefore  increasing  blood  circulatory  times   22 
(Zhang et al., 2002; Berry et al., 2003). Absorption of PEG chains has shown the 
most promise in delaying clearance to the RES (Park et al., 2002; Owens et al., 
2006) however, complete RES evasion is still proving difficult. Another property 
exerted  by  PEG  is  its  ability  to  encourage  internalisation  by  membrane  fusion, 
increasing  the  cellular  uptake  of  cytotoxic  drugs  or  particles  in-vitro  and  thus 
enhancing their detrimental affect to the cells (Yamazaki et al., 1990; Lentz et al., 
1999; Zhang et al., 2002; Gupta et al., 2004). 
 
1.6.3 Surface functionalisation  
 
Cell  uptake  of  SPIONs  can  be  encouraged  by  surface  functionalisation  with  a 
targeting  moiety.  Coupling  of  SPIONs  to  ligands  specific  for  receptors  over-
expressed  on  cancers  cells  has  been  successfully  demonstrated  with  transferrin 
(Kresse et al., 1998) and luteinizing hormone releasing hormone (LHRH) (Zhou et 
al.,  2006;  Leuschner  et  al.,  2006).  Antibodies  and  more  recently  recombinant 
antibody fragments have also demonstrated the ability to enhance selective SPION 
uptake into cancer cells in vitro and in vivo (Weissleder et al., 1992; Tiefenauer et 
al., 1993; Suzuki et al., 1996; Suwa et al., 1998; Shinkai et al., 2001; Artemov et al., 
2003; Funovic et al., 2004; Toma et al., 2005; Reynolds et al., 2006; Zhou et al., 
2007; Natarajan et al., 2008; Yang et al., 2009). 
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As coating on SPION      Chemical Structure 
 
A.  Dextran 
 
 
 
 
B.  Liposome  
 
 
 
 
 Phosphatidyl ethanolamine 
 
C. Polyetheylene glycol 
 
 
Fig.  1.5  Chemical  structure  and  schematic  representations  of  A)  Dextran,  B)  Liposome 
(Phosphatidylcholine and phosphatidylethanolamine) and C) Polyethelene glycol (Adapted 
from Mornet et al., 2004). 
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1.7 Magnetic resonance imaging 
 
Magnetic Resonance imaging (MRI) was first developed in 1973 and used mainly for 
brain and spinal cord imaging. Due to the signal to noise ratio caused by breathing 
and other movements, MRI could not be used to image below the abdomen (Wallis et 
al., 1999). Over the last 5 years, MRI technology has advanced considerably, with 
the  development  of  faster  imaging  sequences,  improved  gradient  and  magnet 
designs, advanced transmit and receiver coils and recently contrast enhancing agents. 
This has allowed for higher quality hepatic and abdominal images, enhancing its 
diagnostic potential. 
 
The  MRI  imager  consists  of  a  powerful  magnetic  field  generated  by  super 
conducting magnets with a field strength used clinically of 1-1.5 Tesla. To create an 
image,  MRI  relies  on  the  nuclear  magnetic  resonance  signal  from  protons  of 
hydrogen  nuclei  within  water  and  lipid  molecules  in  tissues,  when  in  a  static 
magnetic field B0 and a radiofrequency field (Pankhurst et al., 2003). In a magnetic 
field  (B0)  the  protons  align  against  the  field  generating  a  net  magnetic  moment. 
Through  application  of  radiofrequency  (RF)  pulses,  the  net  magnetic  moment 
becomes excited at a frequency known as Larmour frequency (Wallis et al., 1999; 
Pankhurst et al., 2003). Through switching off the RF pulse, the protons return to a 
state of equilibrium known as relaxation (Lanza et al., 2004). There are two types of 
relaxation  signals  generated.  Firstly,  longitudinal  relaxation,  also  termed  T1  spin 
lattice recovery, involves hydrogen nuclei releasing absorbed energy to surrounding 
tissues, enabling its return to ground state B0. Secondly, transverse relaxation, which 
involves the exchange of energy between spinning protons, also termed T2 decay or 
spin-spin relaxation (Lanza et al., 2004; Mornet et al., 2004).  
 
To obtain high contrast images various sequence parameters such as repetition time 
(TR)  and  echo  (delay)  time  (TE)  can  be  optimised.  Relaxation  signals  from  the 
protons are collected and reconstructed to give a 3-D image (Mornet et al., 2004). 
The MRI contrast seen from the different tissues is mainly due to the concentration 
of hydrogen nuclei within the tissues. All tissues have a different concentration of   25 
hydrogen nuclei, causing relaxivity rates to differ, allowing a contrast to be seen 
(Mornet et al., 2004).  
 
Using  contrast  agents,  MR images  can be  enhanced.  The most  common  contrast 
agent  used  is  paramagnetic  gadolinium  ion  complexed  with 
diethylenetriaminepentaacetic  acid  (DTPA)  (Artemov  et  al.,  2003;  Mornet  et  al., 
2004).  Gadolinium  ions  directly  influence  nearby  H  nuclei  atoms  causing  a 
shortening in their T1 relaxation times, leading to enhanced positive contrast of the 
respective tissue (Artemev et al., 2003; Mornet et al., 2004). 
 
1.7.1 Application of SPIONs in MRI 
 
Advances in superparamagnetic materials (SPM) have shown SPIONs to also exhibit 
an MRI contrast enhancement potential. SPIONs cause a shortening in the T2 signals, 
which leads to a negative contrast (Renshaw et al., 1986; Weissleder et al., 1990; 
Pankhurst et al., 2003; Pardoe et al., 2003; Bulte et al., 2004).  
 
Superparamagnetic  materials  have  a  higher  magnetic  susceptibility  compared  to 
paramagnetic material. Upon application of a magnetic field the magnetic moments 
within the SPIONs align in the direction of the field, this gives rise to a large net 
magnetic moment, in comparison, paramagnetic material exhibit only a small net 
magnetic moment (Goshima et al., 2004; Mornet et al., 2004). The large magnetic 
moment generated by SPIONs leads to a disturbance in the local magnetic field, 
causing  a  shortening  of  the  hydrogen  nuclei  relaxation  times.  This  shortening  in 
proton relaxation times leads to a detectible change in the T2 MRI signal (Mornet et 
al., 2004). Due to SPM larger magnetic moment, only nanomolar concentrations of 
SPIONs are needed, compared to millimolar concentrations of Gd complexes to be 
effective as MRI contrast agents (Kohler et al., 2004). 
 
Currently  there  are  two  FDA  approved  SPION  contrast  enhancement  agents,  
Endorem® EU (Ferridex USA; Guerbet/Berlex lab) and Resovist® (Schering AG), 
both  used  for  liver  and  spleen  imaging.  Sinerem  EU  (Combidex  USA; 
Guerbet/Advance Magnetics) is another SPION contrast agent currently in phase III 
trial for application in lymph node imaging.    26 
Endorem® consists of multiple 5nm iron oxide core crystals embedded in a dextran 
matrix to give a hydrodynamic diameter of 80-150nm (Wang et al., 2001; Thorek et 
al., 2006). Resovist® also consists of multiple 5nm iron oxide core crystals but these 
are  embedded  in  carboxymethylated  dextran  matrix  and  have  a  hydrodynamic 
diameter of 60nm (Wang et al., 2001; Thorek et al., 2006). Even though Endorem® 
and  Resovist®  are  stabilised  in  dextran,  the  particles  are  only  partially  coated, 
increasing the likelihood of agglomeration. The application of these SPIONs is for 
liver specific imaging, therefore it is a requirement for the particles to be taken up by 
the body’s RES. The SPIONs accumulate in the organs of the RES, with 80% taken 
by Kupffer cells within liver and 5-10% in the spleen (Wang et al., 2001).  
 
In  comparison  to  Endorem®  and  Resovist®,  the  contrast  enhancement  agent 
Sinerem consist of a single 5nm iron oxide core crystal covered more completely in 
dextran and has a hydrodynamic diameter of 20-40nm (Wang et al., 2001). Due to 
Sinerem’s hydrodynamic radii and its thicker dextran coat, opsonisation by plasma 
proteins and recognition by RES is reduced. This allows the particles to remain in the 
blood longer; increasing its blood half-life (Jung et al., 1995a). Whilst in the blood, a 
percentage  of  SPIONs  can  leak  into  the  interstitium,  where  clearance  is  via 
macrophages  of  the  lymphatic  system.  The  accumulation  of  SPIONs  within  the 
lymph nodes in-turn allows for MRI imaging of lymph node metastases (Rockall et 
al., 2005). 
 
At present, the FDA approved SPION contrast agents work by passive accumulation 
within healthy macrophages within organs of the RES. However, in areas of organs 
of the RES that are cancerous the macrophages function is altered, preventing uptake 
of the SPIONs. Cancerous tissues therefore, appear brighter (positive contrast) as 
they contain no SPIONs, in comparison the healthy tissues appear darker due to the 
T2 negative contrast caused by the uptake of SPIONs.  
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1.8 Hyperthermic therapy 
 
Tumour cells have shown a greater sensitivity to heat treatments compared to healthy 
cells (Zee et al., 2002). This has led to the use of thermo-ablation and hyperthermic 
therapies in the clinic, often in combination with other treatments. The use of heat to 
treat illnesses dates back to the time of Hippocrates (460-370 BC), who said “ Those 
diseases which medicines do not cure, the knife cures; those which the knife cannot 
cure,  fire  cures;  and  those  which  fire  cannot  cure,  are  to  be  reckoned  wholly 
incurable” (Ito et al., 2005). 
 
Hyperthermia is classed into two categories; themo-ablation and mild hyperthermia. 
Thermo-ablation is where a temperature rise exceeds 46
oC and causes cell necrosis 
(Jordan  et  al.,  1999;  Gneveckow  et  al.,  2004).  Mild  hyperthermia  is  where  the 
temperature increase is between 41
oC – 46
oC (Lao et al., 2004). This temperature 
rise is high enough to cause partial cell kill and to damage and sensitise cancer cells 
to chemotherapy and radiotherapy (Jordan et al., 1999b; Wust et al., 2002; Gupta et 
al., 2005b; Okayama et al., 2009).  
 
The adjuvant affect of hyperthermia with radiotherapy has shown to cause increase 
blood flow into radio-resistant, hypoxic, low pH areas, causing oxygenation of the 
tissues, in turn increasing the cells radio-sensitivity (Song et al., 1996; Griffin & 
Corry, 2009). Studies have also shown heat treatments to cause protein denaturation 
and affect DNA repair mechanisms, preventing the repair of radiation induced DNA 
damage (Vernon et al., 1996; Zee et al., 2002). Furthermore, thermal treatment can 
enhance the toxicity of chemotherapy (Zee et al., 2002). It is reported that a raise in 
tissue temperature can cause increased intracellular drug uptake and increased blood 
flow in turn, raising intra-tumour drug concentrations and enhancing DNA damage 
(Zee et al., 2002).  
 
In addition, hyperthermia can also activate the immune system through up-regulation 
of heat shock proteins (HSP) (Ito et al., 2003a; Beere 2004; Tabuchi et al., 2008). 
HSP70 has been elucidated to a number of roles including anti-tumour immunity 
(Srivastava et al., 1998; Wang et al., 2000; Ito et al., 2003). Both Todryk et al and   28 
Ito  et  al  reported  that  the  induction  of  HSP70  after  hyperthermic  treatments 
encouraged the recruitment of macrophages and dendritic cells into the tumour and 
furthermore, mediated the up-regulation of the cell surface major histocompatibility 
class I molecules (MHC-1) (Todryk et al., 1999; Ito et al., 2001). Tumours have 
managed to evade immune detection due to a number of reasons including inefficient 
MHC  expression  (Costello  et  al.,  1999;  Garcia-Lara  et  al.,  2003).  Through  up-
regulation of the MHC-I expression, increased presentation of functional MHC-I-Ag 
complexed to cytotoxic T lymphocytes was reported (Tabuchi et al., 2008). This 
suggests HSP70 increases the immunogenicity of the tumour cells by priming them 
for immune recognition and attack (Ito et al., 2001; Tabuchi et al., 2008).   
 
Clinical approaches to hyperthermia have included immersion of the body part in 
question in hot water, the use of hot irons, hot probes, and fever therapy, however, all 
with limited success (Zee et al., 2002). More conventional thermal therapies used 
include lasers (Amin et al., 1993; ,Vogl et al., 1999), focused ultrasound (Jolesz et 
al., 2002), microwaves (Seki et al., 1999) and radiofrequency probes that can be 
placed in the lesion (Gazelle et al., 2000; Shinkai et al., 1999, 2002). Though all 
have  shown  evidence  of  cell  necrosis,  no  benefit  to  patient  survival  has  been 
reported.  There  are  a  number  of  limiting  factors  with  these  macroscopic  heating 
methods including  lack of specificity to the tumour cells, heterogeneous distribution 
of  temperature  over  the  target  site  and  poor  temperature  control  leading  to  a 
detrimental affect on normal healthy cells (Samanta et al., 2008). New approaches 
are  currently  under  investigation  to  separate  the  energy  source  from  the  heating 
source, enabling control over thermal release. Such approaches include near infrared 
irradiation (NIR) and magnetic induced thermal therapy. Near infrared irradiation 
involves metal nanoshells (Hirsch et al., 2003), nanorods (Huang et al., 2006) or 
nanotubes (Chahraverty et al., 2008) being placed in the area of the tumour, followed 
by  irradiation  with  an  infrared  laser  from  outside  of  the  body.  However,  due  to 
limited  penetration  depth,  NIR  is  not  effective  at  treating  deep-seated  tumours 
(Samanta et al., 2008).   
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1.8.1 Application of SPIONs in hyperthermia 
 
Magnetic  induced  thermal  therapy  also  known  as  magnetic  fluid  hyperthermia 
(MFH) was first reported by Gilchrist in 1957. Gilchrist et al showed that injection of 
magnetic particles into lymph nodes in dogs, caused a temperature increase during 
exposure to an alternating magnetic field (AMF) (Gilchrist et al., 1957). Over the last 
decade, MFH has re-emerged. A number of groups have reported promising results 
in vivo, where iron oxide particles were injected directly into the tumour (Jordan et 
al., 1997; Hilger et al., 2001, 2005) and more recently in the clinic, where an intra-
tumoural temperature rise of 40
oC-44
oC was achieved and reported to be sufficient 
for radio-sensitisation (Johannson et al., 2007; Maier-Hauff et al., 2007). 
 
By exposing SPIONs to an AMF energy is created in the form of heat, this thermal 
energy dissipates into the surrounding tissues and if the temperature is high enough 
can destroy or weaken cancerous cells (Berry et al., 2003; Pankhurst et al., 2003). 
Using  SPIONs  to  generate  heat  can  overcome  the  issue  of  non-specific  tissue 
heating, as the application of the alternating magnetic field can be localised to the 
area of the body where the SPIONs have collected. Through varying the frequency, 
current  parameter of the AMF  and the size and composition  of the SPIONs, the 
temperature generated from the SPIONs can be controlled (Pankhurst et al., 2003; 
Okawa et al., 2006; Hergt & Dutz, 2007). 
 
Unlike  micron  sized  particles,  which  exhibit  heating  through  hysterisis  loss 
(Pankhurst  et  al.,  2003),  SPIONs  are  thought  to  generate  heat  through  Néel 
relaxation and Brownian motion whilst in an AMF (Fig. 1.3) (Maier-Hauff et al., 
2006). In the case of Néel relaxation, the AMF causes the magnetic moments within 
the SPIONs to rotate, generating internal friction. When the field is off the moments 
return to equilibrium, this is where energy is released in the form of heat (Pankhurst 
et  al.,  2003;  Mornet  et  al.,  2004).  Brownian  motion  requires  the  rotation  of  the 
SPION as a whole therefore, the heat is generated through frictional movement in its 
surroundings (Mornet et al., 2004). However, SPIONs can become trapped within 
biological tissues, this in-turn blocks free rotation of the particles, preventing the 
generation of frictional heat (Hergt et al., 2004a; Mornet et al., 2004). 
   30 
 
  a)          b) 
 
  
 
 
 
 
Fig 1.6. Schematic representation of a) Néel rotation, where magnetic moments within the 
SPION rotate and b) Brownian motion, where the SPION rotates as a whole. 
 
 
The  specific  absorption  rate  (SAR)  Wg
-1  is  the  measurement  of  thermal  energy 
generated  from  magnetic  particles  and  is  defined  as  the  power  of  heating  of  a 
magnetic material per gram. SAR is measured as: 
 
        SAR = C 
D D D DT/Dt       (Equation 1.2) 
 
Where  C  is  the  specific  heat  capacity  of  the  sample  (Jg
-1  K
-1),  DT  is  change  in 
temperature and Dt is change in time. The SAR values are affected by a number of 
parameters firstly, the specific heat capacities of the surrounding liquid in the body, 
blood  flow  and  tissue  perfusion  can  act  as  a  cooling  mechanism  (Mornet  et  al., 
2004). Second, size, physical and chemical composition of the SPIONs can affect 
heat generated, with the optimum core diameter proposed as 10 nm-20 nm (Hergt et 
al., 2004b ) and third, particle heating can be affected by frequency and amplitude of 
the  alternating  magnetic  field  applied  (Hergt  et  al.,  2004b).  Above  a  certain 
threshold, the field strength can cause physiological problems by inductive heating 
(Hergt et al., 2004b) such as, stimulation of peripheral, skeletal and cardiac muscles 
(Mornet et al., 2004). At present, the only AMF coil generated for patient use is 
limited to 18kA/m at a fixed frequency of 100 kHz (Gneveckow et al., 2004). 
 
The concentration of SPIONs delivered to the target site is also a limiting factor in 
generating toxic levels of heat (Hilger et al., 2001). Direct injection into the tumour   31 
allows for delivery of high concentrations of SPIONs to the target area therefore, 
allowing other areas of the body to remain unaffected by AMF heating. The first 
clinical study of magnetic fluid hyperthermia by Johannsen et al showed that direct 
injection of 12.5 ml SPION suspension into the prostate at concentrations of 120 
mg/ml was well tolerated (Johannsen et al., 2005).  Systemic application of SPIONs 
however, proves more difficult due to their rapid clearance from the blood by the 
RES and therefore, reducing the concentration of SPIONs reaching the target organ. 
To improve the systemic application of SPIONs functionalisation with a targeting 
moiety would be advantageous.  
 
1.9 Research aims 
 
The central hypothesis for this thesis is that SPIONs can be used for diagnosis and 
targeted  therapy  of  cancer.  The  aims  of  this  thesis  was  to  generate  scFv-SPION 
conjugates  that  would  selectively  target  SPIONs  to  cancer  cells  and  test  their 
imaging potential by MRI and therapeutic potential by magnetic fluid hyperthermia 
(MFH). 
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Chapter 2 
 
 
General Materials and Methods 
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2.1 Materials  
 
Table 2.1 Microbial culture media and solutions for yeast fermentations 
Media  Formula 
YEPD medium/glucose primary culture 
medium 
Dissolve 10 g Bacto yeast extract, 20 g 
Bacto peptone, 10 g glucose into 1 litre 
dH2O. Autoclave  
Basic salt medium  Dissolve 5.4 g CaSO4, 88 g K2SO4, 70 g 
MgSO4
. 7H2O, 54 g (NH4)2SO4 and 300 ml 
glycerol into 5 litre dH2O. Autoclave. 
Sodium hexametaphosphate  Dissolve 150 g in 1 litre dH2O. Filter sterilise 
Trace element solution (PTM1; for 1 litre)  Dissolve 5.99 g CuSO4
.(H2O)5, 8 ml 10X NaI 
stock solution (0.4 g NaI per 40 ml dH2O), 3g 
MnSO4
. H2O, 0.2 g Na2MoO4
. (H2O)2, 0.5 g 
CoCl2
. (H2O)6, 20.04 g ZnCl2
. (H2O)5, 65.05 g 
FeSO4
. (H2O)7, 800 µl of 100X H3BO3 stock 
solution (1 g  H3BO3 per 40 ml dH2O), 19.2ml 
96.2% H2SO4, 0.4 g D-biotin in 970 ml dH2O. 
Autoclave. 
Secondary culture medium  300 ml basic salt medium, 30 ml sodium 
hexametaphophate, 1 ml trace element 
solution. Filter sterilise. 
Fermentation medium  4.7 litre basic salt medium, 1 litre sodium 
hexametaphosphate, 1 ml anti-foam, 24 ml 
trace elements. Autoclave in fermenter. 
Limited glycerol feed  300 ml glycerol, 300 ml dH2O. Autoclave. 
Add 7 ml trace element solution. 
Limited methanol feed  2 litre methanol, 24 ml trace element solution 
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Table 2.2 Solutions for His tagged protein isolation and purification on 
expanded bed adsorption immobilized-metal affinity chromatography (EBA 
IMAC) 
Buffer  Formula 
Copper sulphate  Dissolve 75 g CuSO4
. (H2O)7 in 3 litre dH2O. 
Autoclave. 
1X PBS, 1 M NaCl  Dissolve 96 g PBS powder and 584 g NaCl 
into 10 litre dH2O. Autoclave. 
2X PBS, 2 M NaCl  Dissolve 192 g PBS powder and 1169 g 
NaCl into 10 litre dH2O. Autoclave. 
Imidazole wash buffer 40 mM  Dissolve 48 g PBS powder, 292 g NaCl and 
13.6 g Imidazole into 5 litre dH2O. 
Imidazole elution buffer 200 mM  Dissolve 48 g PBS powder, 292 g NaCl and 
68.01 g into 5 litre dH2O. 
50 mM EDTA  Dissolve 75 g EDTA into 4 litre dH2O. 
Autoclave 
Sanitizing solution: 1 M NaOH, 1 M NaCl  Dissolve 400 g NaOH and 584 g NaCl into 
10 litre dH2O. 
20% (vol/vol) ethanol  Dilute 2 litre 100% ethanol in 8 litre dH2O. 
 
 
Table 2.3. Buffers for protein manipulation 
Buffers  Formula 
2X SDS-PAGE loading buffer  1.25 mM Tris-HCL, pH 6.8; 20%(w/v) 
glycerol; 2% (w/v) b-mercaptoethanol; 0.1% 
(w/v) bromophenol blue; 0.1% (w/v) SDS 
1X SDS-PAGE running buffer  25 mM Tris-HCl, 192 mM Glycine; 0.1% 
(w/v) SDS 
1X transfer buffer  25 mM Tris-HCl, 192 mM Glycine, 20% (w/v) 
methanol 
Coomassie gel stain  0.1% (w/v) coomassie blue R-250, 45% (w/v) 
methanol, 10% (w/v) glacial acetic acid 
Coomassie gel destain  30% (w/v) methanol, 10% (w/v) glacial acetic 
acid 
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 Table 2.4: Solutions for scFv-SPION sodium periodate conjugation 
Buffers  Formula 
Sodium Acetate 10 mM  Dissolve 5.4 g NaAc into 4 litre dH2O. Adjust 
to pH 4 with acetic acid. Filter to sterilise. 
Sodium Acetate 0.2 M  Dissolve 2.7g NaAc into 100 ml dH2O. Adjust 
to pH 6 with acetic acid. Filter to sterilise 
Sodium periodate oxidation buffer 10 mM  Dissolve 0.02 g NaIO4 into 10 mls 0.2 M 
NaAc buffer. Keep in dark. 
Sodium borohydride reduction buffer 0.1 M  Dissolve 0.06 g NaBH4 into 10 mM NaAc 
buffer. 
 
 
Table 2.5: Solutions for scFv-SPION carbodiimide conjugation 
Buffers  Formula 
MES buffer 0.5 M  Dissolve 9.75 g 2-(4-morpholino) 
ethanesulphonic HCl into 100 ml dH2O. 
Adjust to pH 6.3 with Na2CO3 (sodium 
carbonate). Filter to sterilise. 
MES buffer 0.1 M  Dissolve 78 g 2-(4-morpholino) 
ethanesulphonic HCl into 4 litre dH2O. Adjust 
to pH 6.3 with Na2CO3 (sodium carbonate). 
Filter to sterilise 
EDC/ NHS activation buffer  Dissolve 0.6 mg 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide 
hydrochloride and 1.2 mg N-
hydroxysuccinimide into 200 µl 0.5 M MES 
buffer 
Glycine 25 mM  Dissolve 0.18 g Glycine into 100 mls 1XPBS. 
Filter to sterilise  
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Table 2.6 Solutions for scFv SPION cyanogen bromide conjugation 
Buffers  Formula 
Activation Buffer  0.1 M Sodium hydrogen phosphate buffer 
pH9. Filter to sterilise  
Glycine 25 mM  Dissolve 0.18 g Glycine into 100 mls 1XPBS  
 
 
Table 2.7 Solutions for tissue culture 
Buffers  Formula 
Culture medium  To 500 ml RPMI medium add 1% 100x L-
glutamine, 10% Foetal calf serum 
Trypsin  Versene EDTA and trypsin 
Freezing medium  Mix 1 ml dimethyl  sulphoxide (DMSO) with 
9ml foetal calf serum 
 
 
Table 2.8 Solutions for immunostaining adherent cells 
Buffers  Formula 
Fixing buffer  4% Parafilm aldehyde 
Quenching buffer  10 mM Tris. Adjust pH 7.5 with HCL 
Permeabilisation buffer  0.05% Triton-X-100 in PBS 
Blocking buffer  3% BSA in PBS 
 
 
Table 2.9 Solutions for ferrozine assay 
Buffers  Formula 
FeCl3 standard  Disslove in 1 litre H2O 
Lysis buffer  50 mM NaOH 0.2 g dissolved in 100 ml H2O 
Iron Releasing Buffer  Dilute 3.5 ml of 4 M HCL into 10 ml H2O add 
to  10 ml solution of 0.45 g of KMnO4 
dissolved in H2O  
Iron Detection Buffer  Dissolve in 5 mls H2O 0.015 g ferrozine, 
0.015 g neocuproine, 0.96 g ammonium 
acetate and 0.99 g ascorbic acid.    37 
Table 2.10 Solutions for Prussion blue staining 
Buffers  Formula 
Prussian blue  4g potassium ferrocyanide dissolved in 20ml 
H2O added to 20ml and 2% HCL  
 
All  chemicals  were  purchased  from  Sigma-Aldrich  (St  Louis,  USA  Ltd)  unless 
specified.  All  buffers  were  filtered  through  0.2µm  Nalgene  filter  (VWR 
International, Leicestershire, UK). 
 
 Pre-cast  Tris-Glycine  SDS-PAGE  minigels  (10  well,  12%  Polyacrylamide,  1mm 
thick)  and  protein  molecular  weight  marker  “SeeBlue  Plus  2
”  (Fig.2.1)  were 
obtained  from  Invitrogen  Ltd  (Paisley,  UK).  Sequencing  grade  0.45  µm 
polyvinylidene difluoride (PVDF) membrane and chromatography filter paper was 
purchased at BioRad laboratories Ltd (Hemel Hempstead, UK). 
 
Fig.  2.1. Molecular weight calibrants for gel filtration chromatography were purchased from 
Bio-Rad laboratories (UK). Apparent molecular weights of SeeBlue Plus2 markers subjected 
to SDS-PAGE (4-20% Tris-Glycine).  Molecular weight markers correspond as follows: (1) 
Myosin; (2)BSA; (2b) Phosphorylase B; (3) Glutamic Dehydrogenase; (4) Alcohol 
Dehydrogenase; (5) Carbonic Anhydrase; (6) Myoglobin; (7) Lysozyme; (8) Aprotinin;   
Taken from Invitrogen catalogue. 
 
 
2.1.1 Microbial strains 
 
The wild type yeast strain X-33 was obtained from Invitrogen (UK). 
SeeBlue Plus2
250 kDa (1)
148 kDa (2b)
98 kDa (2)
64 kDa (3)
50kDa (4)
36 kDa (5)
22 kDa (6)
16 kDa (7)
6 kDa (8)
SeeBlue Plus2
250 kDa (1)
148 kDa (2b)
98 kDa (2)
64 kDa (3)
50kDa (4)
36 kDa (5)
22 kDa (6)
16 kDa (7)
6 kDa (8)  38 
2.1.2 Proteins 
 
Laboratory  stock  of  carcinoembryonic  antigen  (CEA)  was  kindly  donated  by  Dr 
Graeme Denton and Professor Alan Perkins (Nottingham University). 
 
2.1.3 Human cell lines 
 
The human CEA expressing colorectal cancer cell line LS174T and human CEA 
negative melanoma cell line A375M were purchased from the European catalogue of 
Human and Animal Cell Culture (ECACC; UK). 
 
2.1.4 Antibodies 
 
The murine anti-CEA scFv, MFE-23, was originally selected from a combinational 
phage  display  library  produced  from  mice  immunised  with  CEA  (Chester  et  al., 
1994). The humanised high affinity anti-CEA scFv, Sm3E, was constructed by site 
directed  mutagenesis  of  MFE-23  (Graff  et  al.,  2004).  MFE-23,  and  Sm3E  were 
purified by EBA IMAC (Tolner et al., 2006), from induced Pichia Pastoris yeast 
cells transformed with pPICzaA/ MFE-23 HIS and  pPICzaA/ Sm3E respectively. 
 
Laboratory  stocks  of  polyclonal  antibodies  were  raised  against  MFE-23  by 
immunisation of a rabbit with purified MFE-23. Mouse tetra his (anti-HIS) antibody 
was obtained from Qiagen (Crawley, West Sussex, UK). Mouse anti dextran was 
obtained from StemCell research (Stemcell Technologies Inc, Vancouver, Canada). 
Mouse  anti  LAMP1  was  kindly  donated  by  Dr  Shane  Minogue  (Department  of 
Medicine, Royal Free and University College Medical School). 
 
The  conjugated  antibody  goat  anti-rabbit  horse  rabbit  peroxidase  (HRP)  was 
purchased from Sigma-Aldrich (St Louis, USA Ltd). Sheep anti-mouse HRP, Goat 
anti-mouse Alexa Fluor 564 and 488, nuclear stain Hoechst and ProLong gold anti-
fade was purchased from Molecular Probes (Invitrogen, Oregan US).  
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2.1.5 Superparamagnetic iron oxide nanoparticles 
 
Details of the SPIONs investigated are shown in Table 2.10, which gives simplified 
nomenclature, SPION coating, number of SPIONs per mg, commercial name and 
supplier.  
 
 
Table 2.11 Details of SPIONs investigated includes simplified nomenclature 
of SPIONs used in thesis.  
SPIONs  Coating  Commercial 
name 
Supplier   SPIONs 
/mg 
Hydrodynamic 
diameter 
D50  Dextran   50nm nanomag-
D-spio 
Micromod 
Partikeltechnologie 
GMbH 
 
 
1x10
13 
50nm 
d100  Dextran  100nm nanomag-
D-spio 
Micromod 
Partikeltechnologie 
GMbH  
 
 
1x10
12 
100nm 
PEG-d20  Dextran-
PEG-
COOH 
20nm nanomag-
D-spio-PEG-
COOH 
Micromod 
Partikeltechnologie 
GMbH  
 
 
1x10
14 
20nm 
PEG-d50  Dextran-
PEG-
COOH 
50nm nanomag-
D-spio-PEG-
COOH 
Micromod 
Partikeltechnologie 
GMbH  
 
 
1x10
12 
50nm 
DX200  Dextran  200nm 
FluidMAG-DX 
Chemicell GMbH   
2 x10
11 
200nm 
DX100  Dextran  100nm 
FluidMAG-DX  
Chemicell GMbH   
 
2 x10
12 
100nm 
CMX200 
 
Dextran-
COOH 
200nm 
FluidMAG-CMX  
Chemicell GMbH   
 
2 x10
11 
200nm 
CMX100  
       
Dextran-
COOH 
100nm 
FluidMAG-CMX  
Chemicell GMbH   
 
2 x10
12 
100nm 
CMX50 
 
Dextran-
COOH 
50nm FluidMAG-
CMX 
Chemicell GMbH   
 
2 x10
13 
50nm 
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2.2 Methods 
 
2.2.1 Protein expression  
 
2.2.1.1 Fermentation of Pichia pastoris X-33 cells 
 
Fermentation  of  Pichia  pastoris  X-33  cells  was  performed  with  the  help  of  Dr. 
Berend Tolner and Mr Tim Hillyer (Department of Oncology) (Tolner B et al., 2006) 
using  a  BioFlo  3000  Batch/Continuous  Bioreactor  (New  Brunswick  Scientific, 
Edison, NJ, USA). Fermentation medium was prepared in the fermentor and was 
composed of the components as listed in Table 2.1.1, subsequently the fermentor 
containing the media was autoclaved. A primary seed lot in a 2 litre conical flask 
containing 250 ml of YEPD glucose medium was started by  inoculation with one 
frozen vial containing 1 ml of seed lot and grown overnight at 30
oC at 200 rpm to an 
OD600 of 12. Upon reaching OD600 of 12, 2 ml of the primary culture was used to 
inoculate the secondary culture medium (Table 2.1.1). The secondary culture was 
grown overnight at 30
oC at 200 rpm to an OD600 of 5. Once this was reached the 
secondary culture was added to the fermentation medium and the fermentation run 
was  started.  The  pH  at  the  start  of  the  fermentation  was  set  to  5.0  and  was 
automatically maintained by addition of 100% NH4OH base solution or 10% ortho 
phosphoric  acid  solution.  The  dissolved  oxygen  probe  was  set  to  40%  and  the 
temperature was set to 30
  oC. At 22-24 hrs after inoculation, a sharp increase in 
dissolved  oxygen  (spike)  was  observed,  which  is  indicative  of  depletion  of  the 
glycerol (carbon source) in the vessel. At this point a limited glycerol feed (Table 
2.1.1) was started and the pH reset to 6.5. One hour after the start of the limited 
glycerol feed, 12 ml of limited methanol feed (Table 2.1.1) was directly injected into 
the fermenter. During the run the flow rates of the glycerol and methanol limited 
feeds  were  altered  (Table  2.2.1).  The  fermentation  run  was  stopped  after 
approximately 72 hr post inoculation, ready for protein capture. 
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Table  2.12  Flow  rates  for  addition  of  glycerol  and  methanol  during  yeast 
fermentation 
 
Time post limited feed 
start (hr) 
Flow rate glycerol 
(ml/hr) 
Flow rate methanol 
(ml/hr) 
0  120  0 
1.0  120  0 
1.5  100  0 
2.0  80  0 
2.5  60  0 
3.0  40  0 
3.5  20  0 
4.0  0  10 
6.0  0  20 
8.0  0  30 
10.0  0  42-45 
 
 
2.2.2 Protein purification 
 
2.2.2.1  Expanded-bed adsorption immobilized metal affinity chromatography (EBA 
IMAC) 
 
Large scale purification of the hexahistidine-tagged proteins straight from the Pichia 
pastoris fermentation was performed using the expanded bed adsorption IMAC (GE 
Healthcare). All application to the column were in an up-flow except for the elution 
step. Briefly, the EBA column was connected to the spectrophotometer and zeroed 
with water. The column was charged with 0.1 M copper sulphate solution at flow 
rate 300 cm/h (Table 2.1.2) and unbound ions were washed off with dH2O until UV 
signal returned back to baseline. Ten column volumes of loading buffer (Table 2.1.2) 
were then run through the column. 
 
   42 
The bioreactor contents from the Pichia pastoris fermentation was first diluted 1:1 
with 2 M NaCl in 2x PBS, then loaded onto the charged EBA column at flow rate 
300 cm/h. Once all the bioreactor contents had been applied to the column loading 
buffer  was  run  through  until  the  UV  signal  reached  baseline.  To  remove  non-
specificically bound  contaminants,  40 mM Imidazole wash buffer was applied to 
the column at a flow rate 300 cm/h until the UV signal returned to baseline. Finally, 
the column  flow was reversed and  the  target hexa-histidine-tagged  proteins were 
eluted off the column by application of 200 mM  Imidazole elution buffer to the 
column  at  flow  rate  150  cm/h  fraction.  Peak  fractions  containing  protein  were 
determined  spectrophotometrically  at  an  OD280,  these  fractions  were  collected, 
pooled, filtered through a 0.2  M Nalgene filter and dialysed against PBS overnight. 
Fractions were either stored as 25 ml aliquots at -80
oC or further purified by size 
exclusion chromatography. 
 
The EBA column was washed with sterile dH2O until the UV signal returned to 
baseline, and regenerated with 4 litre 50 mM EDTA, removing the copper sulphate. 
Five column volumes of dH2O were applied to the column to displace the EDTA 
solution, the EBA column was further washed in sanitizing solution for 1 hr and 
stored in 20% ethanol. 
 
2.2.2.2 Size-exclusion chromatography 
 
Proteins  were  separated  according  to  molecular  weight  by  size  exclusion 
chromatography (SEC) using an AKTA FPLCÔ system (GE-Healthcare, Amershan, 
UK). For resolution of smaller proteins, a Superdex 75 SEC column (GE-Healthcare) 
was used. For loads of less than 2mls the Superdex 75, 16/60, (matrix volume 120ml) 
was used. Protein samples were loaded via the 2 ml injection loop at a constant flow 
rate of 2 ml/min PBS. For protein samples of up to 25 mls the Superdex 75, 25/60 
column (matrix volume 500 mls) was used. Protein samples were loaded onto the 
column at a flow rate of 5 ml/min PBS. Fractions were collected and peak fractions 
were pooled. One millilitre aliquots were made and samples stored at -80
oC ready for 
further analysis. 
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For separation of larger molecules such as magnetic particles, a Sephacryl 300 high 
resolution SEC column 16/25 (30 ml) and 16/60 (120 ml) (GE-Healthcare) were 
used. Magnetic particles and protein samples were injected onto the column at a 
constant  flow  rate  of  0.5  ml/min  PBS.  Magnetic  particle  fraction  was  collected 
throughout the void volume; peak fractions were pooled and stored at 4
oC ready for 
further analysis.  
 
For calibration, the Gel Filtration Standard kit (Bio-Rad) was prepared and applied to 
columns as directed by manufacturers. 
 
2.2.3 Protein characterisation 
 
2.2.3.1 Protein quantification 
 
The  concentration  of  proteins  was  determined  spectrophotometrically  using  the 
following equation: 
 
      A280=e280 x c x l        (Equation 2.1) 
 
Where  A280  is  the  absorbance  at  280  nm  of  protein  samples  measured  in  quartz 
cuvettes on a Cecil  CE2041 2000  series spectrophotometer, e280 is the extinction 
coefficient (0.1%, 280 nm, 1 cm path length) of the protein calculated based on the 
protein  primary  amino  acid  sequence  using  the  Expasy  Protparam  web  tool 
(http://www.expasy.ch/tools/protparam.htlm), c is the protein concentration, l is the 
path length of the cuvette (cm). For MFE-23, e280 = 1.9; for Sm3E, e280 = 1.9 
 
2.2.3.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Electrophoresis of proteins was performed under reducing conditions. Samples were 
prepared by the addition of 2X SDS-PAGE reducing buffer (Table 2.1.3) followed 
by denaturation at 95
oC for 5 min. Samples were loaded onto 12% Tris-Glycine pre-
cast  mini-gels  (Invitrogen)  and  separated  on  an  XCell  IIÔ  Mini-Cell  system 
(Invitrogen)  in  1x  SDS-PAGE  Running  buffer  (Table  2.1.3)  on  an  automated   44 
program of 90 min at 35 mA (125 V, 5 W) using a PowerEase 500 power supply 
(Invitrogen). Following electrophoresis, proteins were either stained with coomassie 
blue (Table 2.1.3) or subjected to Western blotting (section 2.2.4.3). 
Gels were stained with Coomassie blue stain for 2-4 hrs at room temperature. To 
enable visualisation of proteins the gels were de-stained with de-stain solution (Table 
2.1.3) for 2-4 hrs with repeated de-stain solution changes. Gels were rinsed in dH2O 
followed by 15 min incubation in Gel drying solution (Invitrogen) in preparation for 
drying using the Invitrogen Gel drying kit. Two gel drying plastic sheets (Invitrogen) 
were soaked in the Gel drying solution, the gel was sandwich between them and left 
to dry in a drying rack overnight at room temperature. 
 
2.2.3.3 Western blot analysis 
 
Following  electrophoresis  proteins  were  transferred  to  polyvinylidene  difluoride 
(PVDF) membrane (Bio-Rad Laboratories Ltd), pre-treated by soaking in methanol 
for 10 min. Gels were sandwiched with the PVDF membrane between several sheets 
of pre-wetted chromatography filter paper (Whatmen, Maidstone, UK) and sponges. 
This was submerged in an XCell II Blot Module (Invitrogen) filled with 1x Transfer 
buffer (Table 2.1.3). Proteins were transferred using an automated program of 90 min 
at 125 mA (25 V, 17 W). 
 
Following  electro-transfer,  PVDF  membranes  were  blocked  in  5%  (w/v)  Marvel 
skimmed milk powder (Marvel, UK) in PBS for at least 1 hr. The blocked blots were 
washed  in  PBS  and  incubated  on  a  rocker  at  room  temperature  for  1  hr  in  the 
appropriate primary antibody diluted in 1% (w/v) Marvel/PBS. The blots were then 
washed with 3x 0.1% (v/v) Tween-20 in PBS, then 3x PBS followed by incubation 
on a rocker at room temperature for 1 hr in the appropriate secondary horseradish 
peroxidase (HRP)-conjugate antibody diluted in 1% (w/v) Marvel/PBS. Following 
incubation,  the  blots  were  washed  as  before  and  proteins  visualised  with  DAB 
substrate solution (0.25 mg/ml 3, 3’-Diaminobenzidine tetrahydrochloride, 0.5 µl/ml 
H2O2 in dH2O). The reaction was stopped by rinsing the membrane in dH2O. The 
membrane was left to dry at room temperature. 
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Table 2.13 Antibody dilutions 
Primary Antibody (dilutions)  Secondary Antibody (dilutions) 
Tetra His 1/1000 (Qiagen)  Sheep anti-mouse-HRP 1/500 (GE-
Healthcare) 
Anti-MFE-23  rabbit  sera  1/1000 
(Laboratory generated stock) 
Goat anti-rabbit-HRP 1/1000 (Sigma-
Aldrich) 
Anti-dextran 1/1000 (Stemcell)  Sheep anti-mouse-HRP 1/500 (GE-
Healthcare) 
 
 
2.2.3.4 Enzyme-linked immunosorbent assay (ELISA) 
 
ELISAs were performed on 96-well micro-titre plates (Costa, High Wycombe, UK) 
coated for 1-2 hr with 100 µl 1 µg/ml CEA in PBS or PBS. Wells were washed 2x 
with PBS and blocked with 200 µl 5% (w/v) Marvel/PBS for 2-16 hrs. Fifty to one 
hundred micro-litres of samples (neat supernatant or purified proteins diluted in PBS) 
were applied to CEA or PBS coated wells in triplicate and incubated for 1 hr. After 
incubation the wells were washed 3x with PBS. Wells were then incubated for 1 hr 
with 100 µl primary antibody diluted in 1% (w/v) Marvel/PBS. Following incubation 
wells  were  washed  3x  in  PBS/0.1%  (v/v)  Tween-20  followed  by  3x  PBS,  then 
incubated for 1 hr with 100 µl HRP-conjugated secondary antibody diluted in 1% 
(w/v)  Marvel/PBS.  Wells  were  washed  as  before  and  100  µl  OPD  (O-
phenylenediamine dihydrochloride; 0.4 mg/ml dissolved in phosphate citrate buffer, 
pH  5.0)  was  added.  Reactions  were  stopped  with  50  µl  4  M  HCL  and  the 
absorbances were measured at 490 nm using Opsys MRÔ Microplate Reader (Dynex 
Technologies). See Table 2.2.2 for antibody dilutions.  
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2.2.4 Antibody-SPION conjugation chemistry 
 
2.2.4.1 Sodium periodate conjugation 
 
Conjugation of the available OH groups on the dSPIONs to the available NH3 groups 
on the scFvs was achieved by adaptation of the sodium periodate method (Molday et 
al., 1982). Briefly, 5 mg/ml of the dSPION (1 ml) was added to 1 ml 10 mM sodium 
periodate (Sigma-Aldrich) and incubated at room temperature for 1 hr in the dark on 
a rotating shaker to allow partial oxidation of the dextran. The oxidation reaction was 
terminated by application to a PD-10 desalting column (GE-Healthcare) equilibrated 
with 10 mM sodium acetate buffer pH 4. The same buffer was used for elution of the 
SPIONs. Conjugation was achieved by addition of the eluted oxidised dSPION (3 ml 
at 3 mg/ml) to the scFv (1 ml of 0.1 mg/ml in 10 mM sodium acetate buffer pH 4) 
and incubation on a rotating shaker for 24 hrs at room temperature. Subsequently the 
mixture was reduced by addition of 0.5 ml at 0.1 M sodium borohydride (Sigma-
Aldrich) for 15 min at room temperature. The reaction was terminated by application 
to a PD-10 desalting column as described above for the oxidation reaction. The scFv-
dSPION  conjugate  (7  ml)  was  concentrated  to  2  ml  using  Vivaspin  15R 
concentrators with a 5000 MW cut off (Sartorios Stedim Biotech GmbH, Germany) 
at 3082 g and purified by size exclusion chromatography (SEC) using Sephacryl 
300HR (GE Healthcare) in PBS buffer (Section 2.2.3.2.).  
 
2.2.4.2 Carbodiimide conjugation. 
 
Conjugation of the available COOH groups on the PEG-dSPIONs to the available 
NH3 groups on the scFvs was achieved using a modification of the carbodiimide 
method (DeNardo et al., 2005).  Briefly, 5 mg/ml of PEG-dSPION were activated by 
incubation  with  EDC/NHS  activation  buffer  (Table  2.1.4)  for  1  hr  at  room 
temperature on a rotating shaker. The reaction was terminated by application to PD-
10 desalting columns equilibrated with 0.1 M MES buffer pH6.3. The same buffer 
was used for elution of the SPIONs. The activated PEG-dSPIONs (2 ml at 2 mg/ml) 
was added to the scFv (1 ml of 0.1 mg/ml in 0.1 M MES buffer pH6.3) and the 
conjugation reaction was achieved by incubation for 24 hrs on a rotating shaker at 
room temperature. After 24 hr, 0.1 ml of 25 mM Glycine in PBS was added to the   47 
conjugation reaction and the mixture was incubated for a further 30 min at room 
temperature on the shaker to block remaining reactive sites. The resulting scFv-PEG-
dSPION  conjugates  (3ml)  were  concentrated  to  2ml  using  Vivaspin  15R 
concentrators  with  a  5000  MW  cut  off  at  3082  g  and  then  purified  by  SEC  on 
Sephacryl 300HR in PBS (Section 2.2.3.2.).  
 
2.2.4.3. Cyanogen bromide conjugation 
 
Conjugation  of  the  available  OH  groups  on  the  FluidMAG-DX  SPIONs  (DX-
SPION) to the available NH3 groups on the scFvs was achieved by adaptation of the 
cyanogen  bromide  conjugation  chemistry  from  the  Chemicell  GMbH  website. 
Briefly,  10  mg/ml  DX-SPIONs  diluted  in  activation  buffer  (Table  2.1.6)  was 
activated by incubation with 0.05 ml of CNBr (Sigma-Aldrich). The solution was 
vortexed and incubated on ice for 10 min. The reaction was stopped by running the 
particles through a PD-10 desalting column equilibrated with PBS; the same buffer 
was used for elution of the SPIONs. The activated DX-SPIONs (2 ml at 4.5 mg/ml) 
were added to the scFv (1 ml of 0.1 mg/ml in PBS) and the conjugation reaction was 
achieved by incubation for 24 hr on a rotating shaker at room temperature. After 24 
hr, 0.1 ml of 25 mM glycine in PBS was added to the conjugation reaction and the 
mixture was incubated for a further 30 min at room temperature on the shaker to 
block remaining reactive sites. To remove unbound scFv and glycine, four overnight 
magnetic washes with PBS were performed. The scFv-DX-SPION conjugate sample 
was diluted to 6 ml with PBS and placed in 6 x 1 ml holders on the DynalMagnet 
(Millipore). After the final magnetic wash the pellets were resuspended to 1 ml in 
PBS and pooled.   
 
2.2.5 ScFv-SPION conjugation analysis 
 
2.2.5.1 Ratio of scFv-SPION in conjugate solution 
 
The  protein  concentration  of  the  scFv-SPION  conjugate  was  estimated  using  the 
Bradford assay. Firstly, (non-conjugated) scFv protein concentration standards were 
prepared in PBS buffer at concentration 0, 2.5, 5, 7.5 and 10 µg/ml. To 500 µl of 
each standard 500 µl of Bradford reagent (Sigma-Aldrich) was added and mixed   48 
gently by hand. The samples were left to incubate at room temperature for 15 min. 
The absorbance of each standard was measured at 595 nm in quartz cuvettes on a 
Cecil  CE2041  2000  series  spectrophotometer.  The  absorbance  vs.  the  protein 
concentration for each standard was plotted. 
 
Subsequently,  the  concentration  of  conjugated  scFv  in  the  purified  scFv-SPION 
conjugate  solutions  was  determined  using  the  Bradford  assay  above  and  the 
absorbance was measured at 595 nm on the spectrophotometer which was blanked 
against  non-functionalised  SPIONs.  The  absorbance  value  was  then  referenced 
against the standard curve of Bradford assayed serial dilutions of the scFv.  
 
The  number  of  scFv  molecules  in  the  scFv-SPION  conjugate  solution  was  then 
calculated  following  the  equations  2.2  and  2.3  below,  where  nSm3E  equals  the 
number of Sm3E molecules and NA equals Avogadro’s constant 6.022 x 10
23 
 
 
 
[ ][ ]
[ ] kDa MW
ml g E Sm
moles
/ 3 m
=           Equation 2.2                                       
A N moles ml E nSm ´ = 3         Equation 2.3    
 
 
 
Absorbance readings at 490 nm were performed to estimate the concentration of the 
SPIONs in scFv-SPION conjugate solutions. Firstly, SPION concentration standards 
were prepared in PBS buffer at concentrations 0, 0.125, 0.25, 0.375 and 0.5 mg/ml. 
The absorbance of each standard was measure at OD 490 nm in quartz cuvettes on a 
Cecil  CE2041  2000  series  spectrophotometer.  The  absorbance  vs.  the  SPION 
concentration for each standard was plotted. 
 
The absorbance of the purified scFv-SPION conjugates at 490 nm was subsequently 
referenced  against  the  standard  curve  of  their  respective  serial  diluted  SPIONs, 
allowing the concentration of the SPIONs to be determined.  Following equation 2.4   49 
the number of SPIONs in the conjugate solution can be calculated. See section 2.1.5 
for the number of SPIONs per mg (nSPION) as stated by the manufacturer. 
 
 
[ ][ ] mg nSPION ml mg SPION ml nSPION ´ = / /   Equation 2.4 
 
 
Finally,  the  number  of  Sm3E  scFvs  bound  per  SPION  was  calculated  following 
equation 2.5.  
 
 
ml nSPION
ml E nSm
nSPION E nSm
3
3 =       Equation 2.5 
 
 
2.2.5.2  Ferrozine assay to estimate iron concentration 
 
To quantify the concentration of Fe
2+ in the SPIONs, FeCl3 standards were firstly 
prepared. One hundred microlitre FeCl3 standards at concentrations 0, 0.05, 0.1, 0.25, 
0.5, 1, 2.5, 5, 7.5 and 10  g/ml in 10 mM HCL were incubated in 100  l 50 mM 
NaOH and 100  l iron releasing buffer (Table 2.1.9) at 60
oC on a heat block for 2 
hrs. After incubation the samples were cooled to room temperature for 10 min, 30  l 
iron detection buffer (Table 2.1.9) was subsequently added to all the samples. The 
iron detection buffer forms a complex with ferrous iron that absorbs strongly at 550 
nm. The samples were mixed and incubated for 30 min to allow for maximum colour 
change. Following incubation the absorbance of the standards was read at 550 nm 
using Opsys MRÔ Microplate Reader (Dynex Technologies). The absorbance vs. the 
Fe
2+ concentration for each standard was plotted. This assay was then performed for 
all the SPIONs at concentrations 0, 0.5, 1, 2.5, 5, 10, 2.5, 5, 10, 25, 50 and 100  g/ml 
in 10 mM HCL.  The absorbance vs. the SPION concentration for each standard was 
plotted. The SPION concentration was then plotted against its corresponding Fe
2+ 
concentration. 
 
2.2.5.3 Magnetic resonance imaging (MRI) potential of SPIONs 
  
To determine the MRI potential of the SPIONs, serial dilutions of the SPIONs were 
prepared  in PBS at concentrations 0, 7.5, 37.5  and  75  g/ml.  The  samples  were   50 
aliquoted into 250  l MRI eppendorf tubes and placed in a rack inside a 50 ml falcon 
tube  containing  2.5  g/L  CuSO4.  The  samples  were  then  scanned  using  a  2.35T 
horizontal bore SMIS system (3 cm coil, 128 x 128 matrix, 2mm slice along the 
eppendorf  cross  section,  2  averages,  FOV  40mm,  TR = 1s at multiple TEs).  T2 
values were determined. 
 
2.2.5.4 Alternating magnetic field (AMF) heating potential of SPIONs 
  
To  determine  the  AMF  heating  potential  of  the  SPIONs,  a  range  of  SPION 
concentrations were prepared in water and placed into the coil of the AMF heating 
apparatus. Two AMF heating systems were used, applying a field strength of 300V, 
0.62 A and 139.8 Hz or 150 V, 0.74 A and 1 MHz. The temperature increase over 20 
min was measured using a Luxtron thermometer probe placed in the SPION solution.  
 
2.2.5.5 Zeta Potential of SPIONs   
The  SPION  zeta  potential  measurements  were  performed  with  the  help  of  Dr. 
Khuloud Al-Jamal (Nanomedicine lab, The school of pharmacy). The hydrodynamic 
Z-average  diameters  and  zeta  potentials  of  the  SPIONs  were  measured  using  a 
Zetasizer Nano ZS (Malvern Instruments, Malvern) at concentration range of 0.01-
1mg/ml in deionised water or at pH 7.4. The average of three measurements provided 
results expressed as zeta potential (mV) ± S.D. 
 
2.2.6  Cell culture 
 
Following standard tissue culture techniques, cell culture procedures were carried out 
in a class II Hood. Culture medium (see Table 2.1.7), PBS and Trypsin/EDTA were 
pre-warmed to 37
oC before use. All cell cultures were incubated at 37
oC in a tissue 
culture incubator humidified with a CO2 concentration of 5%. 
 
2.2.6.1 Taking cell lines into culture 
 
Cell lines were purchase and stored in frozen aliquots, to bring them into culture the 
aliquots were thawed at 37
oC and resuspended by drop wise addition of 10 ml culture   51 
medium (Table 2.1.7). The cells were pelleted at 1300RPM for 3 min in a bench top 
centrifuge. The cells were resuspended in 5 ml of culture medium and seeded into 
T25 culture flasks until confluent.  
 
2.2.6.2 Propagation of adherent cell lines CEA+ve LS174T and CEA-ve A375M  
 
Once confluent, cells were sub-cultured routinely twice weekly in a split ratio of 1:5. 
Culture medium was poured off and cells washed once in 10 ml PBS. The PBS wash 
was  poured  off  and  cells  were  released  from  the  flask  by  incubation  in  5  ml 
trypsin/EDTA for 5 min at 37
oC (Trypsinisation). For complete release of cells the 
flasks were whacked twice and an equal volume of fresh culture medium was added 
to resuspend the released cells. Two millilitres of resuspended cells was pelleted at 
1300  g for 3  min. The cells were resuspened in 2  ml  fresh culture  medium and 
seeded into T75 flasks containing 13 ml fresh culture medium. 
 
2.2.6.3 Cryogenic storage 
 
Once cells were confluent, culture medium was poured off and cells washed once in 
10 ml PBS. The PBS wash was poured off and cells were releases from the flask by 
trypsinisation (Section 2.2.7.1). Equal volume of fresh culture medium was added to 
resuspend the released cells. Resuspended cells were pelleted at 1300 g for 3 min. 
The cells were resuspened in 5 ml freezing medium (see Table 2.1.7) and aliquoted 
into 1 ml cryovialÔ (Nalgene). The cryovials were stored at -80
oC.  
 
2.2.7 In-vitro analysis of scFv-SPIONs 
 
2.2.7.1. Ferrozine assay to measure cell SPION  uptake. 
 
Cellular  uptake  of  the  scFv  functionalised  and  non  functionalised  SPIONs  were 
quantified following the adapted ferrozine assay based method (Riemer et al., 2004). 
Briefly  exponentially  growing  cells  were  trypsonised  and  seeded  at  a  density  of 
5x10
4 cells/ml, 2 ml/well in 24 well plates and incubated in culture medium (Table 
2.1.7) for 5 days. On the 5
th day, the culture media was removed and replaced with 1   52 
ml filter sterilised scFv functionalised and non-functionalised SPIONs at 0.1 mg/ml 
in culture media. Cells were incubated overnight followed by 3 x washes in cold 
PBS. After completely removing the PBS, the cells in three of the media control 
wells were trypsonised and counted to determine the number of cells per well. The 
cells in the rest of the wells were frozen and stored at -20
oC. Cells were lysed with 
300  l 50 mM NaOH for 2 hrs on a shaker at room temperature. The cell lysates 
were subsequently transferred to 1.5 ml eppendorf and mixed with 300  l of 10 mM 
HCL  and  300   l  of  the  iron  releasing  reagent  (Table  2.1.9),  the  samples  were 
incubated for 2 hrs at 60
0C on a heating block. After incubation the samples were 
cooled to room temperature, 30 µl iron detection buffer (Table 2.1.9) was then added 
to all the samples. After gentle mixing by hand the samples were incubated at room 
temperature for a further 30 min to allow for maximum colour change. Absorbance 
readings  at  550  nm  were  performed  using  the  Opsys  MRÔ  Microplate  Reader 
(Dynex Technologies), values were referenced against standard curve of ferrozine 
assayed SPIONs at known concentrations (Section 2.2.5.3). The SPION uptake per 
cell was calculated following equation 2.6, where nCell equals the number of cells. 
 
[ ] [ ][ ]
well nCell
well g SPION
g cell SPION
/ m
m =       Equation 2.6  
 
 
2.2.7.2 MTT toxicity assay 
 
Toxicity of the SPIONs was investigated using a cell viability assay based on 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)  (Sigma-Aldrich) 
(Mosmann 1983). Briefly, exponentially growing cells were trypsonised and seeded 
at  a  density  of  1x10
5  cells/ml,  200µl/well  in  96  well  plates.  The  plates  were 
incubated in a humidified incubator with a CO2 concentration of 5% for a minimum 
of 16 hours to allow adherence of the cells. Once adhered the cells were incubated 
overnight  0.1ml  with  culture  medium  containing  non-functionalised  SPIONs  at 
particle concentrations of 1mg/ml, 0.5mg/ml and 0.1mg/ml or functionalised scFv-
SPIONs at a particle concentration of 0.1mg/ml. The cells were then washed and 
incubated  a  further  96  hours  in  fresh  culture  media.  MTT  (20µl;  5mg/ml)  was 
subsequently added to each well and incubation allowed to proceed for a further   53 
4hrs.  Media was then carefully removed and the purple formazan crystals (indicating 
cell viability) were solubilised using 100µl/well of DMSO.  Absorbance at 550nm 
was measured using the Opsys MRÔ Microplate Reader (Dynex Technologies). The 
percentage cell survival was determined by comparison with untreated control wells. 
All tests were performed in triplicate. 
 
2.2.7.3 Immunostaining of adherent cells incubated in scFv-SPIONs. 
 
The specificity  and cellular uptake of scFv functionalised and non functionalised 
SPIONs to the CEA+ve LS174T or CEA-ve A375M cells were examined by indirect 
immunofluorescence confocal microscopy. Briefly, cells were seeded onto 13 mm 
circular  coverslips  (VWR)  in  24  well  plates  at  a  density  of  1x10
5  cells/ml,  500 
 l/coverslip. The cells were incubated overnight at 37
oC in a humidified incubator 
with  a  CO2  concentration  of  5%,  to  allow  adherence  of  the  cells.  Following 
adherence  the  cell  medium  was  removed  and  the  cell  coated  coverslips  were 
incubated overnight with 500 µl of culture media containing i) no SPIONs ii) filter 
sterilised non functionalised SPIONs at 0.1 mgSPION/ml or iii) filter sterilised scFv-
SPIONs at 0.1 mgSPION/ml. Following incubation cells were washed in PBS and 
fixed in 4% paraformaldehyde for 20 min.  To quench residual paraformaldehyde the 
cells were washed 3x in PBS followed by incubation in 10 mM Tris/HCL pH 7 for 
10 min at room temperature. After incubation the cells were again washed 3x in PBS 
then blocked in 500  l blocking buffer (Table 2.1.8) for 20 min at room temperature. 
The  cell  coated  coverslips  were  again  washed  3x  in  PBS,  the  coverslips  were 
removed from the 24 well tissue culture plate using tweezers and incubated cell face 
down in 50  l mouse anti-dextran antibody 1/100, on parafilm for 45 min at room 
temperature. After incubation the coverslips were washed 3x in PBS, placed cell face 
up in 12 well plates and further incubated with 500  l goat anti-mouse antibody 
labelled with Alexa Fluor 564 1/500 (Molecular Probes) and counterstained with 
nuclei stain Hoechst 1/5000 (Molecular Probes) for 30 min, in the dark, at room 
temperature,  on  a  rocker.  To  remove  unbound  secondary  antibody  cell  coated 
coverslips were washed 3x in PBS followed by 1 PBS wash on the rocker for 1 min 
and 1 wash in dH2O. The coverslips were mounted cell face down on coverslides in   54 
ProLong antifade (GE-Healthcare) imaged by using a Zeiss LSM 510 meta confocal 
microscope.  
 
For the endosomal co-localisation study the mouse anti-LAMP1 IgG2b antibody was 
incubated together with the mouse anti-dextran IgG. Following PBS washes, the cells 
were incubation with the goat anti mouse IgG2b labelled with Alexa Fluor 488 1/500 
(Molecular Probes) in addition to the goat anti mouse IgG1 labelled with Alexa Fluor 
564 and the nuclei stain Hoechst 33342. Coverslips were mounted and imaged as 
before.  
 
2.2.7.4  Magnetic  resonance  imaging  (MRI)  of  adherent  cells  incubated  in  scFv-
SPIONs 
 
The  MRI  imaging  and  specificity  of  scFv  functionalised  and  non-functionalised 
SPIONs  to  the  CEA+ve  LS174T  or  CE-ve  A375M  cells  were  examined.  Cells 
cultured in a T75 flask were incubated overnight  in 10 ml of medium containing i) 
no SPIONs ii) filter sterilised non-functionalised SPIONs at 0.1 mgSPION/ml or iii) 
filter sterilised scFv-SPION at 0.1 mgSPION/ml under cell culture conditions.  After 
incubation the cells were washed in PBS, released from the flask with VerseneÔ 
followed by 2x PBS washes by centrifugation and fixed in 4% paraformaldehyde for 
20 min. Following fixation the cells were washed in PBS and pelleted into 250  l 
MRI eppendorf tubes and subsequently placed in a rack inside a 50 ml falcon tube 
containing 2.5 g/L CuSO4. The samples were then scanned and T2-weighted images 
were  acquired  with  a  2DFT  spin-echo  sequence  using  a  2.35T  horizontal  bore 
scanner interfaced to a SMIS console (3cm RF coil, 256x256 matrix, 1 mm slice, 2 
averages, FOV 60 mm, TR=1s, TE=80 ms).  
 
2.2.8 Hyperthermic in vitro studies 
 
2.2.8.1 Incubator heating of adherent cells: viable cell counts 
 
To  determine  at  which  temperature  cell  viability  becomes  affected  cell  viability 
counts  were  performed  after  heat  treatment.  The  CEA+ve  LS174T  cells  were   55 
cultured to 75% confluency in T25 flasks and incubated in triplicate at temperatures 
of 37
oC, 40
oC, 43
oC and 47
oC for 30 min. Following treatment the cells were left to 
recover for 1 hr at 37
oC. The viability of the cells was determined by cell viability 
counts using trypan blue stain. Briefly, the treated cells were washed 3 x in PBS and 
released  from  the  flask  by  trypsonisation  (Section  2.2.6.2).  The  cells  were 
subsequently  centrifuged  and  the  cell  pellet  was  resuspended  in  10  ml  culture 
medium, 100  l of resuspended cells was added to 100 µl Trypan Blue stain and 
mixed by pipetting. Viable cells were counted using a haemocytometer, under an 
inverted phase contrast microscope; the total viable cell number was calculated using 
equation 2.7, where nCell equal the average number of viable cells, 2 is the dilution 
factor when using trypan blue and Tvol is the total volume of resuspended cells 
 
[ ] [ ] ml Tvol ml cells nCell ´ ´ ´ = / 10 1 2
4   
                  Equation 2.7 
 
2.2.8.2 Incubator heating of adherent cells: MTT assay 
 
To determine at which temperature cell viability becomes affected MTT viability 
assay was performed after heat treatment. The CEA+ve LS174T cells were seeded at 
a  density  of  1  x  10
5  cells/ml,  200  µl/well  into  96  well  plates.    The  plates  were 
incubated for a minimum of 16 hours to allow the cells to adhere to the wells. Once 
cells had adhered the plates were incubated at increasing temperatures of 37
 oC, 38
 
oC, 39
  oC,  40
  oC, 41
  oC, 42
  oC,  43
  oC, 44
  oC, 45
  oC,  46
  oC and 47
  oC  for 1 hr. 
Following treatment  the  plates were  returned to 37
  oC  and left  to incubate for  a 
further 96 hr in a tissue culture incubator humidified with a CO2 concentration of 
5%. MTT (20 µl; 5 mg/ml) was subsequently added to each well and incubation 
allowed to proceed for a further 4 hr.  Media was then carefully removed and the 
purple formazan crystals (indicating cell viability) were solubilised using 100 µl/well 
of DMSO.  Absorbance at 550 nm was measured using the Opsys MRÔ Microplate 
Reader  (Dynex  Technologies).  The  percentage  cell  survival  was  determined  by 
comparison with untreated control wells. was determined from the control wells.    
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2.2.8.3  Incubator  heating  of  adherent  cells:  heat  shock  protein  70 
immunocytochemistry Staining 
 
To determine at which temperature the heat shock protein 70 (HSP70) is expressed, 
the CEA+ve LS174T cells were heat treated in an incubator and stained for HSP70 
expression. Briefly, cells were seeded at a density of 1x10
5 cells/ml, 500 µl/well onto 
sterile 13 mm circular coverslips (VWR) placed in 24 well tissue culture plates. Cells 
were incubated 2 days at 37
oC in a tissue culture incubator humidified with a CO2 
concentration  of  5%.  In  triplicate  the  cell  coated  cover-slips  were  incubated  at 
temperatures of 37
oC, 38
oC, 39
oC, 40
oC, 41
oC, 42
oC, 43
oC, 44
oC, 45
oC,  46
oC and  
47
oC for 30 min then left to recover for 1 hr at 37
 oC. Following treatment cells were 
washed 3x in PBS, then fixed in 500 µl 4% paraformaldehyde for 20 minutes at room 
temperature. To quench residual paraformaldehyde the cells were washed 3x in PBS 
followed by incubation in 10 mM Tris/HCL pH 7 for 10 min at room temperature. 
After incubation the cells were again washed 3x in PBS then blocked  in 500  l 
blocking  buffer  (Table  2.1.8)  for  20  min  at  room  temperature.  The  cell  coated 
coverslips were again washed 3x in PBS, the coverslips were removed from the 24 
well tissue culture plate using tweezers and incubated cell face down in 50  l mouse 
anti-HSP70  antibody  1/100,  on  parafilm  for  45  min  at  room  temperature.  After 
incubation the coverslips were washed 3x in PBS, placed cell face up in 12 well 
plates  and  further  incubated  with  500   l  goat  anti-mouse  antibody  labelled  with 
Alexa  Fluor  564  1/500  (Molecular  Probes)  and  counterstained  with  nuclei  stain 
Hoechst 1/5000 (Molecular Probes) for 30 min, in the dark, at room temperature, on 
a rocker. To remove unbound secondary antibody cell coated coverslips were washed 
3x in PBS followed by 1 PBS wash on the rocker for 1 min and 1 wash in dH2O. The 
coverslips were mounted cell face down on coverslides in ProLong antifade (GE-
Healthcare) imaged by using a Zeiss LSM 510 meta-confocal microscope.  
 
2.2.8.4. AMF Heating of Adherent Cells Incubated in SPIONs: Viable Cell Counts 
 
Viability cell counts were performed to determine whether AMF activated SPIONs 
and scFv-SPION conjugates can induce a hyperthermic cell death. Briefly; CEA+ve 
LS174T cells were grown to 75% confluency in a T25 flask culture medium. The 
cells were then washed 3 times in PBS and released by trysonisation. The cells were   57 
centrifuged and cell pellet resuspended well in 1ml culture medium containing no 
SPIONs, 1 mg/ml, 5 mg/ml, 10 mg/ml or 25 mg/ml SPIONs. The samples were 
placed  into  AMF  system  1.  An  alternating  magnetic  field  of  300V,  0.62A  and 
139.8Hz was applied for 20min.  
 
To  determine  cell  viability  the  cells  was  centrifuged,  washed  3x  in  PBS  and 
resuspended in 10ml culture medium. One hundred microlitres of resuspended cells 
was mixed with 100µl Tryphan Blue stain which stains non-viable cells. The cells 
were  counted  x3  using  a  haemocytometer,  under  an  inverted  phase  contrast 
microscope. Total viable cell number of was calculated using equation 2.7. 
 
2.2.8.5 AMF heating of adherent cells incubated in SPIONs: MTT assay 
 
MTT viability assay was performed to determine whether AMF activated SPIONs 
and scFv-SPION conjugates can induce a hyperthermic cell death. Briefly, cells were 
seeded at a density of 1x10
5 cells/ml, 200 µl/well into 4 wells of sterile strip-wells (1 
stripwell per test). The strip-wells were placed into a 96 well frame.  
 
The cells to be treated with the scFv-SPION conjugates +/- AMF were incubated for 
1 day at 37
oC in a tissue culture incubator; media was then replaced with 100 µl of 
filtered sterilised scFv-SPION at 0.1 mgSPION/ml in culture media and incubated 
for a further 24 hr at 37
oC in a tissue culture incubator. After incubation the wells 
were washed 3x PBS and 100  l of fresh media was added to each well. 
 
The cells to be treated with non functionalised SPIONs +/-AMF were incubated for 2 
days at 37
oC in a tissue culture incubator. Following incubation the medium was 
removed and replaced with 100  l filter sterilised medium containing 5 mg/ml, 2.5 
mg/ml, 1 mg/ml 0.5 mg/ml or 0.1 mg/ml SPIONs, 2x strip-wells per concentration, 
one to be AMF control and the other to be treated with the AMF.  
 
One strip-well at a time was exposed to the AMF of 150 V, 0.74 A and 1 MHz for 30 
min. To remain sterile the cell coated strip-wells was placed into a 15 ml test tube, 
with the lid screwed loosely on, this was then placed inside the AMF heating coil. 
Ambient  temperature  was  maintained  at  37
oC  using  the  Air-Therm.  After  AMF   58 
treatment the strip-wells were placed back into the 96 well frames, the cells were 
then washed and incubated a further 96 hr in fresh media. MTT (20 µl; 5 mg/ml) was 
subsequently added to each well and incubation allowed to proceed for a further 4 hr.  
Media was then carefully removed and the purple formazan crystals were solubilised 
using 100 µl/well of DMSO.  Absorbance at 550 nm was measured using the Opsys 
MRÔ Microplate Reader (Dynex Technologies). The percentage cell survival was 
determined by comparison with untreated control wells.  
 
2.2.8.6  AMF heating of adherent cells incubated in SPIONs: heat shock protein 70 
immunocytochemistry staining 
  
Confocal  microscopy  was  performed  to  determine  whether  AMF  treated  cells 
incubated in scFv functionalised or non-functionalised SPION can induce HSP70 
expression. Briefly, cells were seeded at a density of 1x10
5 cells/ml, 500 µl/well onto 
sterile 13 mm circular coverslips (VWR) placed in 24 well tissue culture plates. Cells 
were incubated 2 days at 37
oC in a tissue culture incubator humidified with a CO2 
concentration of 5%.  
 
In triplicate the cell coated cover-slips were incubated with either filter sterilised 
media  containing  scFv-SPIONs  (0.1  mgSPION/ml)  overnight,  followed  by  PBS 
washed to remove unbound SPION and incubated in 500  l fresh medium or filter 
sterilised media  containing  1 mg/ml SPION before AMF  treatment.  Cell coated 
cover-slips were exposed to the AMF of 300 V, 0.62 A and 139.8 Hz for 30 min 
using AMF system 1. To remain sterile the cell coated strip-wells was placed into the 
lid of a 7 ml bijou tube, immersed in either media or SPIONs, with the tube screwed 
tightly on, the tube was placed inside the AMF heating coil. The ambient temperature 
was  maintained  at  37
oC  using  an  Air-Therm.  Following  AMF  treatment  the  cell 
coated coverslips were placed into 24 well plates and washed 3x in PBS followed by 
further incubated in fresh medium for 4 hr in tissue culture conditions. The cells were 
again washed 3x in PBS, then fixed in 500 µl 4% paraformaldehyde for 20 min at 
room temperature. To quench residual paraformaldehyde the cells were washed 3x in 
PBS  followed  by  incubation  in  10  mM  Tris/HCL  pH  7  for  10  min  at  room 
temperature. After incubation the cells were again washed 3x in PBS then blocked in   59 
500  l blocking buffer (Table 2.1.8) for 20 min at room temperature. Once blocked 
the cell coated cover-slips were washed 3x in PBS, using tweezers the cover-slips 
were removed and incubated cell face down in 50  l mouse anti-HSP70 antibody 
1/100, on parafilm for 45 min at room temperature. After incubation the cover-slips 
were washed 3x in PBS, placed cell face up in 12 well plates and further incubated 
with  500   l  goat  anti-mouse  antibody  labelled  with  Alexa  Fluor  564  1/500 
(Molecular Probes) and counterstained with nuclei stain Hoechst 1/5000 (Molecular 
Probes)  for  30  min,  in  the  dark,  at  room  temperature,  on  a  rocker.  To  remove 
unbound  secondary  antibody  cell  coated  cover-slips  were  washed  3x  in  PBS 
followed by 1 PBS wash on the rocker for 1 min and 1 wash in dH2O. The coverslips 
were mounted cell face down on coverslides in ProLong antifade (GE-Healthcare) 
imaged by using a Zeiss LSM 510 meta-confocal microscope.  
 
2.2.9 In vivo biodistribution study 
 
All animal work was carried out according to home office license with the help of Mr 
Matthew Robson (Department of Oncology) in the Comparative Biology Unit at the 
Royal Free Hospital. 
 
2.2.9.1 LS174T colorectal tumour xenografts 
 
The  CEA+ve  LS174T  cell  line  was  used  to  develop  a  xenograft  model  by 
subcutaneous implantation of small tumour pieces (~1mm
3) in the left flank of male 
nude mice and were used at 2-3months old weighing 20-25 g at the start of the 
experiment. Subsequent passaging was performed under halothane anaesthesia by 
continuous subcutaneous implantation of the original xenograft. Mice were used 3 
weeks after passaging when the mean tumour volume was approx 0.5-1 cm
3. 
 
2.2.9.2 Biodistribution of Sm3E-SPION conjugates 
 
Biodistribution  study  of  the  functionalised  SPIONs  was  performed  into  mice  to 
determine  the  biodistribution  of  the  SPIONs  following  systemic  injection.  Two 
hundred  microlitre  of  Sm3E  functionalised  and  non  functionalised  SPIONs  were 
injected  intravenously  via  tail  vein  in  mice  bearing  CEA+ve  LS174T  tumour   60 
xenografts. Two mice were used per time point. At 5 min, 1 hr, and 24 hr post 
administration, mice were sacrificed, the tumours, liver and spleen were removed 
and snap frozen in liquid nitrogen and stored at -80
oC ready for cryo-sectioning. 
 
2.2.9.3 Prussian blue staining of frozen tissue sections 
 
Prussian blue staining was used to stain the SPIONs in tissue section. Using Coplin 
jars, cryo-sectioned tissue on slides were submerged and fixed in acetone for 10 min. 
The slides were air dried for 1 min then rehydrated in distilled water for 1 min. To 
detect the iron of the SPIONs the hydrated tissues were submerged in 25 ml Prussian 
blue staining solution (see Table 2.10) for 30 min then washed 3x in distilled water. 
The slides were placed on a tray and covered in 0.1% Nuclear fast red for 5 min 
following this the cells were washed 3x in distilled water. Once washed the slides 
were dehydrated in alcohol then washed in histo-clear. Slides were mounted onto 
coverslips coated with a drop of DPX resin and imaged under light microscope.  
 
.  
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Chapter 3 
 
 
Conjugation of Anti CEA ScFvs to 
SPIONs 
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3.1 Introduction  
 
The overall aim of the work in this thesis was to generate antibody targeted SPION 
conjugates  for  imaging  and  therapy.  The  first  aim  of  the  work  described  in  this 
chapter was to develop a system to chemically conjugate recombinant scFv antibody 
fragments in functional form to SPIONs. 
 
The targeting antibodies used were the anti CEA scFvs MFE-23 and Sm3E. The 
murine scFv MFE-23 was tested as it has been extensively characterised (Chester et 
al., 2000), the humanised high affinity version Sm3E was tested as it is thought to be 
more  applicable  for  the  clinic,  minimising  the  chance  of  HAMA  responses.  The 
scFvs were conjugated to SPIONs via free amines presented on lysine groups. Amine 
coupling reactions are one of the most common conjugation methods, generally easy 
to perform, resulting in good conjugation yields (Haugland et al., 2001).  
 
Nine different SPIONs were tested (see section: 2.1.5 Superparamagnetic iron oxide 
nanoparticles). These had different composition, size, and surface chemistry, which 
could  influence  the  chemistry  used  for  scFv  functionalisation.  Three  conjugation 
chemistries were evaluated: 1) sodium periodate oxidation, 2) carbodiimide and 3) 
cyanogen bromide. The stability during purification and storage was investigated and 
immunoreactivity of the scFv-SPION conjugates to CEA was tested.  
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3.2 Objectives 
 
The objectives of the research described in this chapter were to: 
 
1.  Generate anti CEA scFvs 
 
2.   Select suitable SPIONs for this study  
 
3.  Establish and optimise conjugation chemistries for SPIONs  
 
4.  Establish  ELISA  method  to  test  immunoreactivity  of  the  scFv-SPION 
conjugates to CEA 
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3.3 Results 
 
3.3.1 Generation of anti CEA scFv 
 
3.3.2.1 MFE-23 
 
MFE-23 was kindly donated by Dr Berend Tolner (Cancer Institute UCL) and had 
been generated using the Pichia pastoris expression system. SDS-PAGE/Coomassie 
and ELISA confirms purity, size and immunoreactivity of MFE-23 (Fig. 3.1). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Pooled MFE-23 was tested for purity and CEA binding. A) Coomassie stained 12% 
Tris glycine SDS-PAGE gel, shows purity of MFE-23. Lane M contains the molecular weight 
marker. B) CEA ELISA of MFE-23. Detection of binding was performed with a mouse anti-
His primary antibody, followed by a sheep anti-mouse HRP. PBS was used as a negative 
control. 
 
3.3.1.2 Sm3E 
 
Sm3E  was  expressed  and  purified  from  the  yeast  Pichia  pastoris  in  a  10  litre 
fermenter  (see  section:  2.2.1  Protein  expression  and  2.2.2  Protein  purification). 
Following EBA-IMAC purification, SDS-PAGE/coomassie gel analysis shows the 
majority  of  Sm3E  to  elute  in  the  200  mM  imidazole  fractions  10-15  (Fig.  3.2). 
Fractions  10-15  were  pooled  to  give  a  300  ml  Sm3E  protein  fraction.  From 
absorbance readings at 280 nm the concentration of Sm3E at this point was estimated 
to be 0.7 mg/ml.  
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Fig.  3.2.  Coomassie  stained  12%  Tris/glycine  gel  containing  fractions  from  EBA-IMAC 
purification of Sm3E. Lane M contains the molecular weight marker. Fractions taken at each 
purification are shown: lane 1-4, product present in bioreactor at elapsed fermentation times 
(EFT) of 46, 50, 54 and 72 hrs; lane 5 and 6, wash steps with 40 mM imidazole; lanes 7-20, 
successive 200 mM imidazole elution fractions; lane 21, pooled fractions 10-15; lane 22, 
EDTA fraction. There is very little Sm3E in the 40 mM wash and EDTA wash, most of the 
scFv is in the 200 mM fractions.  
 
 
Further purification of the Sm3E scFv by SEC using Superdex 75 matrix revealed 
two peaks (Fig. 3.3). Western blot results (Fig.  3.4) showed the proteins in both 
peaks to be reactive to the mouse anti His mAb. This result indicates Sm3E is eluted 
in both peaks. From reference to MW standards used as calibrants on the Superdex 
75 column, Sm3E is presumably in dimer and monomer form.  From the amino acid 
sequence of Sm3E-His, the MW of Sm3E is 27 kDa. Therefore, the Sm3E fractions 
eluted in the 2
nd peak, close to the 27 kDa mark, were pooled and assumed to be the 
monomeric form of the protein. SDS/PAGE/coomassie gels shows the fractions to be 
pure, giving a single band of approx 27 kDa (Fig. 3.4). From absorbance readings at 
280 nm the concentration of the Sm3E was estimated to be 0.3 mg/ml. ELISA of the 
pooled Sm3E fractions confirms its immunoreactivity to CEA (Fig. 3.5). 
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Fig.  3.3  Size  exclusion  chromatography  of  P.pastoris  expressed  Sm3E.  25  ml  of  Sm3E 
purified from streamline was applied to the 500 ml Superdex 75 column at flow rate 4 ml/min 
in PBS buffer. Two peaks corresponding to monomeric (M) and dimeric (D) are present with 
the majority of Sm3E being in the monomeric form. The elution volumes of MW standards 
are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.4.  SDS-PAGE  of  SEC  purified  Sm3E.  Coomassie  stained  12%  Tris  glycine  SDS-
PAGE gels and Western blot containing fractions from SEC purification. Lane M contains the 
MW  marker.  Fractions  taken  across  the  2  elution  peaks  are  shown:  lane  1-18  contain 
fractions 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42. Fraction 14-
30 contained majority of monomeric Sm3E and were pooled. The blots were developed with 
a mouse anti-His mAb as a primary antibody, followed by sheep anti-mouse mAb HRP. 
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Fig. 3.5 CEA binding analysis of purified P. pastoris expressed Sm3E. Pooled Sm3E fraction 
was tested for binding to CEA by ELISA. Detection of binding was performed with a mouse 
anti-His  as  primary  antibody,  followed  by  sheep  anti-mouse  HRP.  PBS  was  used  as  a 
negative control. 
 
 
3.3.2 SPION stability 
 
The stability and solubility of the SPIONs in physiological buffers are important 
parameters for handling and purification when developing scFv-SPION conjugates. 
Therefore,  the  stability  and  solubility  of  the  SPIONs  after  three  commonly  used 
purification  methods,  centrifugation,  magnetic  separation  and  size  exclusion 
chromatography were assessed prior to attachment experiments. Briefly, SPIONs at 
1mg/ml were either centrifuged at 13000 RPM for 30 min, placed on a high field 
magnet overnight or applied to SEC column. Application to the SEC column was 
either by gravity, in the case of Sephadex –G25 or by peristaltic pump at a flow rate 
of  1  ml/min  for  the  Sephacryl  300HR.  The  solubility  of  the  SPIONs  following 
resuspension or elution was assessed visually. 
 
Results showed that, the d100, d50, PEG-d50, PEG-d20 and CMX50 remained in 
solution  following  centrifugation  and  magnetic  separation.    In  comparison,  the 
DX200, DX100, CMX200 and CMX100 were successfully separated from solution 
by  centrifugal  and  magnetic  force  (Fig.  3.6).  However,  only  DX200,  DX100, 
CMX200 and CMX100 SPIONs that were separated out by magnetic force could be 
resuspended. The SPIONs separated out by centrifugation remained insoluble.  
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Fig.  3.6.  Magnetic  separation  of  SPIONs.  From  left  to  right,  DX200,  DX100,  CMX200, 
CMX100  and  CMX50.  All  SPIONs  were  successfully  pulled  out  of  solution,  except  the 
CMX50. 
 
 
Purification  of  the  SPIONs  by  size  exclusion  chromatography  (SEC)  was 
investigated with two matrixes, the Sephadex-G25 and the Sephacryl 300HR.  
 
All the SPIONs tested (d50, d100, PEG-d50, PEG-d20, DX100, DX200, CMX50, 
CMX100, CMX200) moved freely through the Sephadex G-25 and remained soluble 
after elution. However, due to the low molecular weight filtration threshold (<5kDa) 
of  Sephadex  G-25,  the  matrix  appeared  to  be  unsuitable  for  separating  unbound 
scFvs (27kDa) from the scFv-SPION conjugate solution, as both the unbound scFv 
and conjugate would appear in the void volume. The Sephacryl 300HR matrix with a 
filtration  threshold  of  1.5x10
3kDa  is  more  appropriate  for  separation  of  unbound 
scFvs from the scFv-SPION conjugates. 
 
Size exclusion chromatography using the Sephacryl 300HR matrix was successful 
for the d50 (Fig. 3.7), d100, PEG-d20, PEG-d50 and the DX100 (Fig. 3.8). However, 
the CMX50 appeared to interact with the column as observed by the late elution and 
retention of the SPIONs on the column. From the elution profile the CMX50 can 
therefore, not be separated from unbound scFv. Similar results were also found with 
all other CMX-SPIONs.  
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Fig. 3.7 Size exclusion chromatography profile of A) d50, B) DX100 and C) CMX50. 2 ml of 1 
mg/ml sample was loaded onto a Sephacryl 300HR 30 ml column at flow rate 1 ml/min in 
PBS elution buffer. Profile shows the d50 and DX100 to elute off in the void volume, whereas 
the CMX50 eluted late off the column. 
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From these results, all the SPIONs except the CMX50 were taken forward to the next 
stage of scFv functionalisation. See Table 3.1 for summary of results. 
 
Table 3.1. Summary of successful purification procedures and SPIONs taken forward for 
scFv functionalisation. SPION shaded in red was not taken forward for further investigation.  
SPIONs  Successful separation 
procedures 
SPIONs taken 
Forward 
d50  Sephadex G-25 SEC 
Sephacryl 300HR SEC 
 
YES 
d100  Sephadex G-25 SEC 
Sephacryl 300HR SEC  
YES 
PEG-d20  Sephadex G-25 SEC 
Sephacryl 300HR SEC  
YES 
PEG-d50  Sephadex G-25 SEC 
Sephacryl 300HR SEC 
YES 
DX200  Sephadex G-25 SEC 
Magnetic separation 
 
YES 
DX100  Sephadex G-25 SEC 
Sephacryl 300HR SEC 
Magnetic separation 
 
YES 
CMX200  Sephadex G-25 SEC 
Magnetic separation  
 
YES 
CMX100      Sephadex G-25 SEC 
Magnetic separation 
 
YES 
CMX50 
 
Sephadex G-25 SEC 
 
NO 
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3.3.3 SPION iron content  
 
For comparability and consistency the SPION concentration (iron oxide plus coating) 
and the iron oxide, content for all the SPIONs was measured. The SPION (iron oxide 
plus coating) concentration was measured at an absorbance reading of 490nm and the 
iron  oxide  content  of  the  SPIONs  was  measured  using  the  ferrozine  assay  (see 
section:  2.2.5.2).  Results  found  the  PEG-dSPIONs  contained  approximately  40% 
iron oxide (Fig. 3.8), indicating the other 60% to be the dextran-PEG coating. In 
comparison, the dSPIONs at the same SPION concentration contained approximately 
14% iron oxide, under half the amount of iron compared to the PEG-dSPIONs (Fig. 
3.8). The concentration of the PEG-dSPIONs and dSPIONs was further analysed by 
spectrophotometric  absorbance  readings  at  490  nm.  Results  revealed  the  PEG-
dSPIONs  to  be  twice  as  concentrated  as  the  dSPIONs  (Fig.  3.9).  These  results 
therefore, suggest that the dSPIONs were supplied at the same concentration as the 
PEG-dSPIONs,  5  mg/ml  instead  of  the  stated  10  mg/ml.  For  comparability,  the 
dSPION concentration was assumed to be 5 mg/ml.  
 
Ferrozine assay analysis showed the DX-SPIONs to consist of 60% iron oxide (Fig. 
3.10), suggesting the other 40% to be dextran.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8. Iron concentration of serial diluted SPIONs as measured by the ferrozine based iron 
assay. Detection of Fe
2+ was performed at absorbance of 550 nm. Values were compared 
against a calibration curve of FeCl3 standards.  
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Fig. 3.9. Absorbance readings at 490 nm of serial diluted SPIONs. Absorbance values were 
used as reference to determine the concentration of the SPIONs in the conjugate solution.  
 
 
3.3.4 Sodium periodate conjugation of MFE-23 to SPIONs  
 
The feasibility of successfully conjugating scFvs to SPIONs was first investigated 
using the MFE-23 scFv and the d50 SPION. 
 
The sodium periodate oxidation chemistry, schematically represented in Fig. 3.10 
and  detailed  in  section  2.2.4.1  was  used  to  conjugate  MFE-23  to  the  d50.  This 
chemistry was chosen due to the available hydroxyl groups on the d50’s dextran 
coat.  
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Fig.  3.10.  Schematic  representation  of  sodium  periodate  conjugation  chemistry.  The 
available OH groups on the dextran coat are oxidised by sodium periodate creating reactive 
aldehyde functions, which react with free amine groups on lysines or unblocked N-terminus 
found in the protein structure of MFE-23. The bond is reduced with sodium borohydride to 
create a stable covalent bond. 
 
 
To establish the chemistry, 5 mg/ml of oxidised d50 was incubated with 0.5 mg/ml 
MFE-23 for 3 hrs. Isolation of MFE-23-d50 conjugates from unbound MFE-23 was 
performed  by  SEC  using  the  Sephadex-G25  and  Sephacryl  300HR  matrix.  The 
elution profile from the Sephacryl 300HR purification (Fig. 3.11) shows two peaks 
one in the void volume and the other at 27 kDa. The first peak was assumed to be the 
SPIONs, as the eluate was brown in colour.  Fractions were collected and analysed 
by  ELISA  (Fig.  3.12)  and  Western  blot  (Fig.  3.13)  using  mouse  anti  His  mAb. 
Results revealed both peaks to contain MFE-23. This result indicates that the MFE-
23 eluted in the first peak was bound to the d50 SPIONs and the protein in the 2
nd 
peak was free MFE-23. This is further supported by the fact the 2
nd peak is in the 
area  MFE-23  would  elute.  These  results  therefore,  demonstrate  the  feasibility  of 
conjugating MFE-23 to the dextran coated SPIONs via amine conjugation, whilst 
retaining its immunoreactivity to CEA (Fig. 3.13).  
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Fig. 3.11. Size exclusion chromatography of MFE-23-d50 at concentration 0.5 mg: 5 mg. 2 
ml of the conjugated MFE-d50 were applied to Sephacryl 300HR 30 ml column at flow rate 1 
ml/min in PBS elution buffer. The first peak is in the void volume corresponding to the d50. A 
small  peak  is  seen  where  unbound  MFE-23  has  eluted.  The  elution  volumes  of  MW 
standards are show. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.12.  CEA  protein  ELISA  of  SEC  purified  MFE-23-d50.  Detection  of  binding  was 
performed with a mouse anti His primary antibody, followed by a sheep anti mouse HRP. 
MFE-23  was  used  as  positive  control  and  un-conjugate  dSPION  and  PBS  as  negative 
controls. Symbols used: B.S: before separation by SEC;  A.S: after separation by SEC. 
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Fig.  3.13.  SDS-PAGE  of  MFE-23-d50  before  and  after  SEC  purification.  Western  blot 
transferred from 12% Tris glycine SDS-PAGE gel containing fractions from SEC purification. 
Lane  M  contains  the  MW  marker.  Lane  1:  non-functionalised  d50,  lane  2:  MFE-23 
functionalised d50 before separation, lane 3-7: Peak fractions at 11-14 mls from SEC elution 
profile of MFE-23-d50, lanes 8-10: SEC fractions taken at 15-18 mls and lanes 11-16: SEC 
fractions taken at 19-24 mls showing presence unbound MFE-23. Lane 17: MFE-23 control. 
The  Western  blots  were  developed  with  a  mouse  anti-His  mAb  as  a  primary  antibody,  
followed by sheep anti-mouse mAb HRP. 
 
 
3.3.5 Optimisation of MFE-23-SPION conjugation 
 
Results  from  the  MFE-23-d50  conjugation  showed  that  a  substantial  amount  of 
MFE-23 remained unattached to the SPIONs. Optimisation of the sodium periodate 
procedure to reduce the amount of unbound MFE-23 was performed. The excess of 
unbound MFE-23 maybe due to the reactive sites of the d50 being exhausted. It was 
postulated  this  could  be  improved  by  increasing  the  number  of  reactive  sites  by 
further oxidation with sodium periodate. However, following incubation with sodium 
periodate at a concentration of 20 mM the d50 precipitated.   
 
Since  it  was  not  possible  to  increase  the  number  of  reactive  sites  an  alternative 
approach was taken to reduce the  loss of MFE-23. The ratio of MFE-23 to d50 was 
reduced from 0.5 mg: 5 mg to 0.1 mg: 5 mg. Following purification by SEC on the 
Sephacryl 300HR the elution profile revealed 1 peak in the void volume (Fig. 3.14). 
The fraction eluted at this peak was brown in colour therefore, was assumed the d50. 
The fraction was analysed by Western blot using mouse anti His mAb (Fig. 3.15). 
Results revealed the fraction to contain MFE-23, indicating MFE-23 was attached to   76 
the  d50.    No  peak  was  seen  at  the  point  where  unbound  MFE-23  would  elute, 
suggesting majority of the MFE-23 to have bound to the d50. However, a small 
amount of unbound MFE-23 was detected by Western blot (Fig. 3.15). 
 
To  test  whether  increasing  the  incubation  time  would  further  improve  the 
scFv:SPION binding ratio the time for conjugation was increased from 3 hrs to 24 
hrs.  Following  purification,  the  MFE-23-d50  (24  hr)  fractions  were  analysed  in 
parallel with MFE-23-d50 (3 hr) by CEA ELISA using mouse anti His mAb (Fig. 
3.16).  The  results  show  the  MFE-23-d50  (24  hr)  to  have  a  small  but significant 
(p<0.001) increase in binding on the ELISA assay compared to the MFE-23-d50 (3 
hrs), suggesting 24hr incubation time and a scFv to d50 ratio of 1:50 to be more 
favourable.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14. Size exclusion chromatography profile of MFE-23-d50 (0.1 mg: 5 mg), after 3 hr 
incubation.  2  ml  of  the  conjugated  MFE-23-d50  was  applied  to  Sephacryl  300HR  30  ml 
column at flow rate 1 ml/min in PBS elution buffer. The peak in the void volume corresponds 
to MFE-23-d50. No peak is seen where unbound MFE-23 should elute. The elution volumes 
of MW standards are shown. 
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Fig. 3.15. Western Blot analysis of MFE-23-d50 (0.1 mg: 5 mg) after incubation for 3hrs. 
Western blot  transferred from  12%  Tris  glycine  SDS-PAGE gel  containing fractions  from 
SEC purification. Lane M contains the MW marker. Lane 1: MFE-23 control, lane 2: Non-
functionalised d50, lane 3: MFE-23-d50 before separation, lane 4: MFE-23-d50 pooled SEC 
fractions  and  lane  5:  unbound  MFE-23  pooled  SEC  fractions.  The  Western  blots  were 
developed with a mouse anti-His mAb primary antibody, followed a sheep anti-mouse mAb 
HRP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.16.  CEA  ELISA  of  the  MFE-23-d50  conjugate  after  SEC  purification.  Detection  of 
binding was performed with a mouse anti-His primary antibody, followed by a sheep anti-
mouse HRP. MFE-23 was used as a positive control and non-functionalised d50 and PBS 
were used as negative controls * p= <0.001 by T-test analysis. 
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These results show that for minimal loss of MFE-23 the optimal ratio scFv to d50 is 
0.1 mg: 5 mg. To allow for maximal binding of the scFvs to d50 an incubation time 
of 24 hrs at room temperature was favourable. Therefore, a ratio 1:50 for scFv to 
SPION and a 24 hr incubation time was used for all subsequent conjugations.  
 
 
3.3.6. Application of optimised conjugation chemistry to the Sm3E scFv 
 
The feasibility of conjugating Sm3E to the DX100, DX200, d100 and d50 using the 
optimised  sodium  periodate  conjugation  chemistry  was  also  tested.  Results  are 
shown below.  
 
3.3.6.1 DX-SPIONs 
 
Oxidation of both the DX100 and DX200 by 10 mM sodium periodate caused the 
SPIONs to become unstable and precipitate. Even upon reducing the concentration of 
sodium  periodate  to  5  mM,  destabilisation  of  the  DX-SPIONs  was  still  visually 
evident. The DX-SPIONs therefore, were unable to be conjugated to the Sm3E scFv 
via the sodium periodate conjugation chemistry. 
 
3.3.6.2 dSPIONs 
 
The d100 and d50 remained soluble throughout the sodium periodate conjugation 
procedure.  The SEC elution profile showed that both the Sm3E-d100 and Sm3E-d50 
eluted in the void volume and that no peak indicative of unbound Sm3E was detected 
(Fig. 3.17). The SPION elution fraction was analysed by ELISA using anti His mAb 
and anti dextran mAb (Fig. 3.18). Results confirmed the eluate to contain immuno-
reactive Sm3E, assumed to be bound to the dSPIONs. ELISA results also show no 
detectable binding of non-functionalised SPIONs to CEA. These results indicate that 
binding  of  both  the  Sm3E-d100  and  Sm3E-d50  to  CEA  was  via  the  conjugated 
Sm3E. 
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Fig. 3.17 Size exclusion chromatography of A) Sm3E-d100 and B) Sm3E-d50. 2 ml of the 
Sm3E-dSPION conjugate solution was applied to the Sephacryl 300HR column at a flow rate 
1 ml/min in PBS elution buffer.  The peak in the  void volume corresponds to the  Sm3E-
dSPIONs,  no  peak  is  seen  where  unbound  Sm3E  should  elute.  The  elution  volumes  of 
molecular weight standards are shown. 
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Fig. 3.18. The Sm3E-d100 and Sm3E-d50 conjugates after SEC purification were tested for 
binding  to  CEA  by  ELISA.  ELISA  A)  detected  with  a  mouse  anti-His  primary  antibody, 
followed by a sheep anti-mouse HRP. Positive control was Sm3E, negative controls were 
non-functionalised d100 and d50 and PBS.  ELISA B) detected with a mouse anti-dextran 
primary antibody, followed by a sheep anti-mouse HRP. Negative controls were Sm3E, non-
functionalised d100 and d50 and PBS.  
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To  further  confirm  and  quantify  the  attachment  of  Sm3E  to  the  d100  and  d50 
SPIONs,  the  conjugate  solutions  were  analysed  by  Bradford  protein  assay  and 
spectrophotometric  readings,  results  were  calculated  using  equation  2.2-2.5  (see 
section: 2.2.5 scFv-SPION conjugation analysis). Results showed approximately 120 
and 28 Sm3E scFvs to bind per d100 and d50 (Table 3.2). 
 
One  limitation  with  SEC  is  the  dilution  of  the  eluted  fractions.  To  increase  the 
concentration  of  the  conjugate  solutions  centrifugation  using  the  Vivaspin  15R 
concentration  tubes  was  tested.  The  Sm3E-dSPION  solution  concentrated 
successfully,  minimal  destabilisation  was  observed  and  loss  was  negligible  as 
measured by absorbance at 490nm. 
 
 
3.3.7 Cyanogen bromide conjugation of Sm3E to DX-SPIONs 
 
The cyanogen bromide (CNBr) conjugation chemistry represented schematically in 
Fig. 3.19 and detailed in section 2.2.4.3 was investigated as an alternative method for 
conjugation of the DX100 and DX200 to Sm3E.  
 
 
 
 
 
 
 
 
 
 
Fig. 3.19. Schematic representation of the cyanogen bromide conjugation chemistry. The 
available  OH  groups  on  the  dextran  coat  are  activated  by  cyanogen  bromide,  forming 
cyanate ester groups which react with free amine groups on lysines or unblocked N-terminus 
found in the protein structure of Sm3E. 
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Incubation of the DX-SPIONs with CNBr causes activation of the hydroxyl groups 
on the dextran coat, allowing it to react with free amine groups on Sm3E. SEC using 
the  Sephadex-G25  was  used  to  purify  the  activated  DX-SPIONs  from  CNBr. 
Following elution from the Sephadex-G25 column, the DX-SPIONs were found to 
remain in solution. Isolation of the Sm3E-DX-SPION conjugates was performed by 
several  magnetic  washes.    Following  conjugation  to  Sm3E,  the  Sm3E-DX200 
became  unstable  and  precipitated.  In  contrast,  the  Sm3E-DX100  remained  stable 
upon subjection to this procedure  (Fig. 3.20). For this reason, the DX200 was not 
taken forward for further investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.20. Stability of the Sm3E-DX100 and Sm3E-DX200 following conjugation. A) Sm3E-
DX200  showed  complete  precipitation,  B)  Sm3E-DX100,  the  majority  remains  soluble  in 
PBS. 
 
 
The  supernatant  from  the  magnetic  washes  and  the  resuspended  Sm3E-DX100 
conjugates were analysed by CEA ELISA using anti His mAb and anti dextran mAb 
(Fig. 3.21). Results showed the Sm3E-DX100 to react with CEA, confirming the 
presence of immuno-reactive Sm3E. Only a minimal amount of unbound Sm3E was 
present in the magnetic washes, indicating the majority of the Sm3E to be chemically 
coupled to the DX100.  
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Fig.  3.21.  CEA  ELISA  of  the  Sm3E-DX100  conjugate  ELISA  A)  also  contains  magnetic 
washes 1-4.  Binding was detected with a mouse anti-His primary antibody, followed by a 
sheep anti-mouse HRP. Sm3E was used as positive control, non-functionalised DX100 and 
PBS were used as negative controls. ELISA B) binding was detected with a mouse anti-
dextran  primary  antibody,  followed  by  a  sheep  anti-mouse  HRP.  Negative  controls  used 
were Sm3E, non-functionalised DX100 and PBS.  
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To quantify the attachment of Sm3E to the DX100, the conjugate solutions were 
analysed  by  Bradford  protein  assay  and  spectrophotometric  readings.  Results 
however,  were inconclusive because the  colour change of  the  sample  due  to the 
Bradford reagents, appeared to be minimal relative to the colour of the actual SPION 
solution.  
 
3.3.8 Carbodiimide conjugation of Sm3E scFv to SPIONs 
 
Unlike the dSPIONs and DX-SPIONs, which present OH terminal groups the PEG-
dSPIONs  and  CMX-SPIONs  present  terminal  COOH  groups.  To  facilitate  the 
conjugation  of  Sm3E  to  the  COOH  groups  presented  by  the  SPIONs  the 
carbodiiminde  conjugation  chemistry,  schematically  presented  in  Fig.  3.22  and 
detailed in section 2.2.4.2, was investigated.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.22. Schematic representation of the carbodiimide conjugation chemistry. The available 
COOH groups on the PEG and carboxymethylated dextran coat are activated by EDC/NHS 
to  form an  ester  group  which  reacts  with free amine groups  on  lysines or unblocked  N-
terminus found within the protein structure of Sm3E.  
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3.3.8.1 CMX-SPIONs 
 
Purification of the EDC/NHS activated CMX-SPIONs was achieved by SEC using 
the  Sephadex-G25.  Following  elution,  the  CMX-SPIONs  were  found  to  remain 
soluble in solution. Isolation of the Sm3E-CMX-SPION conjugates was performed 
by several magnetic washes.  However, throughout the magnetic washes both the 
Sm3E-CMX100 and Sm3E-CMX200 precipitated. Due to insolubility, the CMX100 
and CMX200 SPIONs were not taken forward for further investigation.  
 
3.3.8.2 PEG-dSPIONs 
 
Isolation of Sm3E-PEG-dSPION conjugates from unbound Sm3E was performed by 
SEC using the Sephadex-G25 and Sephacryl 300HR matrix. The elution profile from 
the  Sephacryl  300HR  purification  shows  Sm3E-PEG-d20  and  Sm3E-PEG-d50  to 
elute off cleanly in the void volume, no free Sm3E was evident from the SEC profile 
(Fig. 3.23). The SPION elution fraction was analysed by ELISA using anti His mAb 
and anti dextran mAb (Fig 3.24). From the results the eluted fractions react with 
CEA confirming, Sm3E has been successful coupled to both the PEG-d20 and PEG-
d50 SPIONs and retained its immunoreactivity to CEA.  
 
To determine whether the incubation time of the activated PEG-dSPIONs with Sm3E 
affects the number of scFv binding to the PEG-dSPION, incubation times of 3 hrs 
and 24 hrs were compared. Quantification of the number of Sm3E scFvs bound to the 
PEG-d20, PEG-d50, following incubation for 3 hrs and 24 hrs, was determined by 
Bradford  protein  assay,  and  spectrophotometric  readings  and  calculated  using 
equation 2.2-2.5. Results showed, after 3 hr incubation approx 0.5 and 10 Sm3E 
scFvs had bound per PEG-d20 and PEG-d50. However, by increasing the incubation 
time to 24 hrs approx 2 and 29 Sm3E scFvs bound per PEG-d20 and PEG-d50 (Table 
3.2). 
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Fig. 3.23 Size exclusion chromatography purification of A) Sm3E-PEG-d20 and B) Sm3E-
PEG-d50. 2 ml of the Sm3E-PEG-dSPION conjugates were applied to Sephacryl 300HR 
column at flow rate 1 ml/min in PBS elution buffer. The peak in the void volume corresponds 
to the Sm3E-PEG-dSPION conjugates. No peak is seen where unbound Sm3E should elute. 
The elution volumes of MW standards are shown. 
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Fig.  3.24.  CEA  ELISA  of  SEC  purified  Sm3E-PEG-d20  and  Sm3E-PEG-d50  conjugates.  
ELISA A) binding was detected with a mouse anti-His, primary antibody, followed by a sheep 
anti-mouse HRP. Sm3E was used as a positive control, non functionalised PEG-dSPION 
and PBS were used as negative controls. ELISA B) binding was detected with a mouse anti-
dextran primary antibody, followed by a sheep anti-mouse HRP. Sm3E, non-functionalised 
PEG-dSPION and PBS were used as negative controls.  
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Table 3.2 Details the concentration of Sm3E as determined by Bradford protein assay and 
the  concentration  of  d100,  d50,  PEG-d20  and  PEG-d50  as  determined  by 
spectrophotometric readings. The number of Sm3E binding per SPION was estimated from 
these results.  
 
SAMPLE  SPION 
(mg/ml) 
Number 
SPIONs/mg 
Sm3E 
(ug/ml) 
(total vol 
7mls) 
Number 
scFv 
scFv / 
SPION 
% bound 
Sm3E 
Sm3E-d100 
(24hr incubation) 
0.375  0.25x 10*12  1.4  3 x 10 *13  120  10% 
Sm3E-d50 
(24hr incubation) 
0.35  7 x 10 *12  5  1x10 *14  28  35% 
Sm3E-PEG-d50  
(3hr incubation) 
 
0.28  2.8 x 10 *12  1.4  3x10 *13  10  10% 
Sm3E- PEG-d50  
(24hr incubation) 
0.3  3 x  10 *12  4  8.9x10*13  29  29% 
Sm3E- PEG-d20 
(3hr incubation) 
0.275  0.43 x 10*14  0.6  1x10 *13  0.5  4% 
Sm3E- PEG-d20 
(24hr incubation) 
0.38  0.6 x 10*14  6  1.3x10 *14  2  42% 
 
. 
 
Results  presented  in  this  chapter  for  the  development  of  MFE-23  and  Sm3E 
functionalised SPIONs are summarised in Table 3.3.  
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Table 3.3. Summary of results presented in this chapter regarding the preferred washing 
procedures,  conjugation  chemistry,  stability  of  the  scFv-SPION  conjugates  and  CEA 
reactivity. The SPIONs shaded in read were not taken forward for further investigation. 
 
SPIONs  Separation 
method 
Conjugation 
chemistry 
Stable  CEA 
reactive 
Sm3E-d50  SEC  Sodium 
periodate 
YES  YES 
Sm3E-d100  SEC  Sodium 
periodate 
YES  YES 
Sm3E-PEG-d20  SEC  Carbodiimide 
(EDC/NHS) 
YES  YES 
Sm3E-PEG-d50  SEC  Carbodiimide 
(EDC/NHS) 
YES  YES 
Sm3E-DX200  Centrifuge  
Magnetic 
Cyanogen 
bromide 
NO  Not tested 
Sm3E-DX100  Centrifuge  
Magnetic 
Cyanogen 
Bromide 
YES  YES 
Sm3E-CMX200  Centrifuge  
Magnetic 
Carbodiimide 
(EDC/NHS) 
NO  Not tested 
Sm3E-CMX100  Centrifuge  
Magnetic 
Carbodiimide 
(EDC/NHS) 
NO  Not tested 
Sm3E-CMX50   None  Not tested  Not tested  Not tested 
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3.4 Discussion  
 
The  work  presented  in  this  chapter  has  examined  the  feasibility  of  stably 
functionalising  SPIONs  with  anti  CEA  scFvs.  The  scFv-SPION  conjugates  were 
subsequently used to test the hypothesis that scFv functionalised SPIONs can be 
targeted and bind specifically to CEA. 
 
The  nine  SPIONs  tested  had  different  characteristics,  which  can  affect  their 
behaviour  throughout  the  conjugation  reaction.  Fundamental  to  the  conjugation 
protocol is the development of suitable handling and washing procedures to enable 
stopping of reactions, removal of excess chemicals and purification of scFv-SPION 
conjugates  whilst  maintaining  solubility.  Therefore,  prior  to  attempting 
functionalisation  the  SPIONs  solubility,  following  centrifugation,  magnetic 
separation and SEC was visually assessed.    
 
Due  to  the  solubility  of  the  dSPIONs  and  PEG-dSPIONs,  centrifugation  and 
magnetic separation were unsuitable for separation of these SPIONs from solution 
and therefore were not used as a method to purify scFv-dSPION and scFv-PEG-
dSPION conjugates. The dSPIONs and PEG-dSPIONs however, were successfully 
purified  following  SEC  with  both  the  Sephadex-G25  and  the  Sephacryl  300HR 
matrix. The most likely explanation for the SPIONs solubility is that the dSPIONs 
and PEG-dSPIONs are ferrofluids. Due to the dSPIONs and PEG-dSPIONs thick 
dextran  coating  and  small  size,  Brownian  motion  enables  these  SPIONs  to  stay 
suspended, therefore preventing the SPIONs settling out of solution (Gupta et al., 
2005b). A number of groups (Dutton et al., 1979; Tiefenauer et al., 1993; Maruyama 
et al.; 1995, Kresse et al., 1998; Funovics et al., 2004; Toma et al., 2005) have also 
reported the suitability of using SEC as a method to purify SPION-conjugates.  
 
The DX-SPIONs were also found to separated well by SEC. However, purification 
of  the  CMX-SPIONs  by  SEC,  proved  unsuccessful,  with  the  CMX-SPIONs 
interacting or agglomerating within the Sephacryl 300HR matrix of the column. The 
main  difference  between  the  DX-SPIONs  and  CMX-SPIONs  is  their  surface 
chemistry.  The  CMX-SPIONs  consist  of  negatively  charged  carboxyl  groups.   91 
Electrostatic interaction of the CMX-SPIONs to the matrix may be a reason for the 
delay  in  elution  time.  In  addition,  the  terminal  COOH  groups  could  also  be 
interacting  with  the  N-group  of  the  acrylamide  component  of  the  matrix 
(communication with Dr Nevil Deane GE Healthcare, Amersham, UK), which would 
cause the retention of the CMX-SPIONs on the column. 
 
Furthermore, purification of the CMX-SPIONs by centrifugation was unsuitable, this 
was  also  observed  for  the  DX-SPIONs.  Although  the  CMX  and  DX-SPIONs 
separated out of solution, resuspension proved challenging. The likely reason for this 
behaviour could be due to the harsh conditions of centrifugation. The procedure can 
cause separation of the adsorbed dextran coating from the denser iron oxide cores, 
ultimately  causing  the  particles  to  agglomerate  (communication  with  Dr  Cordula 
Gruettner;  Micromod  Partikeltechnologie  GMbH,  Germany),  as  evident  with  the 
CMX-SPIONs and DX-SPIONs. Even so, this may not be the case for all SPIONs as 
a number of groups (Cerden, 1989; Tiefenauer et al., 1993; Suwa et al., 1998; Toma 
et al., 2005) have successfully used centrifugation as a method to separate SPION 
conjugates, reporting no instability of the SPIONs. 
 
Purification  using  a  high  magnetic  field  successfully  separated  the  CMX100, 
CMX200, DX100 and DX200 SPIONs from their surrounding media. The feasibility 
of using magnetic separation as a procedure for isolation of SPION conjugates has 
been previously reported (Mehta et al., 1997; Koneracká et al., 1999; DeNardo et al., 
2005). Magnetic separation however, was not suitable for separation of the CMX50.  
 
From these results, all the SPIONs were taken forward for conjugation to the anti 
CEA scFvs except the CMX-50, due to its inability to undergo any of the purification 
procedures tested.  
 
Although the DX100 and d100 are of the same hydrodynamic size, their level of 
solubility  was  different.  A  possible  explanation  could  be  the  composition  of  the 
SPIONs. From iron content analysis, the DX100 consists of more iron than the d100 
and  in  turn,  consists  of  less  dextran.  The  dSPIONs  increased  solubility  during 
purification  may  therefore,  be  due  to  the  higher  dextran  content.  This  finding   92 
supports evidence that SPIONs embedded in thicker dextran coat exhibit improved 
stability (Gupta et al., 2005; Mornet et al., 2004).   
 
Functionalisation of d50 with MFE-23 was successfully performed using the sodium 
periodate chemistry (Dutton, 1979; Molday et al., 1982). The hydroxyl groups of 
dextran have been reported to be poorly reactive (Bobbit, 1956; Rothfus & Smith 
1963). Therefore, to facilitate coupling of the dextran coated SPIONs to the free 
amine groups present on the MFE-23, the dSPIONs require oxidation with sodium 
periodate  this  in  turn  oxidises  the  OH  groups  to  create  highly  reactive  aldehyde 
functions (Bobbit, 1956; Rothfus & Smith 1963). Following conjugation an excess 
amount  of  free  MFE-23  was  found,  possibly  due  to  saturation  of  the  reactive 
aldehyde  functions.  The  oxidation  of  the  dextran  hydroxyl  groups  with  sodium 
periodate affects  how  many  C-C bonds are  cleaved and  thus how  many  reactive 
aldehyde functions are generated (Van Lenten & Ashwell 1971; Lotan et al., 1975). 
Attempts to increase the number of reactive aldehyde groups per d50 by increasing 
the concentration of sodium periodate however, proved unsuccessful with the d50 
SPIONs precipitating. It is reported that oxidative stress can lead to instability of the 
dextran polymer (Garden et al., 2006), causing unravelling of the dextran matrix 
from the SPION cores, leading to SPION agglomeration. It was therefore decided 
that  the  concentration  of  sodium  periodate  was  optimal  at  10  mM.  Further 
optimisation of the sodium periodate protocol by reducing the ratio of MFE-23 to 
d50 and increasing the incubation time to 24 hrs did prove successful. The results 
presented confirm the feasibility of generating CEA reactive MFE-23-d50 conjugates 
using the sodium periodate chemistry. Furthermore, a number of other groups have 
also reported success using the sodium periodate conjugation chemistry (Kresse et 
al., 1998; Funovics et al., 2004; Toma et al., 2005). 
 
For  clinical  application  of  scFv-SPION  conjugates  attachment  of  SPIONs  to  the 
humanised Sm3E is preferable. Using the optimised sodium periodate protocol the 
Sm3E,  expressed  and  purified  from  the  yeast  Pichia  pastoris,  was  successfully 
attached to the d50 and d100. The ratio of scFvs per dSPION is exceptionally good, 
with approx 28 Sm3E scFvs binding per d50 and 120 Sm3E scFvs to binding per 
d100. In comparison, Funovics et al., reported a binding ratio of 2 mAbs to 1 SPION 
(Funovics et al., 2004).   93 
 The  sodium  periodate  conjugation  method  however,  was  not  suitable  for  the 
conjugation of scFv to the DX-SPIONs. Oxidation of the DX-SPIONs, even at low 
concentrations of sodium periodate, caused precipitation of the SPIONs. A possible 
reason for the DX-SPIONs reduced solubility following oxidation, could be the DX-
SPIONs low dextran content compared to the dSPION. As mentioned previously the 
degree of oxidation of the OH groups can cause changes in the structure of dextran, 
causing it to unravel from the SPION.  
 
The cyanogen bromide conjugation chemistry was investigated as an alternative to 
the sodium periodate chemistry.  Activation of OH with CNBr is a more sensitive 
method and leads to the conversion of hydroxyl groups to cyanate ester groups, these 
subsequently react and bind with free amine groups (Axen et al., 1967). Activation 
of  the  DX-SPIONs  with  CNBr  proved  successful  with  the  SPIONs  remaining 
soluble.  However,  following  purification  of  the  conjugates,  resuspension  of  the 
Sm3E functionalised DX200 proved challenging. For this reason, the DX200 was not 
investigated further. In comparison, the Sm3E functionalised DX100 remained in 
solution and showed reactivity to CEA. 
  
Due to the availability of free COOH groups on the PEG-dSPIONs and the CMX-
SPIONs the carbodiimide conjugation chemistry was investigated to facilitate the 
coupling  of  free  amines  to  the  carboxyl  groups.  Reaction  with  EDC  and  NHS 
converts COOH groups to stable esters enabling the conjugation to amines (Hoare 
and Koshland 1967; Staros et al., 1986; Gilles et al., 1990).  
 
Conjugation via the carbodiimide chemistry, proved unsuccessful for the CMX100 
and CMX200. In comparison, attachment of Sm3E to the PEG-d20 and PEG-d50 
resulted in soluble Sm3E-PEG-dSPION conjugates reactive with CEA. Attachment 
via the carbodiimide chemistry allows proteins to be conjugated to the distal end of 
the PEG chains, thus minimising the effect of steric hindrance caused by the PEG 
chains (Maruyama et al., 1995).  
 
The  ratio  of  scFv  binding  to  PEG-dSPION  was  dependent  on  incubation  time. 
Following incubation for 3hrs, 0.5 scFvs bound per PEG-d20 and 10 scFvs bound per 
PEG-d50. After 24hrs, this increased to 2 scFvs per PEG-d20 and 29 scFvs per PEG-  94 
d50. The binding of two scFvs per PEG-d20 is consistent with DeNardo et al, who 
reported  conjugation  of  two  ChL6  mAbs  to  the  PEG-d20  by  carbodiimide 
conjugation chemistry (DeNardo et al., 2005).  
 
The  scFv  binding  yield  also  appeared  to  be  dependent  on  SPION  hydrodynamic 
radius for example, as SPION size increased from 20 nm to 100 nm the number of 
scFvs bound increased from 2 to 120. This is as expected, as the more surface area 
available the higher the number of sites for scFvs to bind. Increased multivalency can 
increase the avidity to target antigens, thus improving uptake and retention by the 
tumour  (Plunkthun  et  al.,  1997).  This  would  suggest  the  larger  SPIONs  to  have 
higher binding avidity for CEA, assuming  all Sm3E  scFvs bound  are  functional. 
However, the total percentage of scFv bound to the SPIONs actually decreased with 
hydrodynamic size.  For example in 1mg/ml there was a higher number of scFvs in 
the Sm3E-PEG-d20 sample this is most likely due to there being 10x more 20nm 
SPIONs in 1mg/ml compared to the 50nm SPIONs and 20x more than the 100nm 
SPIONs.  On the other hand, the SPION coating and conjugation chemistry had little 
effect on the number of scFvs binding per SPION. For example, the 50 nm SPIONs, 
whether stabilised in dextran or PEG-dextran both bound approx 28 and 29 Sm3E 
scFvs respectively.  
 
The advantage of all the chemistries investigated is that no prior ligand modification 
or  activation of  the  scFv  is required,  reducing  the risk of  affecting  MFE-23 and 
Sm3E  reactivity  to  CEA.  In  conclusion  this  chapter  has  shown  firstly,  that 
conjugation of dextran and PEG coated SPIONs to both the MFE-23 and Sm3E scFv 
through  different  chemistries  is  possible  and  secondly,  that  these  scFv-SPION 
conjugates can effectively target and bind specifically to the target antigen CEA.  
 
3.5. Summary 
 
The  aim  of  this  chapter  was  to  establish  and  optimise  suitable  conjugation 
chemistries to attach biocompatible SPIONs to the anti CEA scFvs. 
 
A  number  of  commercially  available  SPIONs  were  researched  these  include, 
dSPION, PEG-dSPION, DX-SPION and CMX-SPION with hydrodynamic diameter    95 
of  20  nm  to  200  nm.  Stability  of  the  SPIONs  was  assessed  by  magnetic, 
centrifugation and size exclusion chromatography separation methods. All SPIONs 
except the CMX50 were able to undergo at least one of the separation procedures 
used throughout the conjugation chemistry. 
 
The sodium periodate conjugation chemistry, resulted in approx 28 and 120 scFv 
binding per d50 and d100, respectively. For covalent conjugation of Sm3E to the 
PEG-d20  and  PEG-d50  the  carbodiimide  EDC/NHS  conjugation  chemistry  was 
successfully  employed,  binding  approx  2  and  29  scFvs  per  particle  respectively. 
These two chemistries caused stability issues when attaching the Sm3E scFv to the 
DX-SPION  and  CMX-SPION.  This  stability  issue  could  not  be  resolved  for  the 
CMX-SPIONs.  Conjugation  however,  by  the  cyanogen  bromide  method  proved 
successful  for  conjugation  of  Sm3E to  the  DX100.  All  Sm3E-SPION  conjugates 
retained reactivity to the target antigen CEA by ELISA.  
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Chapter 4 
 
 
Interaction of Functionalised                  
SPIONs with Cancer Cells 
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4.1 Introduction 
 
Having established methods to functionalise SPIONs with scFvs and shown binding 
on ELISA, I next investigated whether the scFv-SPION conjugates could specifically 
target and bind cancer cells. 
 
The aim of the work presented in this chapter was to quantify and characterise the 
interaction of the Sm3E functionalised SPIONs with target CEA expressing cancer 
cells. 
 
Previous  reports  have  shown  functionalisation  of  SPIONs  to  encourage  specific 
uptake  into  target cells  (Mailander  et al., 2008; Villanueva et al., 2009), in  turn 
improving their therapeutic and diagnostic potential. The SPIONs surface properties 
and hydrodynamic radii however, can affect how they interact with the target cells, 
for example internalisation and their relative specificity (Lentz et al., 1999; Zhang et 
al., 2002; Mailänder et al., 2008; Wilhelm et al., 2008; Villanueva et al., 2009). To 
test the influence of surface coatings and size, the Sm3E functionalised d100, d50, 
PEG-d50 and PEG-d20 were investigated.  
 
Furthermore,  it  has  been  reported  that  following  intracellular  uptake,  SPIONs 
accumulate into endosomal compartments within the cell cytoplasm (Wilhelm et al., 
2008;  Villanueva  et  al.,  2009).  To  determine  the  cellular  fate  of  the  Sm3E 
functionalised  SPIONs  co-localisation  studies  using  an  endosomal  marker  were 
performed.  
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4.2 Objectives 
 
The objectives of the research described in this chapter were to:  
 
1.  Test  the  specificity  of  the  different  scFv-SPION  conjugates  to  CEA 
expressing cells in vitro 
 
2.  Quantify uptake of Sm3E functionalised SPIONs using an optimised ferrozine 
based assay 
 
3.  Visualise uptake of Sm3E functionalised SPIONs via confocal microscopy 
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4.3 Results 
 
4.3.1 Quantification of SPION uptake 
 
To measure the specific binding of the Sm3E functionalised SPIONs to CEA+ve 
LS174T an in vitro cell uptake assay was developed (see section: 2.2.7.1). Sm3E 
functionalised and non-functionalised SPIONs, at a SPION concentration of at 0.1 
mg/ml, were incubated with the CEA+ve cell line LS174T. Following incubation the 
cells were washed and SPION uptake measured using a ferrozine based iron assay 
adapted and scaled down from Riemer et al., 2004. 
  
Results showed the cellular uptake  to be dependent  on hydrodynamic  radii, with 
uptake increasing with SPION size. The specific uptake of the Sm3E functionalised 
PEGd20 was 2.4 pgSPION/ml compared to the Sm3E functionalised d100 SPIONs, 
which gave a specific uptake of 6.6 pgSPION/ml.  PEGylation however, showed no 
benefit to the uptake of SPIONs at the pg range, as both the PEGylated and non 
PEGylated Sm3E-d50 demonstrated comparable SPION uptake of 4.7 pgSPION/cell 
and 4.4 pg/cell, respectively. Measurement of non-specific binding was minimal for 
all non-functionalised SPIONs, demonstrating uptake of less than 0.01 pgSPION/cell 
(Table 4.1).  
 
From these experiments, results demonstrate that conjugation of Sm3E is essential 
for specific binding of the SPIONs to CEA+ve LS174T cells.  
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Table. 4.1. Uptake of SPIONs by CEA+ve LS174T cells as quantified by ferrozine based 
assay.  The  absorbance  at  550  nm  was  referenced  against  standard  curve  of  ferrozine 
assayed SPIONs (Fig. 4.1) to obtain SPION uptake per well (µgSPION/ml). Concentration 
per  well  was  divided  by  cell  number  5x10*6  per  well  to  obtain  SPION  uptake  per  cell 
(pgSPION/cell).    The  number  of  SPIONs  taken  up  per  cell  was  calculated  using  known 
number of SPIONs per mg 
 
SPION  Absorbance         SPION uptake   Number  
   550nm  (pgSPION/cell)  Of SPIONs 
d100     0.01  0.00  0 
Sm3E-d100     0.21  6.63 (+/-0.38)  6.6x 10*3 
d50    0.01  0.00  0 
Sm3E-d50      0.14  4.43 (+/-0.11)  4.4 x 10*4 
PEG-d50  0.04  0.00  0 
Sm3E-PEG-d50  0.15  4.73 (+/-0.12)  4.7 x 10*4 
PEG-d20   0.04  0.00  0 
Sm3E-PEG-d20   0.09  2.43 (+/-0.35)  2.4 x 10*5 
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Fig. 4.1. Standard curve of Ferrozine assayed SPIONs, showing absorbance against SPION 
concentration.  
 
 
4.3.2 Specificity of SPION uptake 
 
To further confirm and visualise the specificity of the Sm3E functionalised SPIONs 
to the CEA expressing cells confocal laser scanning microscopy (CLSM) was used. 
For  this  experiment  the  CEA+ve  LS174T  cell  were  again  incubated  with  Sm3E 
functionalised  or  non  functionalised  d50  and  d100  at  a  SPION  concentration  of 
0.1mg/ml. Specific binding of the SPIONs was detected with anti-dextran (red) to 
enable  visualisation  by  CLSM.  To  show  the  presence  of  cells  the  nuclei  stain 
Hoechst (blue) was used. The CEA-ve A375M cell line was used as a control.  
 
The CLSM results clearly show the dextran coated Sm3E-d50 to specifically target 
the  CEA+ve  LS174T  cells,  preferentially  distributing  around  the  cell  surface 
membrane (Fig. 4.2a & 4.2b). In contrast, the non-functionalised d50 SPION showed 
no binding to the CEA+ve LS174T cells (Fig. 4.2c). Neither Sm3E-d50 nor non-
functionalised d50 bound to the control CEA-ve A375M cells (Fig. 4.2e & 4.2f).   
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Fig. 4.2. CLSM images of CEA+ve LS174T cells incubated in, a & b) Sm3E-d50, c) d50, d) 
media only and CEA-ve A375M cells incubated in e) Sm3E-d50, f) d50. Detection of specific 
cell binding was performed with a mouse anti-dextran primary antibody,  followed by a goat 
anti-mouse alexa fluor 594 antibody and  nuclei were stained with Hoechst. All SPIONs were 
applied at  0.1 mg/ml. 
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The CLSM results also show specific targeting of the Sm3E functionalised d100 to 
the  CEA+ve  LS174T  cells  (Fig.  4.3a).  Furthermore,  the  Sm3E-d100  showed  the 
same cell membrane binding behaviour as the Sm3E-d50. No binding to the CEA+ve 
LS174T cells was detected with non-functionalised d100 (Fig. 4.3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. CLSM images of CEA+ve LS174T cells incubated in a) Sm3E-d100 and b) d100. 
Detection of specific cell binding was performed with a mouse anti-dextran primary antibody, 
followed  by  a  goat  anti-mouse  alexa  fluor  594  antibody.  The  nuclei  were  stained  with 
Hoechst. All SPIONs were applied at 0.1 mg/ml. 
 
 
4.3.3 Effect of SPION surface chemistry 
 
The surface properties of SPIONs can affect their uptake into cells. Previous reports 
have suggested PEGylation as well as carboxylation to be involved in spontaneous 
intracellular uptake (Lentz et al., 1994; Mailänder et al 2008). Focusing on binding 
behaviour  and  relative  specificity,  the  PEG-dSPIONs  were  investigated  and 
compared with the dSPIONs.  
 
The experiments were performed as in section 4.3.2, with binding behaviour of the 
PEG-dSPIONs  visualised  by  CLSM.  Under  the  sensitive  conditions  of  CLSM, 
results revealed both the Sm3E functionalised and non-functionalised PEG-d50 to 
associate  with  the  CEA+ve  LS174T  cell  line  (Fig.  4.4a  &  4.4b).  These  results 
suggest  that  the  addition  of  PEG-COOH  chains  to  the  d50  SPIONs  surface 
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10µm 10µm
a) Sm3E-d100 (CEA+) b) d100 (CEA+)
10µm 10µm 10µm 10µm  104 
encouraged  non-specificity.  However,  from  quantitative  analysis  the  non-specific 
uptake was very low <0.01 pg (Table 4.1). Furthermore, PEGylation of the d50 also 
appeared to promote internalisation (Fig 4.4a & 4.4b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4. CLSM images of CEA+ve LS174T cells incubated in a) Sm3E-PEG-d50, b) PEG-
d50 overnight.  Detection of specific cell targeting was performed with a mouse anti-dextran 
primary antibody, followed by a goat anti-mouse alexa fluor 594 antibody. The nuclei were 
stained  with Hoechst. All SPIONs were applied at 0.1 mg/ml. 
 
 
In comparison, CLSM images of the smaller Sm3E functionalised PEG-d20 revealed 
the  SPION  to  specifically  bind  and  internalise  into  CEA+ve  LS174T  cells  (Fig. 
4.5a), with minimal uptake of the non-functionalised PEG-d20 (4.5b). Furthermore, 
neither Sm3E-PEG-d20 nor the non-functionalised PEG-d20 bound to the control 
CEA-ve A375M cells (Fig 4.5c & 4.5d). These results therefore, indicate that the 
specific uptake of the functionalised PEG-d20 is due to the Sm3E-CEA interaction.  
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Fig. 4.5. CLSM images of CEA+ve LS174T cells incubated in a) Sm3E-PEG-d20, b) PEG-
d20 and CEA-ve A375M cells incubated in c) Sm3E-PEG-d20 and d) PEG-d20. Detection of 
specific cell binding was performed with a mouse anti-dextran primary antibody, followed by 
a  goat  anti-mouse  alexa  fluor  594  antibody.  The  nuclei  were  stained  with  Hoechst.  All 
SPIONs were applied at 0.1 mg/ml. 
 
 
4.3.4 Intracellular trafficking 
 
On  the  CLSM  images,  the  internalised  Sm3E-PEG-d50  appeared  to  localise  to 
punctate structures distributed throughout the cytoplasm of the cells (Fig. 4.6a). To 
determine  whether  these  represent  endosomal  compartments  the  cells  were  co-
immunostained with anti-dextran (Fig. 4.6a, red) and anti LAMP1 (Fig. 4.6b, green) 
antibodies. Co-localisation was observed between the antibodies (Fig. 4.6d, white 
arrows)  indicating  that  the  Sm3E-PEG-d50  are  trafficked  to  late  endosomal 
compartments.   
 
A B
d) PEG-d20 (CEA-)
a) Sm3E-PEG-d20 (CEA+) b) PEG-d20 (CEA+)
c) Sm3E-PEG-d20 (CEA-)
10µm 10µm
10µm 10µm
A B
d) PEG-d20 (CEA-)
A B
d) PEG-d20 (CEA-)
a) Sm3E-PEG-d20 (CEA+) b) PEG-d20 (CEA+)
c) Sm3E-PEG-d20 (CEA-)
10µm 10µm 10µm 10µm
10µm 10µm 10µm 10µm  106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. CLSM images of Sm3E-PEG-d50 localising in endosomal compartments (shown by 
white arrows). Sm3E-PEG-d50 SPIONs are shown in red (a), endosomes in green (b) 
and cell nuclei in blue (c). CEA+ve LS174T cells were incubated in Sm3E-PEG-d50 at a 
SPION concentration of 0.1 mg/ml. Co-localisation of Sm3E-PEG-d50 with endosomes was 
detected with a mouse anti-dextran and mouse anti-LAMP1 followed by goat anti-mouse 
IgG1 Alexa Fluor 594 and goat anti-mouse IgG2b Alexa Fluor 488, respectively. The nuclei 
were stained with Hoechst.  
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4.3.5 Surface charge 
Negative surface charge has been reported to encourage non-specific electrostatic 
interaction with cell membranes and facilitate intracellular uptake (Wilhelm et al., 
2003; Patil et al., 2007). The carboxylated PEG coating of the PEG-dSPIONs may 
have  an  affect  on  the  SPIONs  overall  surface  charge,  and  could  therefore  be 
responsible for the internalisation and the non-specificity observed with the PEG-d50 
and PEG-d20.  The surface charge of the SPIONs was determined by zeta potential 
measurements performed at pH 7 using a Zetasizer Nano ZS. Results showed that, 
whilst the d50 SPION had a zeta potential (electrical surface charge) of -1.5 mV, the 
PEG-d20 and PEG-d50 had a surface charge of -4.0 mV and -5.0 mV, respectively.  
The intracellular uptake observed with the PEG-d20 and PEG-d50 may therefore, be 
due to increased negative surface charge, attributed by the absorbed PEG-COOH 
chains.  
  
The results presented in this chapter are summarised in Table 4.2 
 
 
Table.  4.2.  Summary  of  CLSM  results  presented  in  this  chapter  regarding  the  binding 
behaviour of the Sm3E-SPION conjugates to the CEA+ LS174T cells. 
 
SPIONs  Specificity   Cellular behaviour 
d50  No binding  N/A 
Sm3E-d50  Specific  Membrane bound 
d100  No Binding  N/A 
Sm3E-d100  Specific  Membrane bound 
PEG-d50  Non-specific  Internalised 
Sm3E-PEG-d50  Non-specific / specific  Internalised 
PEG-d20  No binding  NA 
Sm3E-PEG-d20  Specific  Internalised 
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4.4 Discussion 
 
 
The  results  described  in  this  chapter  have  shown  that  Sm3E-SPION  conjugates 
specifically bind to CEA expressing tumour cells. In addition, the results indicate 
that the size and surface properties of the SPIONs exert a substantial effect on the 
labelling efficiency, specificity and binding behaviour with the cell.  
 
Specific  binding  to  CEA  expressing  cells  for  all  the  SPIONs  investigated  was 
successfully  achieved  by  conjugation  to  Sm3E,  as  measured  by  iron  uptake. 
Furthermore, uptake of the non-functionalised SPIONs was minimal at less than 0.01 
pg/cell  compared  to  Sm3E  functionalised  SPIONs  at  2-6pg/cell.  These  results 
demonstrate that functionalisation of SPION with a targeting ligand such as scFvs is 
essential  for  specific  uptake  into  target  cells.  The  negligible  uptake  of  the  non-
functionalised  SPIONs  was  also  observed  in  HeLa  cells  (Wilhelm  et  al.,  2003; 
Mailander et al., 2008; Villanueva et al., 2009), CD4+ T cells (Garden et al., 2006), 
CHO cells (Reynolds et al., 2006) and pancreatic MIA paCa-2 cells (Yang et al., 
2009). 
  
From iron uptake measurements, more iron was found to be in the cells incubated in 
the  larger  scFv  functionalised  SPIONs.  Suggesting  cellular  uptake  of  Sm3E 
functionalised SPIONs to be dependent on the hydrodynamic size of the SPIONs, 
with the larger SPIONs demonstrating higher uptake. However, calculation of the 
number of SPIONs taken up per cell found cellular SPION uptake to increase as 
SPION  size  decreased.  For  example,  SPION  uptake  for  the  Sm3E-PEG-d20  was 
approximately  2.7  x  10*5,  compared  to  the  Sm3E-100d  at  6.6  x  10  *3.  Results 
presented  in  Chapter  3  show  the  valency  of  the  SPION  to  increase  with 
hydrodynamic size, with the 20 nm, 50 nm, 100 nm SPIONs binding 2, 29 and 120 
Sm3E scFvs, respectively. The increased valency of the SPIONs can improve their 
avidity to the target cells (Adams et al., 1999, 2006), which would suggest SPION 
uptake to increase with SPION size as observed by Garden et al., and Kaittanis et al., 
who reported an increased cell labelling efficiency of SPIONs with increased valence 
(Garden et al., 2006; Kaittanis et al., 2009). However, this does not appear to be the 
case for the conjugates investigated in this chapter. One possible explanation for the   109 
decrease in Sm3E functionalised SPION uptake with increase SPION size could be 
due  to  the  high  number  of  Sm3E  scFvs  bound  to  the  SPION,  causing  steric 
inhibition.  The  majority  of  the  scFvs  could  therefore  be  functionally  block  from 
reacting with the target CEA, thus reducing the SPIONs avidity to the cell compared 
to if all Sm3E scFvs were functional. Another reason for the difference in SPION 
uptake could be due to the binding behaviour of the different Sm3E functionalised 
SPIONs 
 
Further  investigation  of  the  Sm3E-SPION  conjugates  binding  behaviour  was 
performed by CLSM. Results revealed the Sm3E targeted dextran coated SPIONs to 
specifically  localise  on  the  extracellular  membrane,  as  has  been  reported  with 
dextran coated SPIONs functionalised with whole mAbs (Funovics et al., 2004). In 
contrast, the functionalised PEGylated SPIONs internalised into the cell cytoplasm, 
forming localised clusters. The increase in SPION uptake could therefore be due to 
the fact  the  smaller Sm3E PEG-d20 SPIONs  are able  to be internalised,  making 
available CEA binding sites for more Sm3E-PEG-d20 SPIONs and in addition are 
able to fill a larger space. In comparison, the Sm3E-d100 SPIONs appear to only 
bind to the cell membrane and therefore may saturate all binding sites, thus limiting 
the number of SPIONs from attaching to the cells. The Sm3E-PEG-d50 also shows a 
slightly higher SPION uptake than its dextran only counterpart Sm3E-d50.  
 
The possible reason for the difference in binding behaviour between the dSPION and 
PEG-dSPION could be due to their surface chemistry. Both SPIONs are prepared in 
the same way, except the PEG-dSPIONs have PEG-COOH chains absorbed onto 
their dextran surface (communication with Dr Cordula Gruettner, Micromod). Under 
physiological  conditions  (pH  7),  the  PEG-COOH  chains  are  mostly  in  the 
deprotonated form and therefore negatively charged. In contrast, dextran is generally 
neutrally charged (Okon et al., 1994).  
 
A number of groups have reported that charged SPIONs have a higher affinity to the 
cell membrane. This is thought to be due to electrostatic attraction, which in turn 
encourages internalisation by fluid phase endocytosis (Wilhelm et al., 2003; Alberola 
et al., 2009). Therefore, one possible cause of the observed internalisation would be 
the  negative  surface  charge  conferred  by  the  carboxylated  PEG  chain  terminals.   110 
Indeed, the results show a reproducible decrease in electrical surface charge from -1 
mV  to  -5  mV  upon  addition  of  PEG-COOH,  suggesting  that  this  is  a  likely 
contributing  factor.  In  line  with  these  observations,  dextran  has  previously  been 
reported to exhibit poor internalisation (Wilhelm et al., 2003), an effect attributed to 
its neutral charge (Okon et al., 1994; Mailander et al., 2008). Therefore, without 
functionalisation to internalising targeting ligands, dextran coated SPIONs are unable 
to attach and internalise into cells.  
 
The high solubility of PEG with the cell membrane lipid bilayer could also be a 
reason for the intracellular uptake observed with the PEG-dSPIONs. A number of 
studies  have  previously  reported  on  the  internalisation  property  PEG  exerts  on 
SPIONs (Yamazaki et al., 1990: Lentz et al., 1994: Zhang et al., 2002: Wilhelm et 
al., 2003). PEG can dissolve in both polar and non-polar solvents (Zhang et al., 
2002) inducing defects in the bilayer, which is thought to mediate cell membrane 
fusion  a  process  required  in  endocytosis  (Lentz  et  al.,  1994).  However,  a  high 
concentration  of  PEG  is  required  for  PEG  mediated  membrane  fusion  to  occur 
(Yamazaki et al., 1990), therefore it is unlikely this mechanism alone attributed to 
the binding behaviour seen with the PEGylated SPIONs.  
 
As  well  as  intracellular  uptake,  CLSM  results  revealed  the  PEG-d50  SPIONs  to 
exhibit non-specific uptake however, this was not the case for the smaller PEG-d20. 
A likely explanation could be their PEG-COOH content. From the manufacturers 
data sheet the number of PEG-COOH chains per PEG-d50 was estimated to be 1900, 
in comparison, PEG-d20 was estimated to have 131 PEG-COOH chains per SPION. 
The increase in PEG content of the PEG-d50 correlates with the increase in negative 
surface  charge.  Therefore,  the  increase  in  PEG-COOH  chains  and  furthermore, 
negative charge is a probable contributing factor to the non-specificity of the PEG-
d50 SPIONs. Despite this non-specific uptake of the PEG-d50 was minimal (<0.01 
pg/cell).  
 
Following internalisation the PEG-dSPIONs formed clusters within the cytoplasm of 
the  cell.  CLSM  images,  revealed  the  PEG-dSPIONs  to  accumulate  into  the 
endosomal compartments within the cell, an observation that is well documented 
(Gupta et al., 2004; Mailander et al., 2008; Wilhelm et al., 2008; Villanueva et al.,   111 
2009). Accumulation of PEG-dSPIONs within endocytic compartments are subject 
to the effects of hydrolytic enzymes and low pH, ultimately leading to break down of 
the SPIONs into Fe
2+ and Fe
3+ ions for use towards natural Fe pathways (Okon et al., 
1994; Gupta et al., 2004; Thorek et al., 2006). This has raised questions about the 
benefits of using internalising SPIONs for MRI and hyperthermic applications, since 
the  SPIONs  need  to  be  in  the  form  of  magnetite  Fe3O4  or  maghemite  γFe2O4. 
However,  magnetite  metabolism  is  slow,  reporting  to  take  between  4-7  days 
(Renshaw et al., 1986; Briley-Saebo et al., 2004), giving sufficient time for MR 
imaging or hyperthermia treatment. A recent report by Cartiera et al., has speculated 
however, that the SPIONs incorporated into the endocytic compartments of the cell 
are capable of escaping and localising instead in the Golgi, ER and secretory vesicles 
therefore, bypassing intracellular digestion (Cartiera et al., 2009). 
 
 
 
4.5 Summary 
 
The aim of the work presented in this chapter was to quantify and characterise the 
interaction of the Sm3E functionalised SPIONs with target CEA expressing cancer 
cells. 
 
Specific binding of SPIONs to CEA+ LS174T cells was achieved via conjugation to 
with Sm3E. Size, valency and anionic charge of the SPIONs were demonstrated to be 
important factors in the cellular uptake and binding behaviour of the SPIONs. The 
Sm3E-d100  and  Sm3E-d50  were  shown  to  selectively  bind  the  extracellular 
membrane.  In  comparison,  the  Sm3E-PEG-d50  showed  intracellular  uptake  and 
some non-specificity, both effects thought to be attributed to the size and anionic 
charge of the PEG-d50. By conjugation to the smaller, slightly less anionic PEG-d20 
intracellular  uptake  was  still  observed,  whilst  the  issue  of  non-specificity  was 
overcome.  Upon  internalisation,  the  PEGylated  SPIONs  accumulated  into  the 
endosomal compartments of the cell. 
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Chapter 5 
 
 
Imaging Potential of  
Functionalised SPIONs  
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5.1 Introduction 
 
The work in the previous chapter showed that scFv functionalised SPIONs could 
target  specifically  to  antigen  expressing  cancer  cells.  The  next  stage  was  to 
investigate whether these findings could be extended to exploit scFv functionalised 
SPIONs in MRI. 
 
Reports by others have indicated the potential of mAb functionalised SPIONs as 
targeted contrast agents (Tiefenauer et al., 1993; Suwa et al., 1998; Funovics et al., 
2004;  Toma  et  al.,  2005).  More  recently,  functionalisation  of  SPIONs  with  anti 
EGFR scFvs has shown potential as a tumour-imaging agent (Yang et al., 2009). The 
use of scFvs as targeting moieties has potential advantages over whole antibodies. 
First, the molecular diameter of a whole IgG is approximately 28nm (Roberts et al., 
1995), making scFvs relatively small at approximately 5nm. Therefore, attachment of 
scFvs to SPIONs should not significantly increase the SPIONs diameter. Second, 
scFvs do not contain  the  Fc constant domain  and therefore are unable to  trigger 
potentially  harmful  immune  responses.  Third,  scFvs  are  readily  available  in 
recombinant  form  and  can  be  generated  for  clinical  applications  using  non-
mammalian expression systems (Tolner et al., 2006a). To test the potential of the 
scFv  functionalised  SPIONs  developed  in  this  thesis  as  tumour  targeted  contrast 
agent three functionalised SPIONs i) Sm3E-d50, ii) Sm3E-PEG-d50 and iii) Sm3E-
PEG-d20 were taken forward. 
 
 To  evaluate  the  selective  tumour  imaging  potential  of  the  Sm3E  functionalised 
SPIONs  to  CEA+ve  LS174T  cells,  T2-weighted  images  and  relaxometry 
measurements  were performed.  SPION  hydrodynamic size and surface  properties 
have  shown  to  substantially  affect  binding  behaviour  (see  section:  4.3  Results). 
Therefore, the impact of binding behaviour on the SPIONs imaging potential was 
evaluated by their T2-weighted images and T2 values.  
 
To determine whether Sm3E-SPIONs can be used for specific tumour imaging, the 
targeting potential of the scFv-SPION conjugates  in vivo, following systemic 
injection, was investigated by means of their biodistribution.   114 
5.2 Objectives 
 
The objectives of the research described in this chapter were to: 
 
1.  Assess the toxicity of Sm3E functionalised SPIONs in vitro by MTT assay 
 
4.  Show MRI potential of the SPIONs 
 
5.  Demonstrate the selective MRI potential of Sm3E functionalised SPIONs in 
vitro using MRI 
 
6.  Investigate the biodistribution of Sm3E-SPIONs in vivo following systemic 
injection 
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5. 3 Results 
 
5.3.1 In vitro cytotoxicity  
 
For  SPIONs  to  be  suitable  as  targeted  MRI  contrast  agents,  they  should  show 
minimal  toxicity  to the  targeted  cell.  Images taken by  CLSM  (see section:  4.3.2 
Specificity of SPION uptake) show that 24 hrs following incubation with 0.1 mg/ml 
of  SPIONs  the  cells  appeared  healthy.  The  degree  of  cell  survival  was  further 
evaluated by means of the standard methyl thiazol terazolium bromide (MTT) assay. 
Though the cells looked healthy at 24 hr, the SPIONs may experience delayed cell 
death. Therefore, following 24 hr incubation with SPIONs at 0.1 mg/ml, the cells 
were incubated for a further 96 hrs in fresh media before addition of MTT.  The 
results from the MTT assay show 92-100% cell viability in relation to the control 
sample  (Fig  5.1).  This  result  indicates  that  there  is  no  statistically  significant 
evidence of SPION toxicity to CEA+ LS174T cells at a concentration of 0.1 mg/ml 
(p = 0.36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  5.1.  Cell  viability  of  CEA+ve  LS174T  cells  after  overnight  incubation  with  Sm3E 
functionalised and non-functionalised SPIONs at concentrations 0.1 mg/ml. No significant 
difference in cell viability was observed (ANOVA: p value 0.36) 
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5.3.2 Magnetic resonance imaging potential of SPIONs 
 
To evaluate the MRI potential of the SPIONs, solutions of increasing concentrations 
were prepared and their relaxation times measured using a 2.35 T horizontal bore 
SMIS  imaging  system.  Furthermore,  to  determine  whether  the  relaxivity  of  the 
SPIONs was suitable for diagnostic application, the SPIONs were imaged alongside 
the clinically approved SPION contrast agent Endorem™ at a concentration of 0.035 
mg/ml.  Magnetic resonance images were obtained using a phantom similar to that 
shown  in  Fig.  5.2.  MRI  analysis  of  the  various  concentrations  of  SPIONs  was 
performed at TR 1000 msec at multiple TEs. As magnetite was expected to affect 
mainly T2 relaxation (see section: 1.7.1.Application of SPIONs in MRI), only T2 
measurements were taken.  The T2 relaxation values of the various concentrations of 
the SPIONs were calculated and are shown in Fig. 5.3. The results show that at a 
concentration of 0.035 mg/ml the d50, PEG-d50 and PEG-d20 have a T2 value of 
56.2 ms, 58.3 ms and 51.8 ms, respectively. In comparison, Endorem is only slightly 
higher at 69.4 ms. These results confirm contrast enhancement capabilities of the 
SPIONs,  showing  their  relaxivity  to  be  comparable  to  the  SPION  contrast  agent 
Endorem™. Furthermore, the results show as concentrations of the SPION increase 
the T2 relaxation time decreases. The best signal to noise ratio was found to be at 
0.04 mg/ml. 
 
 
 
 
Fig. 5.2. MRI phantom contains a 0.5 ml eppendorf holder placed inside a 50 ml falcon tube. 
Eppendorf tubes containing samples are placed in the MRI phantom, which is filled with 2.5 
g/l CuSO4 to minimise background.    117 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3. Magnetic Resonance Imaging of serial dilutions of d50, PEG-d50, PEG-d20 and 
Endorem™ (0.035 mg/ml) on a 2.35 T on a horizontal bore SMIS system. All SPIONs are 
shown to cause a decrease in the T2 signal intensity with increasing concentrations of the 
SPIONs.  
 
5.3.3 In vitro MRI of Sm3E-SPIONs 
 
To determine the selective MRI potential of the Sm3E functionalised d50, PEG-d50 
and  PEG-d20  an  in  vitro  MRI  study  was  performed.  For  this  experiment,  the 
CEA+ve  LS174T  cells  and  CEA-ve  A375M  cells  were  incubated  with  Sm3E 
functionalised and non-functionalised SPIONs at 0.1 mg/ml. Following incubation, 
the  cells  were  spun  down,  fixed  and  imaged.  Magnetic  resonance  images  were 
obtained using a phantom consisting of three tubes as shown in Fig. 5.2. The T2 
relaxation  values  of  each  sample  were  calculated  and  are  shown  against  the 
corresponding T2-weighted image in Fig. 5.4.  
 
5.3.3.1 Sm3E-d50 
 
The T2-weighted MR images of the CEA+ve LS174T cells incubated with the Sm3E 
functionalised d50 demonstrate a strong negative T2 contrast (Fig. 5.4), producing a 
47% reduction in T2 values relative to the media only control. Minimal reduction 
(3%)  in  T2  was  detected  for  the  CEA+ve  LS174T  cells  incubated  in  non-
functionalised d50.  
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The T2-weighted images of the CEA-ve A375M cells (Fig. 5.4) incubated in Sm3E 
functionalised  and  non-functionalised  d50  show  no  reduction  in  the  T2  signal. 
However, T2 measurements revealed a slight reduction in the T2 signal compared to 
the media only control of 28% and 22% respectively (Fig. 5.4).  
 
5.3.3.2  Sm3E-PEG-d50 
 
In the previous chapter (see section: 4.3.4 Intracellular uptake) it was shown that 
PEGylated SPIONs can internalise, therefore, it was considered that this may affect 
the MRI signal (Briley-Saebo et al., 2004). 
 
The T2-weighted MR image of the CEA+ve LS174T cell line incubated with Sm3E-
PEG-d50 demonstrate a strong negative T2 contrast of 57% (Fig. 5.4), suggesting 
intracellular uptake to have no detrimental effect on MRI signal.  A minimal T2 
reduction  of  11%  was  detected  for  the  non-functionalised  PEG-d50,  indicating 
specificity  of  the  Sm3E-PEG-d50  to  the  CEA+ve  LS174T  cells.    However,  MR 
images  of  the  CEA-ve  A375M  cells  incubated  with  the  functionalised  and  non-
functionalised  PEG-d50  produced  a  51%  and  49%  reduction  in  T2.  These  results 
reveal non-specific binding of the PEG-d50 with the CEA-ve A375M cells. 
 
5.3.3.3 Sm3E-PEG-d20 
 
From iron uptake measurements (see section: 4.3.1 Quantification of SPION uptake) 
the specific uptake of Sm3E-PEG-d20 was two fold less than the Sm3E-PEG-d50. 
However, the reduction in T2 value for the CEA+ve LS174T cells incubated with 
Sm3E-PEG-d20  was  51%,  only  marginally  lower  than  the  Sm3E-PEG-d50.  A 
negligible T2 reduction of 17% was detected for the non-functionalised PEG-d20, 
confirming specificity of the Sm3E-PEG-d20 to CEA+ve LS174T cells.  
 
Incubation of the PEG-d20 with the CEA-ve A375M cells provided only a slight T2 
reduction compared to the media only controls of 27%, this is comparable with the 
d50.   
 
   119 
 
 
Fig. 5.4. T2 weighted spin echo images (A) and T2 values (B) of CEA+ve LS174T cells and CEA-ve A375M cells incubated in 0.1 mg/ml Sm3E functionalised 
and non-functionalised d50, PEG-d50 and PEG-d20. Percentage T2 values were calculated and compared to media only control values.  120 
5.3.4 Biodistribution of Sm3E-SPIONs  
 
The Sm3E functionalised SPIONs have shown selective MRI potential in vitro. For 
their use as imaging tools in vivo selective uptake into CEA expressing tumour cells, 
following systemic injection is essential. To investigate the biodistribution of the 
Sm3E  functionalised  d50,  PEG-d50  and  PEG-d20  SPIONs  following  systemic 
injection, an in vivo study was performed. For this experiment, Sm3E functionalised 
SPIONs  (0.2mg)  were  injected  intravenously  into  CEA+ve  tumour-bearing  mice. 
After 5 min, 1hr and 24 hr the mice were sacrificed, tumours, livers and spleens 
collected and cryo-sectioned. The tissues were stained with nuclear fast red to detect 
cells and Prussian blue to detect the SPIONs. 
 
The biodistribution results for the Sm3E functionalised and non-functionalised d50, 
PEG-d50 and PEG-d20 appeared similar for all time points. Results in Fig 5.5 show 
uptake for the Sm3E functionalised SPIONs after 1hr. All the SPIONs were found to 
predominantly  localise  within  the  spleen,  only  a  small  amount  of  functionalised 
SPION accumulated in the tumour and  liver. These results suggest that  systemic 
application  of  the  Sm3E  functionalised  d50,  PEG-d50  and  PEG-d20  may  not  be 
feasible due to rapid clearance via the RES, preventing specific uptake in the tumour.  
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Fig  5.5  Biodistribution  study  of  Sm3E-d50,  Sm3E-PEG-d50  and  Sm3E-d20  in  CEA+ve 
tumour bearing mice. Tumour, liver and spleen section were stained with H&E to detect cells 
(red) and Prussion blue to detect SPIONs (blue). The SPIONs predominantly localised in the 
spleen. 
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5.4 Discussion 
 
The  results  described  in  this  chapter  demonstrate  the  potential  of  Sm3E 
functionalised  d50,  PEG-d50  and  PEG-d20  to  deliver  tumour  specific  MRI.  The 
results also showed that size and surface properties strongly influence non-specific 
uptake.  
 
Administration of contrast enhancement agents is generally intravenous, allowing the 
SPIONs to circulate in the blood until they reach their target. To avoid fast clearance 
from the blood, SPION size and surface properties are important. It has been reported 
that SPIONs with a hydrodynamic diameter >100 nm, are readily cleared by the 
reticuloendothelial system (RES) (Gupta et al., 2005b) or are unable to move through 
capillary vessels to reach the tumour (Suwa et al., 1998). The d50, PEG-d50 and 
PEG-d20 were therefore, proposed to be attractive SPIONs for systemic application 
and for this reason were taken forward for investigation into their tumour specific 
MRI potential.  
 
Results from MR relaxometry show that colloidal suspensions of the d50, PEG-d20 
and PEG-d50 reduce T2 relaxation in a concentration dependent manner, a pattern 
previously  reported  (Wang  et  al.,  2001).    In  addition,  SPION  size  and  surface 
properties  had  no  effect  on  T2,  with  all  three  SPIONs  demonstrating  similar  T2 
relaxivity values. These results do not support findings by Wang et al., who reported 
MR signal intensities to depend on the composition and size of the SPIONs (Wang et 
al., 2001). The reduction in T2 generated by all three SPIONs at 0.035 mg/ml was 
almost  equivalent  to  that  generated  by  Endorem™  at  the  same  concentration. 
Therefore, based on the T2 relaxivity results and their comparability with Endorem™, 
all three SPIONs exhibited adequate characteristics for application as MRI contrast 
agents. 
 
For use as a MRI tumour contrast agent, minimal SPION toxicity is a requirement. 
Cytotoxicity of the SPIONs was evaluated by MTT analysis. Results demonstrate no 
effect on the cells proliferation or viability when incubated with the functionalised 
and  non-functionalised  SPIONs  at  a  concentration  of  0.1  mg/ml.  These  results   123 
therefore, show the Sm3E functionalised d50, PEG-d50 ad PEG-d20 can safely and 
specifically,  label  the  target  CEA+ve  LS174T  cells.  The  cytotoxicity  results  are 
consistent  with  previous  reports,  where  dextran  and  PEGylated  SPIONs  at 
concentrations below 0.1 mg/ml exert minimal toxicity (Li et al., 2009; Villanueva et 
al., 2009). 
 
The selective MR imaging potential of the Sm3E-d50 conjugates was investigated in 
vitro  using  the  CEA+ve  LS174T  cells;  the  CEA-ve  A375M  cells  were  used  as 
controls.  Incubation of the Sm3E-d50 with the CEA+ve LS174T cells resulted in a 
marked T2 signal reduction, correlating with increase in SPION uptake (see section: 
4.3.1 Quantification of SPION uptake). These results support the findings that the 
Sm3E functionalised d50 SPIONs specifically bind to CEA+ve LS174T cells and 
furthermore, induce a specific reduction in T2 contrast. Incubation of the d50 with the 
CEA-ve A375M cells resulted in a slight drop in T2 relaxivity however; this was 
negligible and consistent with a recent report by Li et al., who demonstrated a slight 
T2 reduction with control cells containing no SPIONs (Li et al., 2009).   
 
The feasibility of using dextran coated SPIONs as specific tumour contrast agents 
has been previously demonstrated with different antibodies for example, anti CEA 
mAb (Tiefenauer et al., 1993), anti EGFR mAb (Suwa et al., 1998), anti-9.2.27 and 
anti-her2/neu mAbs (Funovics et al., 2004) and anti colorectal mAb A7 (Toma et al., 
2005). However, dextran coated particles may have limited application for tumour 
targeting in vivo, due to rapid clearance by the RES. One way to address this is use 
PEGylated SPIONs. For this reason, the selective MRI potential of the PEGylated 
SPIONs was investigated.  
 
MRI  results  demonstrated  the  Sm3E-PEG-d50  to  specifically  bind  the  CEA+ve 
LS174T  cells,  resulting  in  a  57%  reduction  in  T2  values.  In  contrast  the  non-
functionalised PEG-d50 resulted in an 11% reduction in T2, indicating only a limited 
amount of non-specific interaction with the CEA+ve LS174T cells, consistent with 
iron  uptake  measurements.  These  T2  result  are  very  similar  to  that  of  the  d50, 
suggesting  intracellular  uptake  has  no  imaging  benefit  in  vitro  over  the  non-
internalising  SPIONs.  However,  unlike  the  d50,  there  was  an  approximate  50% 
reduction in T2 value for the CEA-ve A375M cells following incubation with both   124 
the Sm3E-PEG-d50 and non-functionalised PEG-d50. These results strongly suggest 
non-specific  uptake  by  the  CEA-ve  A375M  cell  line  and  also  support  the  non-
specific binding behaviour observed in the CLSM images (see section: 4.3.3 Effect 
of SPION surface chemistry) 
   
The  PEGylated  SPIONs  have  shown  to  internalise  and  localise  in  endosomal 
compartments of the cells (see section: 4.3.4 Intracellular trafficking). Thus it was 
postulated that if further trafficked to the lysosomes the SPIONs were likely to be 
digested  into their Fe2+ and Fe3+ states (Okon et al., 1994; Gupta et al., 2004). The 
disintegration of the magnetite cores has been reported to cause 10 fold loss in signal 
(Briley-Saebo et al., 2004). This however, was not evident from the MRI results. The 
sufficient MRI potential of the PEG-dSPIONs following internalisation is supported 
by a number of other studies (Garden et al., 2006; Li et al., 2009; Yang et al., 2009). 
The fact the SPIONs are still functional could suggest the SPIONs have escaped 
from lysosomal degradation (Cartiera et al., 2009).  
 
As demonstrated in section 4.3.3 (Effect of SPION surface chemistry) non-specific 
uptake was dependent on hydrodynamic radii and PEG content of the PEG-dSPION. 
Indeed, the smaller  Sm3E-PEGd20 was readily visible  on MRI when targeted to 
CEA+ve LS174T cells, resulting in a 51% reduction. This was not the case for either 
the non-targeted PEG-d20 or the CEA-ve A375M cells, demonstrating the Sm3E-
PEG-d20s specificity to the CEA+ve LS174T cells. In conclusion, its small size, 
PEG  coating  and  specific  MRI  potential  makes  the  Sm3E-PEGd20  an  attractive 
SPION for application as a specific tumour contrast agent.  
 
It was evident  from the MRI results  that all the SPIONs  showed  binding  to the 
A375M cells. This non-specific uptake by  the  A375M cell  line compared  to the 
LS174T line may be related to the particular cells and the size and charge of the 
SPIONs. Consistent with this, a number of groups have reported that the rate and 
extent of SPION uptake due to PEGylation (Zhang et al., 2002) and surface charge 
(Villanueva et al., 2009) can differ among cell lines (Cartiera et al., 2009).  
 
The  results  in  this  chapter  show  the  Sm3E-SPION  conjugates  to  deliver  tumour 
specific MRI in vitro. However, whether this can be translated in vivo is uncertain.   125 
From the biodistribution results the Sm3E-d50, Sm3E-PEG-d50 and Sm3E-PEG-d20 
demonstrate minimal uptake in the CEA+ve tumour cells, predominantly clearing to 
the  spleen  via  the  RES.  The  similar  biodistribution  of  all  the  SPIONs  was 
unexpected, as PEGylation and small hydrodynamic size are reported to improve 
RES  evasion,  and  in  turn,  increase  blood  circulation  time.  Nanoparticles  with 
prolonged  circulation  time  have  been  shown  to  exhibit  increased  accumulation 
within tumour tissues via the enhanced permeability and retention effect (Modi et al., 
2006) and when functionalised with a targeting ligand are retained by the tumour 
cells  (Pun  et  al.,  2004).  However,  this  was  not  observed  with  the  Sm3E-SPION 
conjugates investigated, results suggest the PEG-d20 SPION to be just as exposed to 
RES uptake as the non-PEGylated and larger d50. A possible reason for poor RES 
evasion shown by the PEGylated SPIONs could be due to the density and length of 
the PEG chains. The lengths of the PEG chains absorbed onto the SPIONs used in 
this study are  approximately  300 MW.   It  has  been reported that  for  PEGylated 
SPIONs to evade the RES a PEG chain MW of 2000 or greater is required (Owens et 
al., 2006; Er et al., 2009). The longer length PEG chains form a denser protective 
layer  around  the  SPIONs,  effectively  blocking  opsonisation  from  occurring. 
Therefore,  it  is  likely  that  the  short  PEG  chains  are  not  adequately  masking  the 
dextran matrix from plasma protein opsonisation.  
 
5.5 Summary 
 
The  aim  of  the  work  presented  in  this  chapter  was  to  test  the  potential  of  scFv 
functionalised SPION for specific MR imaging of cancer cells.  
 
To  achieve  this,  SPIONs  were  functionalised  with  Sm3E  an  anti  CEA  scFv  and 
tested for their imaging potential with CEA+ve LS174T cells and CEA-ve A375M 
cells. The level of SPION specificity to the target cell was illustrated by T2 weighted 
images and relaxometry values.  
 
The Sm3E functionalised d50 and PEG-d20 exhibited excellent specificity to the 
target CEA+ve LS174T cells causing approximately 50% reduction in T2 relaxation, 
whereas  negligible  reduction  was  seen  for  the  controls.  The  PEG-d50  however, 
caused substantial T2 signal reduction of CEA-ve A375M control cells, revealing its   126 
non-specific  binding  behaviour.  Intracellular  uptake  of  SPIONs  had  no  imaging 
advantage or disadvantage over membrane bound SPIONs, with T2 reduction for all 
three SPIONs found to be similar. In addition, viability of the cells was unaffected by 
exposure  to  the  d50,  PEG-d50  and  PEG-d20  at  a  concentration  of  0.1  mg/ml.  
Biodistribution  results  however,  demonstrated  minimal  uptake  of  the  Sm3E 
functionalised SPION into the tumour cells, with the majority accumulating in the 
spleen. Further optimisation of the Sm3E-SPION conjugates surface properties is 
required to improve their tumour targeting potential in vivo. 
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Chapter 6  
 
 
Therapeutic Potential of        
Functionalised SPIONs  
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6.1 Introduction 
 
Previous work in this thesis has shown that SPIONs can target specifically to cancer 
cells. The aim of the work presented in the present chapter was to test whether scFv-
targeted SPIONs could have the potential to deliver hyperthermic therapy to cancer 
cells  when  subjected  to  an  alternating  magnetic  field  (AMF)  (see  section: 
Application of SPIONs in hyperthermia).   
 
It  has  been  shown  by  others  that  the  hyperthermic  potential  of  the  SPIONs  is 
dependent on the current and frequency parameters of the AMF they are subjected to 
(Hergt  et  al.,  2004b).  To  test  this  and  identify  a  suitable  AMF  for  induction  of 
magnetic fluid hyperthermia MFH, two AMF strengths were investigated. 
 
Another important factor that can affect the hyperthermic potential of the SPIONs is 
the SPIONs chemical and physical characteristics (Wang et al., 2005; Pankhurst et 
al., 2003; Fortin et al 2007; Motoyama et al., 2008). To test this six SPIONs of 
different size and chemical composition were investigated and SPION characteristics 
suitable for AMF induced SPION heating were identified.  
  
In addition, cell loading of SPIONs is also reported to be a crucial factor that can 
affect their hyperthermic potential (Kalambur et al., 2007; Kettering et al., 2007). 
Functionalisation  of  the  SPIONs  with  Sm3E  substantially  increased  specific  cell 
uptake (see section: 4.3.1 Quantification of SPION Uptake). Furthermore, depending 
on  their  surface  properties  the  SPIONs  localised  either  extracellularly  or 
intracellularly. The therapeutic impact of cell loading and intracellular uptake for 
MFH was investigated by viability measurements and cellular response of the heat 
shock protein 70 (HSP70). 
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6.2 Objectives 
 
The objectives of the research described in this chapter were to: 
 
1.  Determine whether hyperthermia can affect cell viability  
 
2.  Identify the AMF strength for optimal SPION heating  
 
3.  Identify optimal SPION characteristics for magnetic fluid hyperthermia  
 
4.  Measure the magnetic fluid hyperthermia cell response on; 
       a) Viability 
       b) Heat shock protein expression  
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6.3 Results 
 
6.3.1  Temperature effect on cell viability 
 
To establish whether heat treatment can affect cancer cells, the CEA+ve LS174T 
cells  were  exposed  to  temperatures  of  37
oC  through  to  47
oC  for  20  min.  To 
determine cell viability, live cell numbers were counted 30 min after heat treatment 
and MTT assays were performed 96 hrs following heat treatment. All results were 
compared against a non-treated control. Results from both the cell viability counts 
and MTT assay show that heat can lead to cell death, with both assays showing 
complete cell death at 46
oC (Fig 6.1). Therefore, a temperature increase of 9
oC is 
enough to cause approx 95-100% cell death. A temperature increase of 5-6
oC was 
sufficient to cause approx 50% cell death. Both assays agree that a 3
oC temperature 
rise has no short term detrimental affect on cell survival. From comparison of cell 
viability  results  taken  at  30  min  and  96  hrs  following  treatment,  no  significant 
difference in cell viability was observed. These results therefore, suggest cell death 
via heat is an immediate effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.1 Effect of environmental temperature on cell survival as measured by cell 
viability counts (pink line) and MTT assay (blue bars). 
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6.3.2  Temperature effect on cellular HSP70 response  
 
Although environmental temperatures below 40
oC caused minimal cell death the low 
increase in temperature may cause stress to the cells. When cells become stressed, 
they up regulate a number of proteins including HSP70. To determine whether an 
increase  in  environmental  temperature  can  cause  cells  to  become  stressed  and 
express  HSP70  an  in  vitro  assay  was  designed  (see  section:  2.2.8.3).  For  this 
experiment CEA+ve LS174T cells were grown on coverslips and incubated at 37
oC, 
40
 oC and 43
 oC. HSP70 expression was detected using an anti HSP70 mAb (red) and 
visualised by CLSM.  
 
Results  from  CLSM  analysis  show  that  a  3
oC  temperature  rise  induces  HSP70 
expression,  as  indicated  by  the  red  fluorescence  (Fig.  6.2).  Furthermore,  results 
reveal  HSP70  expression  to  increase  with  increasing  temperatures,  indicating  the 
cells to become more stressed with increasing temperatures. CLSM results also show 
cell viability to reduce  with  temperature increase, as  fewer cells  are  observed at 
43
oC.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2. Induced HSP70 expression in CEA+ve LS174T cells following heat treatment as 
illustrated by CLSM. The CEA+ve LS174T cells were incubated at temperatures 37
oC, 40
oC. 
and 43
oC. Samples were heated for 20 min, and left for 4 hr at 37
  oC to allow for HSP70 
expression. Detection  of induced  HSP70 (red) was  performed  with  a mouse  anti  HSP70 
primary antibody, followed by a anti mouse alexa fluor 594 antibody. Nuclei were stained 
with Hoechst (blue).  
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6.3.3 Magnetic fluid hyperthermia using AMF system 1  
 
To investigate the MFH  potential of the SPIONs studied in this thesis the AMF 
system 1 (Fig. 6.3) was used, this applies an AMF strength of 300 V, 0.62 A and 
139.8 kHz.  
 
6.3.3.1 AMF induced heating of d100 and DX100 
 
To test whether the AMF strength of 300 V, 0.62 A and 139.8 kHz is suitable to 
induce  magnetic  heating  of  SPIONs,  increasing  concentrations  of  the  d100  and 
DX100 were placed in the AMF coil for 20 min. The temperature increase over time 
was measured using temperature probes. To remove any false heating due to the coil, 
which gets hot itself, the coil was kept cool through constant cycling of cold tap 
water. 
 
 
AMF System 1: 300 V, 0.62 A and 139.8 kHz 
A)                                              B) 
 
 
Fig. 6.3. Image A: AMF system 1, applies a field strength of 300 V, 0.62 A and 139.8 kHz. 
SPION samples at 1 ml are placed into the coil (white arrow), AMF field is applied by power 
generator  for  20  min  (yellow  arrow).  Fluid  temperature  increase  was  measured  using 
temperature probes (red arrow). The coil was kept cool by water cooler (blue arrow). Image 
B: Schematic representation of SPION sample placed into AMF heating coil. 
 
   133 
Following AMF treatment, results from the temperature probes show when starting 
at room temperature the d100 SPIONs to cause no increase in fluid temperature at 
concentrations  of  1  mg/ml  and  5  mg/ml,  and  only  a  2
oC  temperature  rise  at  a 
concentration of 25 mg/ml (Fig. 6.4). In comparison, the temperature probes showed  
the  DX100  to  cause  slightly  better  heating  when  subjected  to  the  AMF.  At  a 
concentration of 5 mg/ml, the AMF treated DX100 generated a temperature increase 
of 2
oC (Fig. 6.4) and at concentrations of 25 mg/ml a temperature increase of 8
oC 
was measured. These results show the SPIONs are capable of generating heat when 
in an AMF of 300 V, 0.62 A and 139.8 kHz. The heating observed was also shown to 
be concentration dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4. Temperature increase of 1 ml of water by the d100 and DX100 at concentrations 1 
mg/ml to 25 mg/ml during AMF treatment (300 V, 0.62 A, 139.8 kHz). Change in temperature 
was  measured  using  probes  placed  into  solution.  Experiments  were  started  at  room 
temperature. 
 
 
6.3.3.2. Cell viability following magnetic fluid hyperthermia  
 
To  determine  whether  the  temperature  increase  generated  by  the  DX100  when 
subjected to AMF system 1 would be enough to cause cell kill, an in vitro MFH 
assay  was  developed  and  cell  viability  determined  by  live  cell  counts.  For  this 
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experiment the CEA+ve LS174T cells were suspended in 1 ml non-functionalised 
DX100 SPIONs at 1 mg/ml, 5 mg/ml, 10 mg/ml, 25 mg/ml and media as a control.  
The samples were placed into the coil of the AMF system. A probe was placed in the 
sample and in the coil to monitor the environmental temperature. The samples were 
subjected  to  the  AMF  for  20  min.  Following  AMF  treatment,  viable  cells  were 
counted. 
 
Results in Fig 6.5 show that before AMF treatment the DX100 SPIONs exhibited 
cytotoxicity. At a concentration of 10 mg/ml and 25 mg/ml over 95% cell death was 
observed  and  at  5  mg/ml  cell  death  was  approximately  75%.  Following  AMF 
exposure,  the  DX100  showed  no  significant  effect  on  cell  viability  at  1mg/ml. 
Furthermore, no effect on cell viability at DX100 SPION concentrations 5mg/ml and 
above  following  AMF  treatment  could  be  observed  due  to  toxicity.  This  result 
suggests that the heat generated by the DX100 SPIONs following exposure to AMF 
system 1 is not sufficient to cause MFH cell death at 1mg/ml. In addition, DX100 
SPIONS 'as are' are toxic to cells at concentrations of 5mg/ml or higher.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.5  Percentage cell survival of CEA+ve LS174T cells suspended in DX100 before and 
after AMF hyperthermic treatment. Following treatment cell viability counts were performed 
and the percentage cell survival determined against media only control. 
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6.3.3.3 Induction of HSP by magnetic fluid hyperthermia 
 
Although no cell death was apparent following MFH in AMF system 1 using DX100 
SPIONs, the cells could be showing signs of stress. As observed is section 6.3.2, a 
small temperature increase can lead to cellular stress and expression of the HSP70. 
To determine whether DX100 SPIONs when subjected to the AMF can up-regulate 
HSP70 expression, an in vitro assay was designed (see section: 2.2.8.5). For this 
experiment, CEA+ve LS174T cells were grown on coverslips and incubated in either 
1 mg/ml DX100 or 0.1mg/ml Sm3E-DX100. For targeted MFH using the Sm3E-
DX100, the cells were washed to remove unbound particles and incubated in fresh 
culture media before AMF treatment. The cells were placed in the AMF for 20min. 
Four controls were used i) media only, ii) media + AMF iii) 1mg/ml DX100 no AMF 
and iv) 0.1mg/ml Sm3E-DX100 no AMF. The expression of the HSP70 was detected 
using mouse anti HSP70 (red) and visualised by CLSM.  
 
Results from CLSM revealed expression of HSP70 to be minimal for control cells 
treated in media only (Fig. 6.6a). Following exposure to the AMF, the media only 
controls  showed  a  small  amount  of  HSP70  expression,  as  indicated  by  the  red 
fluorescence (Fig. 6.6b); suggesting AMF alone to cause stress to the cells. The cells 
also showed up-regulation of HSP70 expression following incubation in 1 mg/ml 
DX100 (Fig. 6.6c), demonstrating the DX100 SPIONs to also cause stress to the 
cells. However, following exposure of the cells incubated with DX100 to the AMF, a 
further  increase  in  HSP70  expression  was  observed  (Fig.  6.6d).  Furthermore, 
following AMF treatment of cells bound to the Sm3E-DX100, a substantial increase 
in HSP70 was evident. These results therefore demonstrate that even when MFH 
does not cause cell death the cells do experience stress, as shown by induction of 
HSP70  expression.  In  addition,  cellular  stress  can  be  further  enhanced  by  AMF 
treatment of CEA+ve LS174T cells specifically labelled with Sm3E functionalised 
SPIONs.  
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Fig.  6.6.  CLSM  images  showing  induced  expression  of  the  HSP70  following  MFH.  The 
CEA+ve LS174T cells were incubated in a) media only, b) media only plus AMF treatment, 
c) 1 mg/ml DX100, d) 1 mg/ml DX100 plus AMF treatment, e) 0.1mg/ml Sm3E-DX100 and f) 
0.1mg/ml Sm3E-DX100 plus AMF.. Samples were incubated for a further 4hrs following AMF 
treatment at 37
oC. Detection of induced HSP70 was performed with a mouse anti-HSP70 
primary  antibody,  followed  with  an  anti-mouse  alexa  fluor  594.  Nuclei  were  stained  with 
Hoechst. 
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6.3.4 Magnetic fluid hyperthermia using AMF system 2  
 
To investigate if the heating potential of the SPIONs could be improved using a 
larger AMF, a second system was developed in collaboration with Professor Quentin 
Pankhurst (The Royal Institution of Great Britain). The AMF system 2 (Fig 6.7) 
applies a higher field strength of 150 V, 0.74 A, 1 MHz. In addition, AMF system 2 
also has  an Air-Therm  ATX attached, which pumps  a constant  air-flow  of 37
oC 
through the coil area, allowing the surrounding temperature to be maintained at 37
oC. 
The application of the Air-Therm ATX was a crude way to represent how blood flow 
may affect the heating potential of the SPIONs, demonstrating the effect dissipation 
of heat would have on the overall rise in fluid temperature.  
 
AMF System 2: 150 V, 0.74 A and 1 MHz 
 
 
Fig. 6.7. Image of AMF system 2, applies AMF strength 150 V, 0.74 A, 1 MHz. 0.5-1 ml 
SPION samples are placed into the coil, the environmental temperature was maintained at 
37
oC by Air-Therm ATX and the AMF coil was kept cool by connection to water supply. The 
AMF  was  applied  for  20  min  and  temperature  increase  was  measured  by  Luxtron 
thermometer probes.  
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6.3.4.1 AMF induced heating of d100  
 
The heating potential of the d100 was tested in AMF system 2 and the effect of the 
Air-Therm ATX was evaluated. Colloidal suspensions of the d100 at 0.05 - 5 mg/ml 
were placed in AMF system 2 and subjected to AMF for 20 min. This experiment 
was performed with and without the Air-Therm ATX.  
 
Results showed that without the 37
oC Air-Therm ATX, the d100 at 5 mg/ml caused a 
fluid temperature increase of 35
oC when subjected to AMF 2 (Fig 6.8). Furthermore, 
a temperature increase of 1
oC was recorded at a d100 concentration of 0.1 mg/ml. 
These results demonstrate that application of the higher AMF strength, using AMF 
system 2, vastly improves the heating potential of the d100. However, following 
application of the Air-Therm ATX, the fluid temperature increase generated by d100 
at 5 mg/ml reduced by 50% to 14
oC. The 50% drop in temperature rise is most likely 
due to the 37
oC airflow, generated by the AIR-Therm ATX. Though the temperature 
increase of the SPION fluid was less when the Air Therm ATX was applied, the 
temperature increase measured was still better than with AMF system 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  6.8.  Temperature  rise  of  0.5  ml  of  water  in  1.5  ml  eppendorf  tubes  by  d100  at 
concentrations 0.1 mg/ml to 5 mg/ml when place in AMF (150 V, 0.74 A, 1M Hz). Change in 
temperature measured (relative to the starting temperature of 37C) using Luxtron probes 
placed into solution. 
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6.3.4.2 AMF induced heating of d50, PEG-d50 and PEG-d20 
 
Following on from the d100, the heating potential of the d50, PEG-d50 and PEG-d20 
were  also  tested  using  AMF  system  2  plus  Air-Therm  ATX.  Results  showed  a 
dramatic difference in the heat generated between the different sized SPIONs (Fig. 
6.9). In comparison to d100, which at 5 mg/ml caused a fluid temperature increase of 
approximately 14
oC when exposed to AMF 2, the d50, PEG-d50 and PEG-d20 at 5 
mg/ml  caused  only  a  3
oC  -  4
oC  temperature  rise.  Results  also  show  the  heating 
potential of the d50 and PEG-d50 to be similar; indicating the adsorption of PEG has 
little effect on the heat generated. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.9. Temperature rise of 0.5 ml of water induced by AMF treatment of the d100, d50, 
PEG-d50  and  PEG-d20  at  concentrations  0.1-5  mg/ml.  Environmental  temperature  was 
maintained at 37
oC with the Air-Therm ATX. The Change in fluid temperature was measured  
(relative to the starting temperature of 37
 oC ) using Luxtron probes placed in solution. 
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The heating potential of the DX100 using AMF system 2 was also tested. Results 
showed AMF system 2 to substantially improve the heating potential of the DX100. 
Results presented in Fig. 6.10 demonstrate even with the Air-Therm ATX attached, 
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the DX100 at a concentration of 5 mg/ml caused a fluid temperature increase of 25
oC 
when exposed to AMF 2. Furthermore, the DX100 at a concentration of 0.25 mg/ml 
and 0.05 mg/ml caused a temperature increase of 2
oC and 0.5
oC (Fig 6.5). From 
comparing the heating profiles of all the SPION tested, the DX100 was found to be 
the superior heater.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  6.10.  Temperature  rise  of  0.5  ml  of  water  in  1.5  ml  eppendorf  tube  by  DX100  at 
concentrations 0.025 mg/ml to 5 mg/ml during exposure to AMF of 150 V, 0.74 A, 1 MHz. 
Temperature  of  solution  started  at  37
oC  using  Air-Therm  ATX.  Change  in  temperature 
measured using Luxtron probes placed into solution. Water was used as control sample. 
 
 
6.3.4.3. Cell viability following magnetic fluid hyperthermia  
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0.1 mg/ml were incubated with the CEA+ve LS174T cell line. Only for the Sm3E 
functionalised SPIONs were the cells washed and incubated in fresh media before 
AMF treatment, this was to allow only the Sm3E-SPIONs bound to the cell to cause 
any hyperthermic affect. The cells were subjected to AMF 2 for 20 min and cell 
viability determined 96 hrs later by MTT assay.  
 
The MTT results presented in Fig. 6.11 show the DX100 at 2.5 mg/ml caused a 25% 
drop in cell viability even before exposure to the AMF, suggesting cytotoxicity of the 
DX100  at  2.5mg/ml  this  is  in  accordance  with  Fig  6.5    which  showed  DX100 
cytotoxicity  at  5mg/ml.  Cell  death  was  further  increased  when  the  DX100  were 
subjected to AMF 2. AMF treatment of the DX100 at 1-2.5 mg/ml was shown to 
cause  approx  95%  cell  death,  most  likely  due  to  MFH.  However,  at  a  DX100 
concentration <0.5 mg/ml, treatment with AMF 2 did not appear to cause cell death. 
Furthermore, binding of Sm3E functionalised DX100 to the cells showed no effect 
on  cell  viability  before  and  after  AMF  treatment.  These  results  suggest  that  the 
DX100 have the potential to cause cell death via MFH when exposed to AMF 2, but 
only at concentrations above 1 mg/ml.  
 
In comparison to the DX100, the d100 was slightly more cytotoxic (Fig 6.11). The 
MTT results show that before exposure to AMF 2 the d100 at 5 mg/ml and 2.5 
mg/ml caused approx 95% and 50% cell death.  Following AMF treatment of the 
remaining 50% of cells incubated in the d100 at 2.5mg/ml, complete cell kill was 
observed,  again  most  likely  due  to  MFH.  However,  cells  incubated  in  d100  at 
concentration <1 mg/ml and when bound to Sm3E functionalised d100 showed no 
cell death before or after treatment in AMF 2.  
.  
Investigation into the MFH potential of the d50, PEG-d50 and PEG-d20 revealed all 
three SPIONs at a concentration of 5-2.5 mg/ml to exhibit some level of cytotoxicity 
before  AMF  treatment  (Fig.  6.12).  In  addition,  results  showed  cytotoxicity  to 
increase with SPION size. Following AMF treatment of the d50, PEG-d50 and PEG-
d20 no effect on cell viability was observed. These results suggest that d50, PEG-d50 
and PEG-d20 are not capable of inducing MFH cell death when subjected to AMF 
system 2.   
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Fig. 6.11. Percentage Cell survival of CEA+ve LS174T  cells incubated in A)  DX100 and 
Sm3E-DX100 and B) d100 and Sm3E-d100 before and after AMF hyperthermic treatment. 
Only  the  cells  incubated  with  0.1mg/ml  Sm3E  functionalised  SPIONs  were  washed  and 
incubated in fresh media before AMF treatment, this was to allow only the Sm3E-SPIONs 
bound to the cell to cause any hyperthermic  affect. Following treatment MTT assay was 
performed; absorbance was read at 550 nm and percentage cell survival determined against 
media only control. 
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Fig. 6.12. Percentage Cell survival of CEA+ve LS174T cells incubated in A) d50 B) PEG-d50 
and C) PEG-d20 before and after AMF hyperthermic treatment. Following AMF treatment 
MTT assay was performed; absorbance was read at 550 nm and percentage cell survival 
determined against media only control. 
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6.3.5  Effect of cellular uptake of SPIONs on magnetic fluid hyperthermia 
 
6.3.5.1 Cell loading 
 
From the previous results (see section: 6.3.3.3) AMF treatment of CEA+ve LS174T 
cells bound to Sm3E functionalised SPIONs caused expression of HSP70 in AMF 
system 1 but no cell kill in vitro. Furthermore, no cell kill was evident with the 
Sm3E-SPION labelled cells following treatment with AMF system 2, even though 
exceptional heating was observed. The lack of cell kill could be due to insufficient 
SPION uptake, the cells tested in section 6.3.3.3 were labelled with approx 6 pg of 
SPIONs per cell (see section: 4.3.1). To increase the cell uptake of SPIONs the cells 
were incubated at 37
oC overnight with Sm3E-DX100 or DX100 as a control, at a 
concentration of 2 mg/ml, 1 mg/ml or 0.5 mg/ml. Following incubation, results show 
SPION uptake to be approx 250 pg/cell, 240 pg/cell and 180 pg/cell respectively 
(Fig. 6.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.13. Uptake of Sm3E-DX100 SPIONs by CEA+ LS174T cells as quantified by ferrozine 
based  assay.  With  reference  against  standard  curve  of  ferrozine  assayed  SPIONs  the 
numbers of SPIONs taken up per cell were calculated following incubation in 0.5mg/ml, 1mg/ml 
or 2mg/ml.  
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To determine if increased SPION uptake leads to MFH cell death the SPION loaded 
cells were subjected to AMF 2. From the MTT results (Fig 6.14) it is apparent that 
the increase in SPION uptake before AMF treatment resulted in a small amount of 
cytotoxicity, causing approx 20% cell death. However, following AMF treatment 
only a slight decrease (10%) in cell viability was observed, and only with the cells 
containing 250 pg of SPIONs. No effect on cell viability due to MFH was observed 
for the cells loaded with 180 pg and 240 pg of DX100 after exposure to AMF 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.14. Percentage cell survival of CEA+ LS174T loaded with Sm3E-DX100 before and 
after  AMF  hyperthermic  treatment.  Following  AMF  treatment  MTT  assay  was  performed; 
absorbance was read at 550 nm and percentage cell survival calculated against media only 
control. 
 
6.3.5.2 Heating mechanism 
 
The lack of cell death following AMF treatment of the SPION loaded cells suggests 
the SPIONs are not heating when bound to the cells. One possible reason could be 
the attachment of the Sm3E-SPIONs to the cells, which may restrict the SPIONs 
movement thus its potential to heat via Brownian motion. To test this, the SPIONs 
0
180
240
250
0
50
100
No AMF
AMF
Sm3E-DX100 (pg/ml)
%
 
c
e
l
l
 
s
u
r
v
i
v
a
l
0
180
240
250
0
50
100
No AMF
AMF
Sm3E-DX100 (pg/ml)
%
 
c
e
l
l
 
s
u
r
v
i
v
a
l  146 
were suspended in two liquids of different viscosity, water and glycerol. Glycerol is a 
high viscosity liquid, which should restrict the frictional movement of the SPIONs 
and thus heating via Brownian motion. Following AMF treatment of the SPIONs, no 
difference in the SPION heating was observed (Fig. 6.15). These results suggest that 
reducing the movement of the Sm3E-SPION conjugates by attachment to CEA+ve 
cells does not affect the SPIONs heating potential when exposed to AMF 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.15. Temperature rise of 5 mg/ml DX100 and  2.5 mg/ml d100 suspended in either 
water or glycerol following exposure to AMF (150 V, 0.74 A, 1 MHz). Temperature of solution 
started at 37
oC using Air-Therm ATX. Change in temperature was measured using probes 
placed into solution.  
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6.4 Discussion 
 
The work presented in this chapter has investigated the heating efficiency of the 
DX100, d100, d50, PEG-d50 and PEG-d20 within 2 AMFs. The results show that 
SPION  size,  concentration  and  AMF  strength  are  important  factors  in  achieving 
optimal  SPION  heating  efficiency.  Although  all  the  SPIONs  caused  a  fluid 
temperature increase when in the AMF, only the DX100 and d100 above 1 mg/ml 
caused hyperthermic cell kill. However, AMF treatment of cells specifically labelled 
with Sm3E-functionalised SPIONs showed increased HSP70 expression, indicating 
even a low temperature increase can cause cellular stress and potentially sensitise 
cells to treatments. 
 
Using heat to destroy or weaken cells towards radiotherapy or chemotherapy has 
been a common procedure in the clinic (Samanta et al., 2008). Furthermore, tumour 
tissues tend to have a higher sensitivity to heat than normal tissues (Cavaliere et al., 
1967;  Shinkai  et  al.,  1995;  Wang  et  al.,  2005).  Viability  results  following  heat 
treatment of LS174T cells found that a temperature increase of 42-43
oC led to a 50% 
drop in cell viability and a temperature rise over 46
oC led to thermoblastation, where 
over 95% cells were destroyed, a number of other groups have also reported similar 
results (Jordan et al., 1999b; Mornet et al., 2004; Lao et al., 2004). Although cell 
viability following a fluid temperature rise of 38
oC – 40
oC was largely unaffected, 
analysis  of  the  HSP70  revealed  mild  hyperthermia  to  cause  cellular  stress. 
Furthermore, the expression of the HSP70 increased with increasing temperature, 
indicating further stress to the cells. Expression of HSP70 could therefore, be used as 
a measurement of the effect of hyperthermia on cells. In addition, HSP70 has been 
reported to induce anti-tumour immunity (See section: 1.4 Hyperthermia). 
 
For MFH the heating potential of the SPIONs should be as high as possible, to allow 
administration of the lowest SPION dose (Hergt et al., 1998). However, from the 
results the tested DX100 and d100 heating potential was very low when exposed to 
AMF  system  1,  resulting  in  an  insufficient  fluid  temperature  increase.  In  AMF 
system 1, therapeutically favourable temperatures could only be reached at already 
cytotoxic SPION concentrations. MFH induced cell kill was therefore not achievable   148 
using  the  d100  and  DX100  in  AMF  system  1.  Although  no  MFH  cell  kill  was 
achieved  using  AMF  system  1,  expression  of  HSP70  was  detected,  indicating 
increased stress in the cells, MFH induced HSP70 expression was also reported by 
Suzuki et al., and Ito et al., (Suzuki et al., 2003; Ito et al., 2004). Furthermore, 
LS174T cells specifically labelled with a low concentration of Sm3E functionalised 
SPIONs (6pg/cell) and exposed to AMF system 1 showed a substantial increase in 
HSP70  expression.  This  would  suggest  that  Sm3E  functionalised  SPIONs  when 
specifically attached to CEA are more effective in generating MFH induced cellular 
stress. 
   
To test whether AMF strength affects the heating potential of the SPIONs a higher 
AMF strength was investigated. Application of AMF system 2 (150 V, 0.74 A, 1 
MHz) substantially improved the heating potential of all the SPIONs and allowed 
therapeutic  temperatures  to  be  reached  at  non-toxic  SPION  concentrations.  This 
result indicates the heating efficiency of SPIONs to be highly dependent on the AMF 
applied. The variation in the SPIONs heating potential when exposed to the two 
different AMFs could be due to the heating mechanism involved. The two heating 
mechanisms, Brownian and Neéls relaxation (See section; 1.2.2) are encouraged by 
different field strengths (Hergt et al., 2004b). Brownian relaxation predominantly 
occurs at 1-10 kHz, where as Neéls relaxation peaks at 200 kHz (Hergt et al., 2004b). 
This would suggest that Neéls relaxation is the main heating mechanism for both 
field strengths even so, results suggest the higher field strength to be more suitable 
for  encouraging  Neéls  relaxation  in  the  SPION  investigated.  A  number  of  MFH 
studies have been reported all using different SPIONs and different AMF strengths, 
and  all  showing  substantial  cell  death  (Yanase  et  al.,  1998;  Jordan  et  al.,  1999; 
Hilger et al., 2001; Hergt et al., 2004; Matsuoka et al., 2004; Kalambur et al., 2005; 
Wang et al., 2005; Okawa et al., 2006; Kettering et al., 2007). Therefore, the optimal 
AMF strength may depend on the characteristics of SPIONs. Indeed, all investigated 
SPIONs showed different heating profiles when exposed to AMF system 1 and 2.  
 
Thus in addition to the applied AMF, the individual SPION characteristics such as 
iron content and core size appear to influence the heating ability of the SPIONs when 
subjected  to  an  AMF.  Among  all  the  tested  SPIONs  the  DX100,  which  has  the 
highest iron content (see section: 3.3.3 SPION iron content) demonstrated the best   149 
heating profile. This suggests the iron content to be significant for optimal magnetic 
heating. However, this contradicts studies by Lao et al., who reported that the iron 
content of SPIONs has no effect on magnetic heating efficiency (Lao et al., 2004). 
Instead,  iron  core  size  was  identified  to  be  crucial  for  optimal  SPION  heating 
(Shinkai et al., 1995; Hergt et al., 2004a; Wang et al., 2005; Okawa et al., 2006; 
Fortin et al., 2007; Kettering et al., 2007). According to Gonzales-Weimuller et al., 
and Kallumadil et al., the optimal iron core size should be approx 12nm with low 
polydispersity (Gonzales-Weimuller et al., 2009; Kallumadil et al., 2009). Indeed, 
comparison of the d100, d50, PEG-d50 and PEG-d20 AMF heating profiles revealed 
the d100, which contains predominantly 10-15nm iron oxide cores, to have a better 
heating  efficiency  than  the  PEGd20,  which  contains  iron  oxide  cores  of  5nm 
(Personnel  communication:  Dr  Cordula  Gruettner  Micromod  Partikelteknologie 
GMbH,  Germany).  The  superior  heating  potential  exhibited  by  the  DX100  may 
therefore, be due to the DX100 consisting of a higher ratio of optimal sized iron 
oxide cores. 
 
As well as SPION characteristics and AMF strength, environmental conditions can 
also affect the SPIONs heating efficiency. To maintain a constant temperature of 
37
oC (body temperature) through the coil and simulating crudely how blood flow in 
the  body  may  affect  the  dissipation  of  heat  the  Air-Therm  ATX  was  used. 
Application of the Air Therm ATX resulted in a 50% drop in the fluid temperature 
increase, most likely due to the 37
oC airflow, quickly dissipating the heat generated. 
These results suggest that the heating potential of SPIONs when in the body will be 
less  efficient  due  to  the  cooling  effect  of  blood  flow,  a  finding  that  has  been 
previously reported (Andra et al., 1999; Moroz et al., 2002).  
 
Even with the Air Therm ATX, the DX100 and d100 SPIONs when in AMF system 
2, were capable of heating their surrounding fluid to therapeutic temperatures and 
therefore individually must reach extremely high temperatures.  Consequently, when 
in close proximity to cells, the hot SPIONs should directly cause intracellular cell 
death, a concept proposed by Gordon et al., (Gordon et al., 1979).  However, from in 
vitro results only the DX100 at >1 mg/ml and the d100 at >2.5 mg/ml caused cell 
death following AMF treatment. Coincidently, only at these concentrations was the 
fluid  temperature  rise  therapeutically  toxic.  These  results  suggest  the  cell  death   150 
observed was due to heating of the surrounding fluid and not directly by the heat of 
the SPIONs.   
 
Specific attachment of Sm3E functionalised SPIONs to CEA+ve LS174T cells also 
showed no effect on cell viability following AMF treatment in AMF system 2. The 
limitations of intracellular hyperthermia have been speculated to be due to SPION 
uptake (Kalambur et al., 2007), with optimal cell loading for heat transfer reported to 
be  in  the  range  of  60-200  pg/cell  (Jordan  et  al.,  1997;  Kettering  et  al.,  2007). 
However, results revealed that even with specific cell loading of 250 pg of Sm3E 
functionalised DX100 SPIONs negligible cell death following AMF treatment was 
observed. Though, it should be mentioned that binding of such a high concentration 
of SPIONs resulted in agglomeration. Agglomeration of SPIONs can decrease the 
heating efficiency of SPIONs as the relaxation behaviour of the iron cores become 
restrained due to inter-particle interactions (Wang et al., 2005).  
 
Another explanation for the poor intracellular MFH cell death could be due to loss of 
Brownian relaxation when the SPIONs are immobilised on or in cells (Hergt et al., 
2004b).  Studies  by  Kalambur  et  al.,  found  that  suspension  of  SPIONs  in  higher 
viscosity fluids, such as glycerol or collagen lead to a reduction in the heat generated 
when exposed to an AMF (Kalambur et al., 2005). This drop in heating was also 
reported  by  Fortin  et  al.,  who  encapsulated  SPIONs  into  vesicles  to  simulate 
intracellular uptake (Fortin et al., 2007). These higher viscosity environments are 
thought to restrict the frictional movement of the SPIONs, thus preventing Brownian 
relaxation (Kalambur et al., 2005), leaving Neéls relaxation to be the predominant 
heating mechanism. However, from the findings in this chapter, resuspension of the 
DX100 and d100 in glycerol caused no difference in their heating efficiency. This 
further confirms Neéls relaxation to be the main heating mechanism used by the 
SPIONs in AMF system 2. Therefore, heating by Brownian relaxation mechanism in 
this study is negligible. 
 
There  are  a  number  of  reports  published  detailing  the  mechanism  of  AMF 
hyperthermia induced cell kill (Gordon et al., 1979; Rabin et al., 2002; Wang et al., 
2005; Fortin et al., 2007). Though, at present the relationship between nanoscale heat 
response  and  macroscopic  heat  release  is  still  not  clear  (Kalambur  et  al.,  2005).   151 
Theoretical studies by Rabin et al., showed for the transfer of enough heat to cause 
cell death a tumour diameter of over 0.9mm fully occupied with SPIONs would be 
required (Rabin et al., 2002). This would enable enough SPIONs to be able to diffuse 
a large amount of heat, collectively raising the tissue temperature above the threshold 
to  cause  hyperthermia  or  thermoblastation  (Rabin  et  al.,  2002).  However,  in  the 
presence of blood flow a larger target region packed with SPIONs would be required 
for hyperthermic cell death to be evident (Rabin et al., 2002). The lack of cell death 
following targeted MFH in vitro may therefore, be due to the number of cells loaded 
with SPIONs being too low to collectively increase their environmental temperature 
to cause hyperthermic cell kill.  This confirms a postulation  by Jordan et al. and 
furthermore  supports  the  results  presented  in  this  chapter;  that  AMF  induced 
hyperthermic  cell  kill  is  due  to  fluid  heating  and  not  by  intracellular  heating  as 
speculated by Gordon et al. (Gordon et al., 1979; Jordan et al., 1999).  
 
At  present,  only  one  group  has  reported  success  with  antibody  targeted  MFH 
(DeNardo et al., 2005). DeNardo et al. reported a decrease in tumour growth after 
AMF treatment of tumours labelled with ChL6-PEG-d20 conjugate (DeNardo et al., 
2005; Ivkov et al., 2005). However, results in this chapter have shown the PEG-d20 
when exposed to an AMF of 150 V, 0.74 A and 1 MHz do not generate enough heat 
to cause hyperthermic cell death. Natarajan et al., describes the tumour growth delay 
reported in DeNardo et al., 2005 to be in response to Eddy currents (Natarajan et al., 
2008) and therefore, not due to Brownian and Neéls relaxation. Exposure of tissue to 
the high AMF employed by DeNardo et al. can cause tissues to heat up through eddy 
currents.  Furthermore,  if  the  tissues  such  as  tumours  contain  SPIONs  the  heat 
generated can be further enhanced (Natarajan et al., 2008), thus, delivering toxic heat 
specifically  to  the  tumour.  Eddy  currents  however,  have  been  reported  to  be 
dangerous to healthy tissues (Hergt et al., 2004) therefore, whether this approach is 
clinically viable still needs to be investigated. 
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6.5 Summary 
 
The aim of the work presented in this chapter was to first, identify optimal conditions 
and SPION characteristics for maximal SPIONs heating and second, investigate the 
MFH  potential  of  the  SPIONs  and  scFv-SPION  conjugates  when  exposed  to  an 
AMF.   
 
All the SPIONs investigated in this chapter were shown to be effective generators of 
heat when exposed to AMF system 2 (150 V, 0.74 A and 1 MHz). However, SPION 
size and concentration  greatly influenced the SPIONs magnetic heating potential. 
The  d100  and  DX100  caused  a  substantially  higher  fluid  temperature  increase 
compared to the smaller SPIONs and in addition, were the only SPIONs to initiate 
hyperthermic cell kill though, only at concentrations above 1 mg/ml.  
 
Specific targeted MFH using Sm3E functionalised SPIONs exposed to AMF system 
1 was found to cause increased expression of the HSP70, indicating cellular stress. 
However,  increased  uptake  of  Sm3E  functionalised  SPION  and  exposure  to  the 
higher AMF strength did not lead to MFH cell kill in vitro. The benefits of Sm3E 
functionalised  SPIONs  for  MFH  maybe  more  apparent  in  vivo,  with  increased 
retention of SPIONs within the tumour and anti-tumour immunity induced by HSP70 
expression. 
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Chapter 7 
 
 
 Conclusion and Future Challenges 
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The work in this thesis has been designed and executed to investigate the hypotheses 
that scFv-targeted SPIONs would have potential for imaging and therapy of cancer. 
To test the hypotheses, a combination of nanotechnology and protein engineering 
was  applied  to  generate  stable  scFv-SPION  conjugates  with  retained 
immunoreactivity  to  the  target  CEA.  Imaging  potential  of  the  scFv-SPION 
conjugates was demonstrated by confocal microscopy and MRI; therapeutic potential 
was demonstrated by developing systems to generate toxic heat by exposure of the 
targeted SPIONs to AMF. The results supported the hypotheses tested and indicate 
that scFv SPIONs have potential to be developed for cancer imaging and therapy, 
where there is a great need for novel treatments.  
 
My work has shown that SPIONs may be successfully targeted to cancer cells using 
scFv. However, for most effectiveness, in MRI or hyperthermia, the scFv-SPION 
conjugates should be targeted systemically in vivo. This is the next challenge; in 
particular  to  address  the  uptake  of  nanoparticles  by  the  RES  which  is  a  widely 
reported  problem  (Gupta  et  al.,  2007;  Barry,  2008).  An  approach  that  has  been 
applied to this problem, with varying degrees of success is to coat the nanoparticles 
with  agents  that  render  them  relatively  less  visible  to  the  RES,  a  property  often 
referred to as ‘stealth’.  A variety of materials have been used to achieve stealth and 
the  most  successfully  reported  of  these  is  high  MW  PEG  (Owens  et  al.,  2006). 
However, although PEGylation has shown promise, with increased blood circulation 
times (Zhang et al., 2002; Berry et al., 2003), complete RES evasion is yet to be 
reported.  Despite this limitation, systemic application of targeted SPIONs has been 
demonstrated in studies using mAb targeted SPIONs for MRI (Toma et al., 2005; 
Reynolds et al., 2006; Yang et al., 2009).  Although a strong T2 signal was also 
reported in the liver and spleen, indicating clearance by the RES (Yang et al., 2009). 
 
For  specific  MR  imaging,  low  concentrations  of  SPIONs  at  the  tumour  site  are 
sufficient (Pinkernelle et al., 2005). Though, for MFH to be effective for cell kill, 
high concentrations of SPIONs are required (Rabin et al., 2002). The accumulation 
of a high concentration of systemically targeted SPIONs within the tumour is not 
only affected by RES uptake, but also target antigen concentration and distribution 
within the tumour. Targeting MFH systemically to cause cell kill may therefore, not 
be a viable approach. Intra-tumoural injection of SPIONs for MFH cell kill has been   155 
demonstrated in vivo and furthermore, has shown promising results in the clinic with 
glioblastoma and prostate cancer (Thiesen et al., 2008).  However, possible diffusion 
of the SPIONs out of the tumour due to tumour vascular permeability could result in 
an overall lower concentration of SPIONs in the tumour and unwanted toxicity thus, 
affecting the efficacy of MFH treatment. Antibody targeting of SPIONs has been 
shown to improve the retention time of SPIONs within the tumour via antibody-
antigen interaction (Li et al., 2009). Therefore, specific attachment of scFv-SPION 
conjugates to tumour cells would potentially reduce the diffusion of the SPIONs 
through or out of the tumour, maintaining the concentration required to cause MFH.  
Furthermore,  work  in  this  thesis  has  shown  specific  attachment  of  scFv-SPION 
conjugates  to  cells  also  increases  cellular  stress  when  subjected  to  an  AMF  this 
would potentially enhance the potency of MFH.  
 
Although high concentrations of SPIONs are required to cause intense heat for MFH 
cell kill, lower temperature rises and thus low SPION doses could lead to therapeutic 
effects. Thus unlike MFH cell kill, mild MFH could be achievable using systemically 
targeted scFv-SPION conjugates. Small temperature increases of 2-5 degrees have 
been shown to increase tumour blood flow and vessel permeability (Bicher et al., 
1980;  Vaupel  et  al.,  1984;  Vaupel  et  al.,  1997)  leading  to  increased  oxygen 
concentration and cytotoxic drug delivery into the tumour (Wust et al., 2002; Song et 
al.,  2005).  Consequently,  systemically  targeted  mild  MFH  could  be  used  as  an 
adjuvant with chemotherapy and radiotherapy regimes. Indeed, studies by Johannson 
et  al.,  showed  combined  MFH  with  external  radiation  to  be  significantly  more 
effective than radiation alone (Johannson et al., 2006).  Furthermore, the application 
of an AMF can be localised to tumour regions, avoiding undesirable heating of RES 
organs. The potential of systemically targeted mild MFH to increase the toxicity of 
chemotherapy and radiotherapy in localised areas would therefore, allow for lower 
drug dosing, reducing the often debilitating side effects.  
 
Mild hyperthermia can also induce expression of HSP70 as evident in this thesis and 
by others (Ito et al., 2001, 2003, 2004). Induction of HSP70 expression by mild MFH 
has  been  shown  to  activate  cell  mediated  and  humoral  immune  responses  (See 
section: 1.4 Hyperthermia). Mild MFH can therefore, lead to a vaccination effect 
resulting in anti-tumour immunity (Yanase et al., 1998; Suzuki et al., 2003). Indeed,   156 
Yanase et al., showed that following MFH, there was not only a reduction in growth 
for the heated tumours but also for the non-heated tumours there was a similar size 
reduction (Yanase et al., 1998). In addition, Suzuki et al., observed cytotoxic activity 
when MFH treated mice were re-challenged with the same tumour cells (Suzuki et 
al., 2003). The generation of anti-tumour immunity could revolutionise the treatment 
of  metastatic  tumours,  as  once  activated,  the  immune  system  could  target  and 
specifically destroy the cancer cells.  
 
To  take  this  work  forward  extensive  characterisation  of  the  SPIONs  is  essential, 
especially if these SPIONs are taken into the clinic. Charaterisation would include; 1. 
Measurements  of  the  iron  core  and  overall  hydrodynamic  size  before  and  after 
conjugation as these properties are important in the magnetic heating properties of 
the  SPION  and  clearance  by  the  RES.  2.  Accurate  calculation  of  the  number  of 
SPION  in  1mg  SPION  solution  as  the  values  stated  on  the  data  sheet  are  only 
estimates.  3.  The  surface  electrical  charge  “zeta  potential”  of  all  the  SPIONs 
investigated before, during and after conjugation to scFvs should be measured, as 
surface charge can dramatically affect cell binding behaviour of the scFv-SPION 
conjugates,  
 
Furthermore, to have better control over the number and orientation of the scFvs 
attached  to  the  SPIONs,  development  of  site  specific  attachments  would  be 
advantageous. One approach could involve engineering of a cysteine group to the N 
terminus of the scFv thus, enabling attachment to the SPION via disulphide bond.  
 
Other future work would include an in vivo heating study, whereby functionalised 
and  non  functionalised  SPIONs  are  directly  injected  into  a  tumour  followed  by 
treatment with an AMF. From heating measurements and histological analysis of cell 
necrosis and  HSP70 expression the adavantge of using tumour specific SPION could 
be identified along with the feasibility of using tumour specific MFH as an approach 
to induce anti-tumour immunity .  
 
In  conclusion,  my  work  has  shown  that  scFv  targeted  SPIONs  are  effective  for 
specific imaging in vitro by MRI. Furthermore, I have established parameters for 
MFH therapy in vitro. My results indicate that scFv targeted SPION have potential   157 
for tumour specific MRI and MFH and support the central hypothesis for this thesis, 
that antibody-targeted SPIONs can be used for diagnosis and therapy of cancer. It is 
envisaged that when the challenge of creating stealth particles for in vivo delivery is 
met, the work in this thesis will form a future platform of understanding for further 
development of SPIONs.   
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